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Abstract 
 
Hutchinson Gilford Progeria syndrome (HGPS) is a rare premature ageing disease 
affecting children. 80% of “classic” HGPS patients share the same mutation in the 
LMNA gene that gives rise to characteristics similar to normal human ageing and 
they usually die in their teens from heart attacks or strokes. Cells taken from progeria 
patients have a short replicative lifespan in culture and this has necessitated the 
generation of immortalised progeria cell lines with unlimited growth potential. 
Evaluation of one such immortalised cell line has revealed loss of progeria cell 
characteristics, such as nuclear shape abnormalities, and a reversion to a normal 
nuclear morphology. We attributed this reversion to an increased rate of breakdown 
of the mutant protein, progerin, which normally causes the nuclear abnormalities. 
Identification of this underlying mechanism has potential therapeutic applications for 
HGPS patients. Based on this finding this study demonstrates the effect of an A type 
lamin target nanobody conjugated to an E3 Ubiquitin ligase, as the first step to a 
nanobody therapy for HGPS.  The development of TAT- lamin A and TAT- progerin 
fusion proteins, which are capable of transducing into human cells at a desired 
concentration, allow for future investigation into progerin dose effects.   
 
“Atypical” progeria patients have unknown mutations which cause a similar disease 
but with more varied degrees of severity. The characterisation of an hTERT 
immortalised cell line, from an “atypical” patient, led to the observation of a genetic 
instability phenotype, which, in combination with whole exomes sequencing, has 
enabled the identification of candidate genes within DNA repair and cell cycle 
regulation. Future identification of another HGPS gene will increase understanding 
of premature ageing diseases and of normal human ageing.  
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1 Introduction 
 
1.1 Hutchinson-Gilford Progeria Syndrome 
 
Hutchinson-Gilford progeria syndrome is an extremely rare premature ageing 
disease first described by Jonathan Hutchinson (Hutchinson, 1886a; Hutchinson, 
1886b) and Hastings Gilford (Gilford; Gilford, 1904a; Gilford, 1904b) in the late 
19th /early 20th century.  Today, worldwide there are 135 children diagnosed as 
having HGPS, however, there may be many more sufferers without a diagnosis 
(Progeria Research Foundation). The incidence of HGPS is estimated at 1 in 4-8 
million live births, with diagnosis primarily based on characteristics (Hennekam, 
2006).  Symptoms of HGPS first manifest at approximately 1 year of age leading to 
an average age of diagnosis of 2.9 years. Characteristics of HGPS include a failure to 
thrive leading to abnormally low weight and height for age, alopecia, lipodystrophy, 
osteolysis of the distal phalanges and scleroderma of the skin. HGPS patients appear 
to have a larger than average neurocranium as a result of osteolysis of the 
visocranium, which results in a small face with a prominent forehead. Osteolysis of 
the mandible causes micrognathia and teeth overcrowding, while thinning of the skin 
causes increased visibility of blood vessels especially over the nasal bridge. This 
group of characteristics give rise to a typical HGPS facial appearance. Patients with 
HGPS very rarely achieve sexual maturity or experience puberty associated growth 
spurts. There is however, normal cognitive function in these patients with studies 
reporting a normal spectrum of intelligence. The incidence of cancer in these patients 
is, however, below the expected frequency with only two cases of neoplasm, both 
osteosarcoma, ever being reported (King et al, 1978; Shalev et al, 2007). As the 
disease progresses patients suffer increased mobility issues through increased 
stiffness of the knees, ankles and hips giving rise to a horse-riding stance. Other 
joints such as the wrists, shoulders and fingers are also affected. The most common 
causes of death in HGPS patients are heart attacks and strokes caused by 
atherosclerosis, at a mean age of 13.5 years (Hennekam, 2006).   
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1.1.1 Search for a gene 
 
The gene responsible for 80% of cases of HGPS was identified simultaneously by 
two groups in 2003. Eriksson et al, 2003 identified two cases of uniparental 
isodisomy of chromosome 1q in HGPS patients. This concurred with a previous 
report which had found a balanced inverted insertion involving chromosome 1 
resulting in loss of heterozygosity (Brown, 1992). Microsatellite genotyping 
identified a 5Mbp region comprising of 80 genes in which the HGPS gene must 
locate (Eriksson et al, 2003). One of the genes within that region was the LMNA 
gene. Direct sequencing of 23 patients identified the G608G mutation in exon 11 of 
the LMNA gene (Eriksson et al, 2003). De Sandre-Giovannoli et al, 2003 also 
identified the G608G mutation (c.1824C>T) in the LMNA gene by comparing HGPS 
to the phenotypically similar Mandibulo-acral dysplasia which is caused by a 
mutation in the LMNA gene. Both papers concluded that G608G is a de novo 
mutation which causes activation of a cryptic splice site (Eriksson et al, 2003; De 
Sandre-Giovannoli et al, 2003). Eriksson et al showed western blot evidence of the 
production of a 50 amino acid truncated protein named progerin which has a 
dominant negative effect on cell function. Patients with the G608G mutation have all 
of the characteristics described above and are termed as having classic HGPS. A 
clinical review of three patients identified a uniform phenotype arising from the 
G608G mutation (Mazereeuw-Hautier et al, 2007). Classic HGPS can also arise 
from a mutation at the same nucleotide as the G608G leading to the conservative 
substitution of glycine to serine G608S. The G608S mutation was found in 1 out of 
20 cases of classic HGPS patients and despite the amino acid substitution it caused 
activation of the cryptic splice site and progerin production in the same way as the 
G608G mutation (Eriksson et al, 2003). Approximately 20% of all patients do not 
have the G608G mutation and are thus subject to a wider degree of severity of the 
condition (Eriksson et al, 2003). These patients are described as having “Atypical 
Progeria” for which several genes have already been implicated (Rodriguez and 
Eriksson, 2010). 
 
 
 
  Page: 21 
 
1.1.2 Laminopathies 
 
As the majority of cases of HGPS are caused by a mutation to the LMNA gene, 
HGPS joins a group of 9 other disease caused by mutations to LMNA called primary 
laminopathies. There have been over 450 different mutations reported in the LMNA 
gene which give rise to different rare diseases (Torvaldson et al, 2015). A similar 
group of disorders, called secondary laminopathies, are caused by mutations in genes 
LMNB1 and LMNB2, coding for B-type lamins, ZMPSTE24 encoding a prelamin A 
processing protein and genes encoding lamin-binding proteins (EMD, TMPO, LBR 
and LEMD3). Laminopathies can be divided into five subcategories; muscular 
dystrophies, neuropathies, lipodystrophies, segmental progeroid syndromes and 
overlapping disorders (McKenna et al, 2013). Figure 1.1 shows a diagram of the 
LMNA gene highlighting common mutations and their associated disease. 
 
Figure 1.1 LMNA Mutations 
Image representing commonly mutated sites within the LMNA gene and the disease 
with which it is associated. CDMA1 - dilated cardiomyopathy type 1, AWS - 
atypical Werner’s syndrome, EDMD Emery-Dreifuss muscular dystrophy, CMT2B1 
- Charcot-Marie-Tooth disorder type 2B1, LGMD1B - Limb girdle muscular 
dystrophy type 1B, FPLD - familial partial lipodystrophy Dunnigan type 2, MAD 
mandibuloacral dysplasia, HGPS - Hutchinson-Gilford Progeria Syndrome and RD -
restrictive dermopathy, MLF - Malouf Syndrome, MDC - Muscular dystrophy, 
Congenital. Image taken from McKenna et al, 2013. 
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A second premature ageing disease associated with the LMNA gene is atypical 
Werner’s syndrome (McKenna et al, 2013). Werner’s syndrome is typically caused 
by mutations in the WRN protein, a RecQ helicase family member involved in DNA 
repair (Yu et al, 1996).  Figure 1.1 shows the R133L mutation in exon 2 of the 
LMNA gene. A further three separate mutations within the LMNA gene have also 
been found to cause atypical Werner’s syndrome (Chen et al, 2003; Doh et al, 2009). 
Like atypical HGPS, atypical Werner’s syndrome has similar clinical findings to 
classic Werner’s syndrome including premature aging starting at around 20 years of 
age, greying hair, scleroderma of the skin, cataracts, atherosclerosis and early onset 
insulin resistant diabetes. Werner’s syndrome is often referred to as adult progeria 
because of its likeness to HGPS apart from the age of onset. The median age of death 
is 54 with most resulting from myocardial infarction or cancer (Hisama et al, 2011; 
Hisama et al, 2012).  
 
Two other laminopathies with similarities to HGPS are restrictive dermopathy (RD) 
and mandibuloacral dysplasia (MAD). RD is characterised by an in utero growth 
failure, pulmonary hypoplasia and tight skin. RD is fatal shortly after birth, making it 
a more sever disease than HGPS (Smigiel et al, 2010; Mok et al, 1990). MAD has a 
less severe phenotype than HGPS with characteristics that include short stature, 
lipodystrophy, alopecia and insulin resistance (Garavelli et al, 2009; Zirn et al, 
2008). An additional LMNA mutation c.1620G>A (p.M540I), not shown in figure 
1.1, has recently been identified in a foetus from a consanguineous marriage, using 
in silico modelling this homozygous mutation is thought to affect protein structure 
(Yassaae et al, 2016). 
 
1.2 Lamin Proteins  
 
The LMNA gene encodes both lamin A and lamin C, which are the main A type 
lamin proteins found in human cells. Both proteins are produced from the same gene 
by the process of alternative splicing (See figure 1.2). Lamin C is comprised of only 
the first 10 exons of the LMNA gene, whereas lamin A is made up of 12 exons 
(Dittmer and Misteli, 2011). The classic HGPS c. 1824C>T mutation results in the 
activation of a cryptic splice donor site, which results in loss of 50 amino acids from 
  Page: 23 
 
exon 11 (Eriksson et al, 2003; De Sandre-Giovannoli et al, 2003). As the HGPS 
mutation occurs in exon 11, lamin C production is unaffected, whereas a lamin A 
variant progerin is produced (Figure 1.2). This reduces the cellular level of wildtype 
lamin A; however, it is the dominant effects of progerin expression that are believed 
to cause the disease (Reddel and Weiss, 2004). Other A type lamins also encoded by 
the LMNA gene are A∆10, which is found only in carcinomas and lamin C2 which is 
specific to male germline cells (Dittmer and Misteli, 2011). 
 
 
 
Figure 1.2 LMNA Alternative Splicing 
Diagram A shows the two normal proteins produced from the LMNA gene, lamin A 
and lamin C and the mutant protein progerin produced in classic HGPS patients. B 
demonstrates the activation of the cryptic splice donor site in exon 11 in classic 
HGPS patients resulting in the loss of last 150 nuclotides of exon 11. B also 
demonstrates the similarity in sequences between the classic c.1824C>T  mutation 
and the consensus sequence for a splice donor site.  
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All lamin proteins are type V intermediate filament proteins which form a 10 nm 
thick filamentous regular meshwork under the inner nuclear membrane, making 
them a component of the nuclear envelope (Aebi et al, 1986). Lamin proteins are 
comprised of a central helical rod domain that forms parallel dimers giving a coiled 
coil conformation (Dechat et al, 2010). The lamin dimer structure also includes two 
globular carboxy terminal domains. Dimer formation in these proteins is the first 
step in polymerisation and the smallest subunit of lamins, as lamins are not believed 
to exist as monomers (Dechat et al, 2010). Figure 1.3 summarises lamin 
polymerisation to form filaments.  
 
 
 
Figure 1.3 Schematic Model of Lamin Polymers 
Lamin dimers form from monomers that associate in a parallel, head-to-head 
manner, forming a coiled coil though the central α-helical domain. Lamin polymers 
then assemble by association of dimers in a polar head-to-tail manner through a 
staggered 2 to 4 nm overlap of the highly conserved amino- and carboxy-terminal 
rod domain ends. Protofilaments are finally produced through anti-parallel 
association of two lamin polymers. Between three and four protofilaments associate 
laterally to form an intermediate filament about 10 nm in diameter. Image and legend 
taken in its entirety from Dittmer and Misteli, 2011.  
 
B-type lamins are a second subgroup of lamin proteins with lamin B1 being encoded 
by the LMNB1 gene and lamin B2 and B3 are encoded by LMNB2, again through 
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alternative splicing (Dittmer and Misteli, 2011). Lamin B1 and B2 are expressed at 
all developmental stages, are believed to be essential for viability and until recently 
had no known disease associations (Dittmer and Misteli, 2011). Lamin B3 is a B-
type lamin variant specific to germline cells (Furukawa et al, 1993). Experiments in 
yeast have shown the ability for A and B type lamins to form heterodimers, however 
it is not known if these arrangement occur naturally in vivo (Ye and Worman, 1995; 
Georgatos et al, 1988). Dimer subunits form fibres in a head to tail arrangement with 
an essential overlapping region. In Vitro heterodimers have been used to produce 
mixed polymers, however, it is unclear if this occurs in Vivo or if separate A and B 
type lamin polmers form. The inability to produce 10 nm long fibres in vitro has 
hindered analysis of this matter (Dittmer and Misteli, 2011).  
 
1.2.1 Post-Translational Modifications 
 
Lamin proteins are subject to post-translational modifications and until processed 
exist as prelamin proteins. Post-translational modifications occur for lamin A, B1 
and B2, which all contain a C-terminal CaaX motif. A CaaX motif is made up of a 
Cysteine residue followed by two aliphatic amino acids and a variable amino acid.  
CaaX motifs undergo a process of farnesylation, which is the addition of a 15 carbon 
molecule produced from the isoprenyl pathway, to the cysteine residue (See figure 
1.4). The addition of this molecule is believed to anchor proteins to membrane, in 
this case the inner nuclear membrane. B-type lamins retain their farnesyl group and 
are permanently anchored to the nuclear membrane. During mitosis these proteins 
stay associated with the membrane in vesicles. Lamin A, however, is further 
processed by the endoproteolytic cleavage of the terminal 18 amino acids by 
ZMPSTE24, removing the farnesylated protein. Lamin A localises to the nuclear 
membrane but is not anchored and during mitosis is found in a soluble state diffused 
throughout the cytoplasm. As lamin C does not contain a CaaX motif it is not 
farnesylated, however, it does associate with the nuclear membrane but shows a 
similar pattern to lamin A behaviour during mitosis. The mutant lamin A protein, 
progerin, also contains a CaaX motif and is thus farnesylated. The 50 amino acid 
region deleted in progerin contains the recognition site for the protease ZMPSTE24 
resulting in the inability to remove the farnesyl group from the protein. This results 
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in the anchoring of progerin to the inner nuclear membrane (Dittmer and Misteli, 
2011; Dechat et al, 2008; Cau et al, 2014).  
 
Figure 1.4 Post-Translational Modifications 
Diagram depicting the post-translational modifications to lamin A, C, progerin and B 
type lamins.  
 
1.2.2 Nuclear Entry of Lamin Proteins 
 
The farnesylation of the lamin proteins has been proposed as a method to enable 
nuclear entry as membrane associated proteins. Conversely the lamin proteins also 
contain an NLS sequence which would allow for nuclear uptake through the nuclear 
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pores (Dittmer and Misteli, 2011). For lamins to enter the nucleus as membrane 
associated proteins farnesylation would have to occur within the cytoplasm. In 
support of this farnesylation of other proteins has been shown to occur at the 
endoplasmic reticulum (Winter-Vann and Casey, 2005). This theory suggests that 
after farnesylation lamins move around the endoplasmic reticulum and enter the 
inner nuclear membrane around pore complexes. The final cleavage to free lamin A 
from the membrane would then take place in the nucleus. The second theory 
suggests that lamins are imported into the nucleus using the NLS where they then 
become farnesylated and lamin A is then cleaved freeing it from the membrane. The 
identification of ZMPSTE24s dual location within the nucleus and the ER offers 
support to the theory of post translational modifications occurring at the ER as this 
theory requires the initial cleavage prior to farneslyation to occur at the ER and then 
the second cleavage event to take place in the nucleus (Barrowman et al, 2008). 
Conversely it could be argued that ZMPSTE24s localisation to the ER is to cleave 
other proteins and that its localisation to the nucleus shows that the whole process 
can be conducted at the INM. Evidence from studies microinjecting prelamin A into 
cells shows that nuclear uptake occurs quicker than the appearance of mature lamin 
A, but as lamin A is not mature until cleaved, these experiments fail to distinguish 
between the theories (Goldman et al, 1992). The most recent evidence comes from 
Knock out experiments of the NLS in prelamin A and progerin, which result in 
protein accumulation at the ER. With time lamin A lacking an NLS appears in a 
soluble state in the cytoplasm. This demonstrates farnesylation and ZMPSTE24 
cleavage occurring at the endoplasmic reticulum although does support previous 
findings that an NLS is required for nuclear uptake of lamin A and progerin (Wu et 
al, 2014). This does lead to the larger question; is farnesylation essential for the 
formation of a nuclear lamina, despite not being a method for nuclear uptake?  
 
1.2.3 Nuclear Envelope 
 
The nuclear envelope functions to separate the nucleoplasm from the cytoplasm by 
surrounding nuclear components in a double membrane layer (Cau et al, 2014). The 
nuclear envelope accommodates nuclear pore complexes which allow nuclear uptake 
of proteins which contain a nuclear localisation sequence (Grossman et al, 2012). 
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The outer nuclear membrane is continuous with the ER again facilitating protein 
uptake (Cau et al, 2014).  
The inner nuclear membrane forms attachments with the nuclear lamina. The nuclear 
lamina, comprised of both A and B type lamin proteins, forms a fibrillar meshwork 
under the inner nuclear membrane. One function of the nuclear lamina is to offer 
structural integrity to the nucleus and protect it from strain (Gruenbaum et al, 2005). 
The inner nuclear membrane is comprised of approximately 80 transmembrane 
proteins, the best characterised of these are the lamin binding proteins, because of 
their involvement in different diseases (Cau et al, 2014). These include the LEM 
domain proteins; LAP2, Emerin and MAN1, as well as SUN1 and SUN2 (LINC 
Complex proteins) and Lamin B Receptor (LBR) (Vlcek & Foisner, 2007). LAP2β 
binding is specific to B type lamins, whereas the splice alternative LAP2α, interacts 
with A type lamins.  
 
B-type lamins remain anchored to the nuclear membrane, whereas lamin A is also 
believed to form filaments in the nucleoplasm (Bridger et al, 1993). Interactions 
between LAP2α and lamin A are believed to take place in the nucleoplasm as LAP2α 
is not membrane associated (Dechat et al, 2000). LAP2α binding has been proposed 
as a mechanism to tether lamin A at intranuclear sites, as well as facilitate 
interactions with chromatin and transcription factors (Markiewicz et al, 2002). BAF, 
a transcription regulator, has been shown to bind directly to homodomain 
transcription activators as well as DNA and lamin proteins (Zheng et al, 2000; 
Mansharamani et al, 2005). Lamin A is also known to bind pRB, a tumour 
suppressing transcription factor that regulates apoptosis (Makiewicz et al, 2002). 
Emerin binds lamin A, BAF and chromatin and is thought to have a role in bringing 
lamin A to the nuclear membrane (Skakaki et al, 2001; Goldman et al, 2002). Lamin 
proteins can also bind DNA and histone proteins directly, suggesting a role in 
nuclear organisation (Zastrow et al, 2004; Bridger et al, 2007). A recent study 
identified 695 genes associated with lamin A of which a majority were 
transcriptionally silent. Loss of lamin A lead to the relocalisation of these genes to 
the nuclear periphery however, this did not cause their activation (Kuben et al, 
2012). Links between the lamina and the cytoskeleton are achieved through Nesprin 
and SUN proteins (Starr et al, 2010), implying a role for the lamina in effecting 
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changes based on external stimuli (Gruenbaum et al, 2005). Figure 1.5 shows the 
organisation of the nuclear envelope. 
 
 
 
Figure 1.5 Nuclear Encelope 
Diagram representing the components of the nuclear envelope, including the nuclear 
lamina and lamin associated proteins. Also shows two different routes of entry for a 
protein into the nucleus (NLS or Farnesylated). Image modified from Goldman et al, 
2002. 
 
 
The attachments made by lamin A suggests that it is involved in maintaining higher-
order chromatin organisation including the anchoring of heterochromain to the 
nuclear periphery, regulation of gene expression and providing structural integrity to 
the nucleus. The mutant protein progerin causes much disruption to all three of these 
functions. 
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1.3 Progerin 
 
1.3.1 Nuclear Structure 
 
The expression of progerin in HGPS patient cells has been shown to have dramatic 
effects on nuclear architecture, levels of DNA damage and cell longevity. Eriksson et 
al, 2003 were the first to identify nuclear shape abnormalities in fibroblasts from 
HGPS patients. These types of abnormalities are also characteristic of other 
laminopathies such as RD, MAD and atypical Werner’s syndrome (Rodriguez and 
Eriksson, 2010). One study using HGPS fibroblasts found that the number of nuclear 
lobulations increased as cells aged and the level of progerin increased (Goldman et 
al, 2004). Another study further categorised the nuclear shape abnormalities into 
blebs, herniations and micronuclei formations and also noted an increase in the 
number of these nuclei in aged HGPS fibroblasts compared to younger HGPS 
cultures. This study also identified a change in the distribution of the nuclear lamina 
from a rim staining pattern observed in young HGPS cells to a lesser rim stain with 
the appearance of nucleoplasmic speckles in aged HGPS cells (Bridger and Kill, 
2004). Electron microscopy has revealed the appearance of a thickened nuclear 
lamina in HGPS (Goldman et al, 2004), which is believed to result from progerin’s 
permanent anchoring to the nuclear lamina due to its farnesyl group (Dechat et al, 
2007).  
 
1.3.2 Nuclear architecture 
 
Observed changes to nuclear architecture in HGPS cells include the clustering of 
nuclear pore complexes (Goldman et al, 2004). In most late passage HGPS 
fibroblasts the nuclear pore complexes were found clustered together usually in 
association with clefts created by nuclear herniations, leading to stretches of the 
nuclear envelope depleted of pore complexes. A further change to nuclear 
architecture is the loss and redistribution of nucleolus associated proteins in the 
presence of progerin (Mehta et al, 2010). Other proteins found to be depleted in 
HGPS fibroblasts are lamin B and the LAP2 family of proteins. These proteins were 
depleted from their normal cellular location by up to six fold when compared to 
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normal control fibroblasts (Scaffidi and Misteli, 2005). LAP2α – telomere 
association has also been found to be reduced in HGPS cells (Chojnowski et al, 
2015). 
 
1.3.3 Genome reorganization 
 
A further change to a nuclear envelope associated structure is the loss of peripheral 
heterochromatin in late passage HGPS fibroblasts (Goldman et al, 2004). The 
protein which acts as an adaptor between lamin A and heterochromatin, HP1α, was 
found at a twofold lower concentration in HGPS fibroblast when compared to 
normal controls (Scaffidi and Misteli, 2005). This down regulation was associated 
with loss of the heterochomatin marker Tri-Me-H3K9. Changes to heterochromatin 
structure have been shown to predate the appearance of abnormally shaped nuclei 
during disease progression (Shumaker et al, 2006). Other changes to 
heterochromatin include the loss of H3K27me3, the marker of heterochromatin 
found on inactivated X chromosomes in female cells and the down regulation of 
EZH2 the methyltransferase responsible for this methylation (Shumaker et al, 2006). 
The level of genome reorganisation in the presence of progerin is not limited to 
heterochromatin as one study showed alterations in the radial position of 
chromosome territories in cells from HGPS patients (Meaburn et al, 2007). The 
redistribution of chromosomes 13 and 18 to a nuclear interior position resembles the 
chromosome organisation of non-proliferating control cells (Mehta et al, 2007; 
Mehta et al, 2010; Mehta et al, 2011).  
 
Global changes in CpG methylation has also been seen in HGPS patients, when 
compared to normal controls, with changes to transcription factor MYB and NF-
kappaB associated pathways, providing evidence of epigenetic changes in disease 
onset (Heyn et al, 2013). 
 
1.3.4 Gene Expression 
 
A study using mouse epithelial fibroblasts (MEF) identified global changes in gene 
expression between control and HGPS models. This study identified lamina-
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associated genes for which expression is moderated by progerin (Kubben et al, 
2012).  
 
Changes in miRNA expression have also been observed in HGPS cells, with one 
study identifying overexpression of 3 autophagy inhibiting miRNAs, which appears 
to holt progerin degradation, exacerbating the phenotype (Roll, 2015). 
 
1.3.5 Proliferation 
 
HGPS fibroblasts have also been shown to have a shortened lifespan in culture. The 
growth of HGPS fibroblasts is characterised by hyperproliferation followed by an 
abnormally high level of apoptosis. Using the marker of cell proliferation Ki-67 
more than 90% of early passage HGPS fibroblasts were found to be proliferative, 
this is comparable to only approximately 60% of normal early passage fibroblasts. 
The level of apoptosis was found at more than a 100 folder higher level in early 
passage HGPS cells compared to normal fibroblasts and increase between 4 and 8 
fold through the lifespan (Bridger and Kill, 2004).   
 
One explanation for the reduced lifespan of HGPS cells is a stochastic loss of 
telomeres. HGPS fibroblasts have been shown to have shorter telomeres than age 
matched controls (Allsopp et al, 1992). A causative relationship between progerin 
and telomere shortening has been established as hematopoietic cell, which do not 
express LMNA, from HGPS patients were found to have telomere lengths within the 
normal range (Decker et al, 2009). Telomere shortening has been shown to activate 
DNA damage checkpoints, which result in cells exiting the cell cycle (Campisi et al, 
2001). As well as telomere shortening HGPS cells have also been found to have 
higher levels of DNA damage, which could also result in cells exiting the cell cycle. 
A mouse model of HGPS (Zmpste24-/-) revealed that HGPS gives rise to more 
chromosome aberrations and increased sensitivity to DNA damaging agents (Liu et 
al, 2005). This was determined using the double-strand break DNA damage marker 
γH2AX. A further study found an increase in the level of aneuploidy in HGPS 
patient fibroblasts (Mukherjee and Costello, 1998). Similarly it has been observed 
that HGPS fibroblasts have constitutively active DNA damage checkpoints, which 
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could lead to early replication arrest (Liu et al, 2006). This may in part be due to the 
interactions between lamin A and the tumour suppressor pRB (Ozaki et al, 1994). 
Entry into S phase is compromised in HGPS fibroblasts, suggesting that mutant 
lamin A proteins may promote cell senescence by enhancing the activity of pRB 
(Chen et al, 2003). Also it has been demonstrated that prelamin A accumulation in 
health endothelial cells results in premature senescence (Bonello-Palot et al, 2014).  
 
1.3.6 Lamina Dynamics 
 
Using time-lapse analysis the nuclear lamina has been shown to demonstrate 
dynamic movement, which includes folding and indenting of large areas (Broers et 
al, 1999). Through Fluorescence recovery after photobleaching (FRAP), the proteins 
of the nuclear lamina were determined to be highly stable, with a low turn-over 
(Broers et al, 1999).  
 
During mitosis progerin was found to co-localise with lamin B and emerin in 
membrane aggregates. Mislocalisation of progerin during mitosis has been shown to 
reduce progerins motility and is linked to an increased number of lagging 
chromosomes and a longer cell cycle (Cao et al, 2007; Dechat et al, 2007).  
 
1.3.7 Cell Motility, Nuclear Rigidity and Mechanical Strength 
 
HGPS fibroblasts have also been shown to have reduced cell motility and 
mechanical strength as well as an increased sensitivity to heat stress (Verstraeten et 
al, 2008; Paradisi et al, 2005). Cell motility was assessed using a wound healing 
assay and it was concluded that HGPS fibroblasts had significantly impaired cell 
migration resulting in a decreased ability for wound closure despite having the 
ability to proliferate (Verstraeten et al, 2008). Similarly it has been shown that 
nuclear envelope dysfunction in older tissue leads to stronger attachments and 
abnormal movement (Mellard et al, 2011). 
 
Late passage HGPS fibroblasts were found to have increased nuclear stiffness when 
compared to early passage HGPS cells and all ages of normal fibroblasts 
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(Verstraeten et al, 2008). In HGPS cells a combination of a stiffened nucleoskeleton 
and softened nuclear interior leads to mechanical irregularities and dysfunction of 
mechanoresponsive tissues in HGPS patients. The sensitivity to mechanical strain 
was, however, found in both young and aged HGPS fibroblasts and resulted in an 
increased level of apoptosis (Verstraeten et al, 2008). As vascular tissue is under 
intense mechanical strain this may explain the prevalence of heart attacks and strokes 
in these patients. The inability to attenuate wound healing can promote plaque 
formation, also increasing the risk of heart attacks and strokes.  
 
HGPS cells were also found to have swollen and fragmented mitochondria and a 
reduction in mitochondrial mobility (Xiong et al, 2016). A downregulation of 
mitochondrial phosphorylation proteins and mitochondrial dysfunction (Rivera‐
Torres et al, 2013; Villa‐Bellosta et al, 2013) along with elevated levels of ROS has 
also been observed (Viteri et al, 2010; Lattanzi et al, 2012). 
 
1.3.8 Exclusion of Progerin 
 
The exclusion of progerin from HGPS cells has been achieved using 
oligonucleotides that target the cryptic splice site, resulting in only wild type 
transcripts (Scaffidi and Misteli, 2005). In these cells a reversal of the progeria 
phenotype was observed, which included restoration of nuclear shape and 
heterochromatin location, rescue of the distribution of lamin associated proteins and 
proper expression of previously misregulated genes (Scaffidi and Misteli, 2005). 
Interestingly, an increase in the nuclear level of lamin A had no effect on this 
phenotype, suggesting that the effects of progerin cannot simply be diluted out 
(Scaffidi and Misteli, 2005). One study identified that progeria cell characteristics 
occur in a progerin dose dependent manner and only become detrimental when a 
threshold level is reached (Chojnowski et al, 2015). This is of particular interest as 
one potential treatment for progeria would involve promoting the production of 
lamin C thus reducing the levels of both progerin and lamin A. This is a viable plan 
as lamin A has been shown not to be essential for viability (Harborth et al, 2001), 
unlike the B type lamins (Vergnes et al, 2004).  
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1.4 Current Treatments 
 
Current treatments for HGPS include statins, bisphosphonates and 
farnesyltransferase inhibitors. All three of these treatments target the isoprenylation 
pathway, which is responsible for the farneslyation of lamin A and progerin. This 
event is believed to permanently anchor progerin to the inner nuclear membrane, 
causing disease progression (Capell et al, 2005), hence its utilization as a target for 
therapy (Capell and Collins, 2006). Figure 1.6 displays the isoprenylation pathway 
and the areas targeted by each therapy.  
 
Figure 1.6 Isoprenylation Mevalonate Pathway 
Diagram showing the isoprenylation pathway and the stages target by current 
treatments for HGPS. Image taken from Capell and Collins, 2006. 
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1.4.1 Clinical Trials 
 
To date there have been four clinical trials for HGPS patients, the first of which 
began in 2007, just four years after the LMNA gene mutation was discovered. 
Funded by the Progeria Research Foundation in Boston, this clinical trial included 25 
classic HGPS patients and used the FTI Lonafarnib (Gordon et al, 2012). FTIs are 
small molecules which reversibly bind farnesyltransferase, inhibiting its ability to 
produce farnesylated proteins (Figure 1.6)(Capell and Collins, 2006). Pre-
commencement of the clinical trial FTIs were shown to improve survival, body 
weight and bone integrity in murine models of HGPS (Yang et al, 2006: Fong et al, 
2006) as well as improve nuclear shape abnormalities in cultured HGPS fibroblasts 
(Capell et al, 2005; Glynn and Glover, 2005; Toth et al, 2005; Mallanpalli et al, 
2005). Since the commencement of the clinical trial FTIs have also been shown to 
restore chromosome territory positions to that of normal proliferating cells as well as 
increase wound healing responses and reduce nuclear stiffness (Mehta et al, 2011; 
Valerie et al, 2008). The results of the Lonafarnib clinical trial were mixed for 
weight gain, a previously predicted marker of successful treatment (Gordon et al, 
2007), with a great degree of variation found between patients. The trial did suggest 
improvements in cardiovascular health, mild changes in hearing ability and reported 
no toxicity to the treatment (Gordon et al, 2012). This trial has been criticised for not 
unequivocally determining the action of lonafarnib on lamin A processing in HGPS 
patients, despite this requiring a skin biopsy (Couzin-Frankel, 2012). The mixed 
results found in this clinical trial may result from geranylgeranylation occurring as a 
result of inhibited farnesylation (see Figure 1.6). In support of this, one mouse study 
identified prenylated prelamin A and progerin and geranylgeranyltransferase activity 
despite the addition of FTIs (Varela et al, 2008). 
 
The second clinical trial began in 2008 in France using a combination of statins 
(pravastatin) and bisphosphonates (Zoledronic Acid). This trial is currently 
underway, therefore, no data has been published, however, a talk by Prof Nico Levy 
at the progeria research day at Brunel University in 2011 suggested that patients are 
experiencing no toxicity and parameters such as weight gain, bone density and 
cardiovascular health are being examined (Bridger et al, 2011). The use of these two 
drugs in combination was evaluated in a mouse model study which concluded these 
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drugs effectively inhibit both farnesylation and geranylgeranylation of prelamin A 
(Varela et al, 2008). They also observed increased longevity in a progeria mouse 
model as well as improvements in weight gain and growth. Similarly improvements 
in the level of DNA damage and nuclear shape abnormalities have also been reported 
in response to these drugs (Bridger et al, 2011).  
 
Finally the third clinical trial, a continuation of the original trial by the Boston group, 
began in 2009, this time combining all three drugs, Lonafarnib, pravastatin and 
Zoledronic Acid. In 2014 it was determined that Lonafarnib treatment extends mean 
survival by 1.6 years (Gordan et al, 2014). This has, however, been subject to 
criticism, based on lack of a matched cohort and placebo-controlled group (Servick 
et al, 2014). There is now mixed evidence about the significance of farnesylation of 
progerin in disease progression (Smallwood & Shackleton, 2010), with a mouse 
model expressing non-farnesylated progerin (LMNAnHG/+) showing a similar 
phenotype to mice expressing farnesylated progerin (LMNAHG/+) (Yang et al, 2008). 
Subsequently, a further non-farnesylated progerin mouse model (LMNAcsmHG/+) was 
created, where the carboxyl-terminal CSIM motif was changed to CSM, removing 
the site for farnesylation. These mice did not develop a progeria like disease, having 
normal body weight and life expectance, leading to the hypothesis that the 
appearance of disease characteristics in the presence of non-farnesylated progerin is 
dependent upon the carboxyl-terminal mutation used to eliminate protein prenylation 
(Yang et al, 2011). This brings into question the ultimate efficacy of FTI treatment 
for HGPS. 
 
1.4.2 Rapamaycin 
 
A further drug for the treatment of HGPS is Rapamycin, the so called “Wonder 
Drug”.  Rapamaycin is a macrolide antibiotic that has been shown to extend life 
expectancy in yeast (Powers et al, 2006), invertebrates (Hansen et al, 2007, Bejdov 
et al, 2010) and mammals (Harrison et al, 2009, Miller et al, 2011). Rapamycin 
targets the mTOR pathway, which activates the process of autophagy; the recycling 
of unneeded proteins. One study using fibroblasts from HGPS patients found that 
treatment with rapamycin restores nuclear structural integrity, heterochromatin 
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distribution and levels of DNA damage (Cao et al, 2011). A second study identified 
improvements in BAF and LAP2α distribution patterns (Cenni et al, 2011). Pre-
lamin A and progerin protein have been shown to be degraded through autophagy in 
response to rapamycin (Graziotto et al, 2012), while lamin C protein levels were 
unaffected (Cenni et al, 2011). They also observed an increased life expectancy in 
these cultures in response to increased degradation of progerin. An increase in 
ZMPSTE24 expression was also observed in response to rapamycin treatment (Cenni 
et al, 2011). LMNA (-/-) mice also enhanced survival and improved cardiac and 
skeletal muscle function in response to rapamycin treatment (Ramos et al, 2012).  
 
Rapamycin is already used as an immunosuppressant and an anti-cancer drug and is 
now being proposed as a treatment for HGPS (Cao et al, 2011). There are mixed 
feelings about the suitability of Rapamycin as a treatment for HGPS, however, a 
phase I/II clinical trial using the rapamycin analogue Everolimus in combination 
with Lonafarnib is now being conducted by the Progeria Research Foundation in 
Boston (ClinicalTrials.gov Identifier: NCT02579044, 2015).  
 
1.4.3 Other Therapy Prospects 
 
Other proposed drug treatments are n-acetyl cysteine (NAC), methylene blue (MB), 
insulin like growth factor 1 (IGF-1) and Remodelin. NACs are ROS scavengers 
which have been shown to reduce the level of unrepaired DNA damage in HGPS 
fibroblasts and increase rates of population doublings. It has been proposed that ROS 
induced DNA damage contributes greatly to poor growth and therefore patients 
would benefit from a NAC therapy (Richards et al, 2011). Similarly treatment with 
the antioxidant methylene blue was shown to improve mitochondrial defects as well 
as improved nuclear structure, restored heterochromatin and correction of gene 
expression in HGPS cells (Xiong et al, 2016). Treatment with recombinant IGF-1 
was found to increase longevity in a mouse model of HGPS by increasing the 
previously down-regulated levels of IGF-1 and restoring somatotroph axis function 
(Marino et al, 2010). The small molecule Remodelin shows an improved nuclear 
shape and decreased markers of DNA damage in HGPS cells through microtubule 
reorganization (Larrieu et al, 2014). 
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1.5 Atypical Progeria 
 
Approximately 20% of cases of HGPS are not caused by the classic G608G or 
G608S mutations of the LMNA gene. Patients with progeria who do not have these 
mutations are described as having atypical progeria (APS). These patients are subject 
to more variation in the clinical phenotype; however, diagnosis is still based on the 
clinical appearance. Atypical progeria can arise from mutations of the LMNA gene at 
different sites to that which gives rise to classic cases. Currently there are more than 
11 other mutations of the LMNA gene known to give rise to atypical progeria, three 
of which result in the production of progerin (McKenna et al, 2013).  
 
An intronic variant IVS11+1G>A, found in one patient, was shown to increase the 
use of the cryptic splice site resulting in higher levels of progerin production than 
those observed in classic cases. The clinical presentation of this patient was more 
severe than that of classic patients with abnormalities of the skin first being 
examined at just 11 weeks of age. This patient experienced rapid development of 
classic characteristics including joint stiffness, alopecia and micrognathia and 
subsequently died aged 3.5 years (Moulson et al, 2007). A second patient found to 
have a V607V mutation (c.1821G4A) also showed elevated use of the exon 11 
cryptic splice site, which resulted in an extremely severe phenotype that was only 
conducive to 26 days of life (Moulson et al, 2007). Due to the severe nature of this 
progeriod syndrome it may be classified as a Restrictive Dermopathy (McKenna et 
al, 2013). Analysis of fibroblasts from both these patients revealed abnormally 
shaped nuclei and treatment of these cells with FTIs suggested that the drug may 
have been an appropriate treatment for these patients (Moulson et al, 2007). 
 
 Not all atypical mutations in the LMNA gene lead to a more severe phenotype as one 
atypical patient lived until the age of 45, an age well beyond the average for classic 
patients (Fukuchi et al, 2004). Growth failure was not observed in this patient until 
approximately 12 years of age, total balding had occurred by age 20 and death 
resulted from a myocardial infarction. The progeria in this patient resulted from a 
T623S mutation which caused activation of a cryptic splice site, giving rise to a 35 
amino acid truncated protein (Fukuchi et al, 2004). The 35 amino acids deleted from 
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this protein are encompassed within the 50 amino acids deleted in progerin, and like 
progerin this mutant protein retains its CaaX motif but has no endoproteolytic 
cleavage site (Fukuchi et al, 2004). It remains unclear why deletion of 35 amino 
acids gives rise to less servere phenotype than progerin.  
 
A further mutation to the tail domain of lamin A is the R644C which alters the 
endoproteolitic cleaveage site of lamin A (Csoka et al, 2004). One study suggested 
that the use of FTIs for this patient would increase the level of nucleoplasmic 
unfarnesylated lamin A and reduce the level of abnormally shaped nuclei observed 
(Toth et al, 2005). This patient had many classic progeria attributes and died aged 20 
years (Csoka et al, 2004), this disorder has subsequently been reclassified as a 
CDM1A (McKenna et al, 2013). 
 
1.5.1 Non-Progerin producing LMNA mutations 
 
Not all mutations in the LMNA gene give rise to progerin production, some 
mutations are found in the early exons and thus affect the rod domains of both lamin 
A and lamin C. For example one patient has been described as having atypical 
progeria symptoms such as scleroderma of the skin, growth failure and osteolytic 
lesions in combination with symptoms of early onset myopathy (Kirschner et al, 
2005). This patient was found to have a S143F mutation of the LMNA gene, which is 
found in a region close to mutations causing other myopathies (Kirschner et al, 
2005). Similarly an E145K mutation, which results in atypical progeria, has also 
been identified (Eriksson et al, 2003).  
 
A late onset APS was found to be caused by a mutation in LMNA gene at position 
c.899A>G (D300G), which caused prominent cutaneous and cardiovascular 
manifestations suggesting this disorder be named LMNA-associated cardiocutaneous 
progeria syndrome (LCPS). This patient also showed a predisposition for cancers in 
particular basal and squamous cell carcinomas (Kane et al, 2013), a phenotype 
distinct from that of classic HGPS. 
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1.5.2 Recessive progeria  
 
All the cases described above result from dominant heterozygous mutations which 
result in disease, however, not all cases of atypical progeria are dominant. One 
Indian family is described as having 5 out of 7 children diagnosed with atypical 
progeria (Plasilova et al, 2004). The cause of death of one other child remains 
unclear and one sibling appears healthy. These children are the progeny of a 
consanguineous marriage which resulted in each affected child being homozygous 
for the mutation K542N of the LMNA gene. This mutation affects both lamin A and 
lamin C and due to its recessive nature is believed not to interfere with lamin 
splicing but disrupt lamin A binding. The clinical manifestation of this inherited 
form of HGPS is similar to that of a classic HGPS patient (Plasilova et al, 2004).  
 
1.5.3 ZMPSTE24 Mutation 
 
As well as alternative mutations in the LMNA gene atypical progeria has also been 
found to arise from mutations in other genes. ZMPSTE24 is the protein responsible 
for the proteolytic cleavage of the farnesylated terminus of the lamin A protein, a 
step that cannot be performed on progerin. Mutations in ZMPSTE24 have also been 
found to give rise to atypical progeria; one patient was found to be a compound 
heterozygote for ZMPSTE24 mutations (c.1085_1086insT and c.794A-G) which 
resulted in a build-up of prelamin A and abnormally shaped nuclei (Shackleton et al, 
2005). The clinical manifestation was observed in this patient and encompassed 
similarities to both MAD and RD. The patient had difficulties in gaining weight, 
impeded movement of the hips, knees and ankles, reduced subcutaneous fat and 
osteolysis. The patient died from an infection caused by cracks in the tight sclerotic 
skin at age 2.9 years (Shackleton et al, 2005).  
 
1.5.4 BANF1 Mutation 
 
A further mutation found to result in atypical progeria (Nestor-Guillermo Progeria 
Syndrome NGPS) occurs in the BANF1 gene, which gives rise to the homodimer 
BAF a binding partner of lamin A (Puente et al, 2011). This mutation was identified 
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in two unrelated relatively long lived atypical patients, one of which resulted from a 
consanguineous marriage. Both patients were found to be homozygous for the A12T 
mutation in the BANF1 gene and had heterozygous unaffected parents and siblings. 
This mutation has been shown to deplete cellular levels of BAF, due to decreased 
protein stability, which resulted in abnormally shaped nuclei and mislocalisation of 
emerin another lamin A binding partner (Puente et al, 2011). The identification of a 
lamin binding partner as a cause of HGPS indicates that other such proteins may also 
have a role in this disease.  
 
The identification of more genes responsible for atypical forms of this disease would 
increase our understanding especially if they are lamin binding partners as this may 
indicate which of lamin A’s functions are related to premature ageing.   
 
1.6 Normal Ageing 
 
The resemblance between the pathology of HGPS and normal human ageing has led 
to much interest in studying the disease as findings may also be applicable to the 
normal ageing process. Aside from the characteristic resemblance (Merideth et al, 
2008), other evidence is gathering for the involvement of the nuclear lamina and 
progerin in normal ageing. The first evidence comes from two invertebrate species, 
C. elegans and D.melanogaster, which both have simpler nuclear lamina structures 
encoded by 1 and 2 genes respectively (Rodriguez and Eriksson, 2010).  One study 
using C.elegans found increasing numbers of abnormally shaped nuclei and loss of 
heterochromatin from the nuclear periphery during normal ageing in all cell types 
except neurons (Haithcock et al, 2005).  Furthermore, RNAi knockdown of CE-
LAMIN caused a significant reduction in lifespan of the worms, but no nuclear 
morphological abnormalities (Haithcock et al, 2005). This shows a link between the 
nuclear lamina, HGPS cell characteristics and normal ageing in multicelluar 
organisms. Similarly the size and number of abnormally shaped nuclei was also 
found to increase with age in drosophila melanogaster (Brandt et al, 2008). The 
development of a drosophila model expressing lamin A and progerin also showed 
characteristic HGPS nuclear changes (Beard et al, 2008). Another study expressed 
farneslyated forms of the endogenous lamins, KUGELKERN and LAMIN B and 
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observed an earlier decline in locomotor behaviour and a shortened lifespan (Brandt 
et al, 2008). Furthermore, expression of these farnesylated proteins in mammalian 
cells led to a similar cellular phenotype to that observed in the presence of progerin 
(Brandt et al, 2008).  
 
1.6.1 HGPS Cell Phenotype in Normal Human Ageing 
 
HGPS-like nuclear defects have also been observed in aged human samples. Scaffidi 
and Misteli, (2006) compared skin fibroblast cell lines from donors aged between 81 
to 96 and 3- 11 years for a number of HGPS characteristics. They observed a more 
rapid increase in the number of abnormally shaped nuclei taken from older donors 
when compared with younger donor nuclei. Cells from older donors were also found 
to have a significantly higher number of DNA damage foci compared with younger 
samples. Disruption of heterochromatin was also observed in cells from aged 
individuals, with decreased levels of staining for HP1α, H3K93Me and the LAP2 
proteins. Between 40 and 90% of cells from older donors showed a reduction in the 
level HP1α, whereas a reduction was observed in only 20-32% of cells from younger 
donors. The percentage of nuclei showing a reduction of these heterochromatin 
markers in aged individuals was similar to the levels observed in HGPS patients; 
however, in HGPS cells the level of reduction is much higher (Scaffidi and Misteli, 
2006). Analysis of 65 signalling pathways identified similarities between those 
active in HGPS patients samples and those from middle aged and old donors (Aliper 
et al, 2015). The observation of these characteristics in aged individuals shows the 
similarities between HGPS and normal ageing at a cellular level.  
 
1.6.2 Progerin Accumulation in Normal Human Ageing 
 
There is also mounting evidence for the involvement of progerin in normal human 
ageing. One study using human fibroblast cells from healthy individuals found 
evidence of use of the cryptic splice site shown to produce progerin in HGPS 
(Scaffidi and Misteli, 2006). This study did, however, fail to show an increase in use 
of this cryptic splice site and subsequent progerin production with age. The use of 
the HGPS cryptic splice site in normal cells was confirmed by a subsequent 
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publication which found that progerin is expressed at more than a 160 fold higher 
level in HGPS compared to age matched controls (Rodriguez et al, 2009). Another 
study also identified progerin in normal fibroblasts and concluded that progerin-
induced telomere dysfunction contributes to cellular senescence (Cao et al, 2011). 
 
A further in vitro study using human skin biopsies again found an increase in the 
level of the progerin protein, with age in dermal fibroblasts and terminally 
differentiated keratinocytes (McClintock et al, 2007). As this was found not to be 
caused by an increase in progerin transcripts it is thought to occur through progerin 
accumulation with age. In support of this, one study examining the cardiovascular 
pathology of ageing found progerin within coronary arteries of both normal and 
HGPS samples, although at a much higher level in HGPS. This study concluded that 
the level of progerin within coronary arteries of normal individuals increased on 
average by 3.34% per year between the ages of 1 month and 97 years (Olive et al, 
2010). Therefore, this study also suggests a gradual accumulation of progerin with 
age.  
 
1.6.3 Differences between HGPS and Normal Human Ageing 
 
Despite the increasing evidence suggesting the roles of the nuclear lamina and 
progerin in normal human ageing other groups remain sceptical suggesting that the 
disease mimics ageing but does not encompass all facets of it (NEJM 
Correspondence 29Th May 2008). That is certainly true with regards to the lack of 
cognitive decline in these patients and the low incidence of cancer, a well-known age 
associated disease. The lack of cognitive decline in HGPS patients may result from 
LMNA gene expression not being believed to be involved in brain development as it 
occurs at a late stage during mouse development (Rober et al, 1989). This idea is 
supported by the fact that no laminopathies result in cognitive neurodegenerative 
diseases (Capell and Collins, 2006). It has also been hypothesised that neural cells 
are protected from progerin accumulation in HGPS due to the expression of miR-9 
modifying progerin expression (Nissan et al, 2012).  
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Cancer is a disease caused by acquired mutations usually resulting from exposure to 
the environment. Despite the premature ageing phenotype of HGPS patients they 
have experienced far less exposure to their environment compared to their rate of 
ageing. Cells from these patients have also been shown to have a far greater affinity 
for apoptosis than normal cells and thus opting for this pathway may be cancer 
protective (Bridger and Kill, 2004). Interestingly ectopic expression of progerin in 
tumour cells led to multi-nucleation and proliferation arrest (Moiseeva et al, 2015).  
 
Ultimately these differences with normal ageing have led to HGPS being termed a 
segmental progeroid syndrome and it will remain as such unless a causative role of 
progerin in normal human ageing can be established (Rodriguez and Eriksson, 
2010). Although HGPS may not encompass all aspects of normal human ageing the 
outlined similarities do suggest that greater understanding of the pathology of human 
ageing could be achieved through studying HGPS.   
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1.7 Aims and Objectives 
 
The overall aim of this thesis was to investigate the effect of hTERT immortalisation 
on HGPS patient’s fibroblasts, to examine how they responded to immortalisation 
and assess their suitability for long-term studies of progeria, such as those for drug 
discovery or for novel disease causing gene identification.  
In order to achieve this aim, several objectives were pursued: 
 
1.     To identify if continued growth of HGPS fibroblasts in the presence of hTERT 
would result in a loss of the progeria cell phenotype, including nuclear abnormalities, 
reduced cell movement and increased DNA damage. The results are described in 
chapter 3. 
2.      To identify if the loss of progerin cell phenotype (chapter 3) in hTERT 
immortalised HGPS fibroblasts occurred through a reduction in the abundance of the 
mutant protein progerin, either through regulation at the expression level or at a 
protein level. The results are described in chapter 4. 
3.   To identify if a reduction in the abundance of progerin in hTERT immortalised 
HGPS fibroblasts (chapter 5) is caused by an increase in progerin degradation and to 
determine if this can be exploited for therapy using a novel E3 Ubiquitin Ligase 
Nanobody raised against A type Lamins.  The results are described in Chapter 5.  
4.      To identify new genes involved in HGPS, by identifying the causative mutation 
in a cell line derived from an atypical HGPS patient, utilising the growth potential 
and characteristics resulting from hTERT immortalisation. The results are described 
in Chapter 6.  
  
Hopefully, the outcome of this research will prove useful in the understanding of the 
biology of both classic and atypical HGPS and will aid in the future treatment of 
progeria patients, in particular through nanobody technology. 
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2 Materials and Methods 
 
2.1 Cell Culture 
 
2.1.1 Cell Lines 
 
All cell lines were cultured in Dulbecco’s modified eagle medium (DMEM) 
GlutaMAX TM (Gibco®) fortified with 15% Foetal Bovine Serum (FBS) and 5% 
Penicillin and Streptomycin. Cell lines were passaged twice weekly in 90mm Nunc 
flasks. A 0.25% trypsin (Gibco®) solution was used to remove cell adhesions to the 
dish. Cells were grown in a humid 37oC environment with constant CO2 at 5%. 
Primary cells were seeded at 2 X 105. Immortalised cell lines (hTERT) were set up at 
1 in 10 (TAG08466 and NB1T) 1 in 4 (TAG06297 Late) or 1 in 3 (TAG06297 
Early) dilutions, depending on growth potential. Table 1 lists all cell lines used in 
this study.  
 
Table 1 Control and HGPS Fibroblast Cell Lines 
Cell Line HGPS Patient (mutation) hTERT Immortalised 
NB1T  Control Yes (Dr Christopher Parris 
unpublished) 
TAG06297 Early Yes (G608G) (Eriksson et al, 2003) Yes (Wallis et al, 2004) 
TAG06297 Late Yes (G608G) (Eriksson et al, 2003) Yes (Wallis et al, 2004) 
TAG08466 
 
Yes (unknown-not G608G)   
(Professor Nico Levy unpublished 
communication) 
Yes (Wallis et al, 2004) 
AG08466 Yes (unknown-not G608G)   
(Professor Nico Levy unpublished 
communication) 
No (Coriell Institute) 
AG08468 Control (Mother of AG08466) No (Coriell Institute) 
AG08469 Control (Father of AG08466) No (Coriell Institute) 
AG08470 Control (Sibling of AG08466) No (Coriell Institute) 
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The control fibroblast cell line used in this study was established from a healthy 
new-born foreskin by Drs Fiona Bolland and Ian Kill, Brunel University London, in 
2005. The NB1 cell line was subsequently hTERT immortalised by Dr Christopher 
Parris, Brunel University London, establishing the NB1T cell line. 
 
The TAG06297 cell line was established through hTERT immortalisation of the 
primary HGPS cell line AG06297, by Professor Richard Faragher’s group at 
Brighton University (Wallis et al, 2004). The AG06297 cell line (Coriell Institute) 
was established in 1972 from a 46XY patient with the classic 2036C>T mutation in 
the LMNA gene. Progerin production in this patient has previously been confirmed 
by Western Blot analysis (Clements et al., in revision). This patient had all the 
classical progeria characteristics and died at age 14 of congestive heart failure. 
“TAG06297 Early” is derived from cells shortly after the establishment of the 
hTERT culture, whereas the “TAG06297 Late” cells are derived from cultures with 
more than two years continual growth. 
 
AG08466, is a primary fibroblast cell line, established in 1985 from an ante-mortem 
skin biopsy from a 46XX patient with “Atypical HGPS” (Coriell Institute). Patient 
was described as having some classic characteristics of HGPS such as loss of 
subcutaneous fat, osteoarthritis and venous prominence; however, the patient 
experienced no alopecia and developed some Marfan syndrome like characteristics 
(Coriell Institute). The underlying causative genetic mutation responsible for HGPS 
has yet to be established. Primary fibroblasts from the Mother (AG08468), Father 
(AG08469) and sibling (AG08470) of AG08466 were utilised (Coriell Institute). 
 
AG08466 cell line was hTERT immortalised, by Professor Richard Faragher’s group 
at Brighton University (Wallis et al, 2004) and subsequently renamed TAG08466 to 
indicate its immortalisation status. 
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2.1.2 Growth curves 
 
At each cell passage the number of population doublings achieved was calculated 
based on haemocytometer readings, using the equation Population doublings = 
3.32[log(number of cells harvested) – log(number of cells seeded)].  This was 
determined for each hTERT immortalised cell line over a 46 day period in culture. 
 
2.2 Cell Imaging 
 
2.2.1 Indirect Immunofluorescence 
 
Cultures were grown for 3-4 days on 0.1 mm thick glass coverslips. Cell were fixed 
using 3.74% formaldehyde and permeabilized using an ice cold 1:1 methanol: 
acetone solution. Blocking was achieved using a 0.1% FBS 1x phosphate buffered 
saline (PBS) Solution. Indirect immunofluorescence was performed by the sequential 
incubation of cells with a primary and secondary antibody in a moist chamber. 
Primary antibodies were raised against the protein of interest and secondary 
antibodies contained a fluorophores for visualisation. Table 2 summarises all 
antibodies used in this study. Coverslips were mounted on Snowcoat® slides using a 
Mowiol mountant containing the fluorescent DNA stain DAPI (4',6-Diamidino-2-
Phenylindole).  
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Table 2 Summary of Indirect Immunofluorescence Antibodies 
 
In most cases cells were visualised under the 40x or 100x objective, of a 
fluorescence Axioscope 2 (Zeiss) microscope. Images were taken using a 
ProgRes®C12 plus camera (Jenoptic) using the ProgRes Capture Pro 2.5 software. 
For transfection analysis slides were viewed using the 100X objective of the HF14 
Leica DM4000 microscope and images captured using the Leica DFC365 FX camera 
using Las AF software. 3D fluorescence microscopy was achieved by taking Z 
stacks using the Elipse Ti microscope (Nikon) and deconvolution using NIS-
Elements Advanced Research Software. Unless otherwise stated, a minimum of 250 
nuclei per coverslip were analysed when using indirect immunofluorescence and all 
staining was performed in triplicated.  
Protein Primary Antibody  
(Dilution) 
Secondary Antibody 
(Dilution) 
Ki-67 Anti-Ki-67 Rabbit monoclonal  
(Dako A0047) (1:30) 
anti-Rabbit TRITC (Dako 
R0156 Swine polyclonal) 
(1:25) 
Lamin A Anti-Lamin A mouse monoclonal 
(abcam® ab8980) (1:50) 
anti-Mouse Goat 
Polyclonal FITC (Sigma® 
F9006) (1:64) 
Lamin A/C NCL-LAM-A/C   
(NovocastraTM mouse monoclonal) 
(1:30) 
anti-Mouse Goat 
Polyclonal FITC (Sigma® 
F9006) (1:64) 
γH2AX Anti-phospho -H2A.X 
 (Upstate 07-164 (1:100) 
anti-Mouse Goat 
Polyclonal FITC (Sigma® 
F9006) (1:64) 
Progerin Anti-Progerin Mouse monoclonal  
(Enzo 13A4) (1:50) 
anti-Mouse Goat 
Polyclonal FITC (Sigma® 
F9006) (1:64) 
T7 Tag Anti-T7 Tag rabbit polyclonal  
(abcam ac117486) (1:200) 
anti-Rabbit TRITC (Dako 
R0156 Swine polyclonal) 
(1:25) 
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2.2.2 Computational shape analysis 
 
Slides were prepared as described in section 2.2.1, without the addition of primary or 
secondary antibodies, allowing for visualisation of DNA using DAPI mountant. 
Cells were visualised and imaged as described in section 2.2.1, using a 40x 
objective. Using the particle analysis tool on ImageJ 1.37c software a threshold level 
was set to incorporate all the nuclei in one image. The highlighted shapes were then 
analysed based on: area, perimeter, major and minor axis, circularity 
(4π(area/perimeter2) and aspect ratio (major axis/minor axis). A minimum of 650 
nuclei were examined per cell line.  
 
2.2.3 Live Imaging 
 
Semi-confluent dishes of cells were selected and put on the inverse mounted, 
Axiovert 200M (Zeiss) microscope. Cells were maintained at 37oC with 5% CO2 
using the incubator attachment and heated stage of the cell observer microscope. 
Phase contrast images were taken every 5 minutes for an 8 hour period. Images were 
opened in ImageJ 1.37c software and converted to a stack, which allowed fluid 
movement through all images, making a video. The manual tracking plugin was used 
to track the position of the nucleus of a specific cell at each time point, giving a list 
of XY coordinates for each frame. The hypotenuse was then calculated to give the 
distance moved between each frame. The sum of the entire hypotenuse for the 8 hour 
period was calculated to give the total distance moved by the cell. A minimum of 30 
cells were tracked per cell line.  
 
2.2.4 Metaphase preparations 
 
Metaphase preparations were created by incubating, approximately 70% confluent 
dishes per cell line, with 1µg of Colcemid (Gibco® 15210-040) in DMEM, for 30 
minutes. Cells were then harvested from the dish using 0.25% trypsin and pelleted 
by centrifugation at 1000rpm for 5 minutes. The pellets were re-suspended drop-wise 
with agitation in a 0.075M hypotonic solution to cause cell swelling. A series of 
pelleting and re-suspending steps, using 3:1 methanol: acetic acid, were used to fix 
the cells (protocol as described by Anderson, 2010). After the final re-suspension, 
  Page: 52 
 
cells were dropped from height onto Snowcoat® slides and incubated in a warm 
environment until dry.  
 
Slides were selected for analysis based on the mitotic index and lack of cytoplasm 
around chromosomes. Large rectangular glass coverslips were placed over the cells 
and secured with a DAPI containing Mowiol mountant. Images of metaphase spreads 
were captured using an Axioplan 2 automated microscope (Zeiss), using Metafer, the 
automated slide scanning and imaging platform. Images were captured using 
Metasystems camera using MSearch software. Up to eight slides were secured into 
the automated stage and the regions containing the cells were mapped out. The focus 
level was then set, before the software scanned the slide and captured images of 
chromosome spread. After the removal of any unusable images, such as unfocused or 
incomplete spreads, the number of chromosomes were counted for at least 100 
images for each cell line.  
 
2.2.5 Multiplex-FISH 
 
Multiplex-FISH was performed by Dr Rhona Anderson, Brunel University London, 
the method for which is discussed in “Multiplex fluorescence in situ hybridization 
(M-FISH)” (Anderson, 2010). M-FISH is a three-step process employed for studying 
complex interchromosomal rearrangements, by creating a 24-colour karyotype. Each 
homologous pair of chromosomes is uniquely labelled, by combining the limited 
numbers of spectrally distinct fluorophores. The superimposing of images, captured 
through different band-pass filters, by M-FISH software enable each chromosome to 
be identified based on its combination of fluorophores. Finally, analysis of these 
Karyotypes can be performed, enabling observation of any structural or numerical 
abnormalities. 
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2.3 Expression Analysis 
 
2.3.1 RT-PCR 
 
Confluent 90 mm dishes of cells were harvested using 0.25% trypsin (Gibco®) 
solution and pelleted. RNA was extracted using Nucleospin® RNA II 
(MACHEREY-NAGEL) extraction columns. The RNA concentrations were 
determined using the NanoDropTM spectrophotometer. 
 
For every 1µg of RNA, 100 ng concentration of d(N)6 primers (Invitrogen) were 
added and allowed to anneal through a 40 second incubation at 90oC (tetrard). The 
reverse transcription reaction was set up as described in table 3 and incubated at 
50OC for 1 hour.  
 
Table 3 Components of Reverse Transcription 
Components of Reverse Transcription 
RNA + d(N)6 primers 
1ST Strand Buffer 
0.5 mM dNTPs (Bioline) 
DTT 
DNase Out 
RT Superscript III enzyme (Invitrogern) 
 
The reverse transcription products were used as the template cDNA for a PCR 
reaction, using primers designed previously (Dr Evgeny Makarov), which amplify 
exons 10-12 of the LMNA gene. Forward primer (Ex10f1) GAA GTG GCC ATG 
CGC AAG CTG. Reverse Primer (Ex12r2) GGT GAG GAG GAC GCA GGA AG. 
Primers that amplify exons 7-9 of ACT4 were used as an endogenous control. 
Forward primer (Ex7f1) CGA CCC TGT CAC CAA CCT GGA C. Reverse Primer 
(Ex9r1) GGC CAG CTT CTC GTA GTC CTC C. Table 4 summarises the 
components of RT-PCR. Table 5 summaries PCR conditions for amplification of 
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exons 10-12 of the LMNA gene. Table 6 summaries the PCR conditions for 
amplification of exons 7-9 of ACT4. 
 
Table 4 Summary of RT-PCR Reagents 
Components of PCR 
Forward Primer (0.5µM) 
Reverse Primer (0.5µM) 
FINNZYMES Buffer (1.5mM Mg2+) 
dNTPs (Bioline) 200µM 
cDNA (1:25 Dilution of RT product) 
FINNZYMES DyNAzymeTM (NEB). 
H20 
 
 
Table 5 Summary of PCR Conditions for the amplification of exon 10-12 LMNA 
Temperature Duration/ Cycles 
94oC 2 minutes 
94oC 30 seconds 30 Times 
62oC 30 seconds 
72oC 1 minute 
72OC 5 minutes 
 
 
Table 6 Summary of PCR Conditions for the amplification of exons 7-9 ACT4 
Temperature Duration/ Cycles 
94oC 2 minutes 
94oC 30 seconds 30 Times 
57oC 30 seconds 
72oC 1 minute 
72OC 5 minutes 
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PCR products were run on 2% Agarose TAE buffer gels with a 0.5 μg/Ml 
concentration of Ethidium Bromide. Agarose gels were visualised using the Gel Doc 
EZ Imager (Bio-Rad). DNA markers used for agarose gels were DNA HyperLadder 
I (Bioline) and DNA Hyperladder II (Bioline). 
 
2.3.2 Quantitative-PCR 
 
Quantitative-PCR probes and primers are the intellectual property of Dr Evgeny 
Makarov and are, therefore, not described in this work. Primer and probe binding 
regions are shown in figure 4.20. qPCR was performed using the QuantstudioTM 7 
Flex Real – Time PCR System (Applied BiosystemsTM) and data analysis performed 
using the QuantstudioTM   Real-Time PCR software Version 1:1 (Applied 
BiosystemsTM). 
 
F1 and F2 are the names given to the pJET1.2 cloning vector plasmids which contain 
a copy of the lamin A and progerin amplicons respectively. The purified plasmid was 
quantified using NanoDropTM spectrophotometer and the number of molecules 
calculated using Avogadro’s constant.   
 
bp (size of double strand product)(330 daltons * 2 
nt/bp)   
 
g/molecule 
Avagadro’s Constant (6.023 x 1023 Molecules/moles) 
 
bp size of double strand product for lamin A = 3641 
bp size of double strand product for progerin = 3491 
This was used to make known concentration points for the calibration curve ranging 
from 1F1/F2 (10 molecules) up to 8F1/F2 (100000000 molecules). 
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2.4 Protein analysis 
 
2.4.1 Western Blot 
 
Western blot samples were established by cell scrapping from a confluent dish on the 
day of passage. A sister dish, set up at the same time, was used to determine the cell 
number by a haemocytometer count. The cell number was used to determine the 
volume of 3x sample buffer containing SDS which should be added to the dish to 
give a final concentration of 2x105 cells per 10 µl of sample.  
 
Equivalent cell numbers were loaded to 10% precast polyacrylamide gels (Mini-
PROTEAN® TGXTM Precast Gel Bio-Rad). Western blot was performed as 
described by Towbin et al, 1979. Gels were run, at a constant voltage of 75V until 
condensed and then 150V until the marker exited the gel. Table 7 shows a summary 
of all antibodies used for western blot analysis in this study.  
  
  Page: 57 
 
Table 7 Summary of Western Blot antibodies 
Protein Primary Antibody  
(Dilution) 
Secondary Antibody  
(Dilution) 
Lamin A/C NCL-LAM-A/C   
(NovocastraTM mouse monoclonal) 
(1:200) 
anti-Mouse Goat polyclonal 
IRDye® 800CW (LI-COR 926-
32210) 
Lamin A/C NCL-LAM-A/C   
(NovocastraTM mouse monoclonal) 
(1:200) 
anti-Mouse Rabbit polyclonal 
Horseradish Peroxidase  
(Dako P0448) (1:10,000) 
T7 Tag Anti-T7 Tag rabbit polyclonal  
(abcam ac117486) (1:1000) 
anti-Rabbit Goat polyclonal 
Horseradish Peroxidase  
(Sigma® A0545) (1:20,000) 
SUN1 Anti-SUN1  
(Abcam ab124916 Rabbit 
monoclonal) (1:1000) 
anti-Rabbit Goat polyclonal 
Horseradish Peroxidase  
(Sigma® A0545) (1:20,000) 
SUN2 Anti-SUN2  
(Abcam ab124916 Rabbit 
monoclonal) (1:1000) 
anti-Rabbit Goat polyclonal 
Horseradish Peroxidase  
(Sigma® A0545) (1:20,000) 
BANF1 Anti-BANF1  
(Abcam ab88464 mouse 
monoclonal) (1:1000) 
anti-Mouse Rabbit polyclonal 
Horseradish Peroxidase  
(Dako P0448) (1:10,000) 
Histidine 
Tag 
Anti-histidine tag   
(Qiagen Mouse monoclonal) 
(1:1000) 
anti-Mouse Rabbit polyclonal 
Horseradish Peroxidase  
(Dako P0448) (1:10,000) 
 
 
 
Horseradish Peroxidase conjugated secondary antibodies were visualised via the 
chemiluminescence generated by catalysed oxidation of Luminol, using the 
Molecular Imager® ChemiDocTM XRS+ (Bio-Rad) using Image LabTM software. 
Exposure times were set based on the level of illumination on individual membranes.  
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IRDye® 800CW fluorophore conjugated secondary antibodies were visualised using 
the Odyssey®Sa Infrared Imaging System (LICOR) using Imaging Studio v3.1 
Software (LICOR). 
 
2.5 Molecular Cloning 
 
2.5.1 TAT-Plasmids 
 
pTATv1 and pTATv2 plasmid were obtained from Professor Steven Dowdy. 
Plasmids were purified from DH5α bacterial cultures using the NucloeSpin® 
Plasmid purification kit (MACHEREY-NAGEL).  Plasmids were confirmed using 
restriction digestions with NotI (Fermentas) in Buffer 0 (Fermentas) and EcoNI 
(New England Biolabs) in NEB4 Buffer (New England Biolabs). Restriction 
digestion products were run on 0.8% Agarose TAE buffer gels with a 0.5 μg/Ml 
concentration of Ethidium Bromide. Agarose gels were visualised using the Gel Doc 
EZ Imager (Bio-Rad). DNA markers used for agarose gels were DNA HyperLadder 
I (Bioline) and DNA Hyperladder II (Bioline).  
 
BamHI and NotI restriction sites were selected for directional cloning. Double digest 
reactions was performed on both plasmids, using BamHI (Fermentas) and NotI 
(Fermentas), in BamHI buffer (NEB). A further double digestion reaction, to reduce 
re-ligation, was performed using SacI (NEB) and SalI (NEB), for which the 
recognition site are in between NotI and BamHI. The vectors were then treated with 
Calf Intestine alkaline phosphatase (CIP- NEB 0450804) again to reduce the 
likelihood or re-ligation of the plasmids without taking up an insert. The plasmids 
were then purified using the Wizard® SV Gel and PCR Clean-Up System (Promega 
A9282). 
 
2.5.2 LMNA Inserts 
 
Lamin A and progerin cDNA sequences were obtained from Professor Susan 
Michaelis, Johns Hopkins University, in plasmids pMM45-1 and pMM46-2 
respectively, see Appendix i. PCR amplification was used to add NOTI and BAMHI 
  Page: 59 
 
restriction sites to dictate the orientation of insertion into the plasmid. Forward PCR 
primer containing BamHI B-LAMorf.f1 CaggatCCGTCCCAGCGGCGCGC and 
reverse PCR primer containing NotI N-LAMorf.r1 
gtgcggccgcCATGATGCTGCAGTTCTGGG.  
 
Table 8 Summary of Molecular Cloning PCR 
Components of PCR 
B-LAMorf.f1 Forward Primer (0.5µM) 
N-LAMorf.r1 Reverse Primer (0.5µM) 
FINNZYMES Buffer (1.5mM Mg2+) 
dNTPs (Bioline) 200µM 
FINNZYMES DyNAzymeTM (NEB). 
(1ng/10ng) DNA  
H20 
 
Table 9 Summary of Molecular Cloning PCR Conditions 
Temperature Duration/ Cycles 
94oC 1 minute 30 seconds 
94oC 30 seconds  
35x 62
oC 30 seconds 
72oC 1 minute 20 seconds 
72OC 3 minutes 
 
Double digest reactions were performed on both lamin A and Progerin inserts, using 
BamHI (Fermentas) and NotI (Fermentas), in BamHI buffer (NEB). The inserts were 
then purified using the Wizard® SV Gel and PCR Clean-Up System (Promega 
A9282). 
 
Plasmid and insert concentrations were estimated using 0.8% Agarose TAE buffer 
gel electrophoresis with a 0.5μg/Ml concentration of Ethidium Bromide. Agarose 
gels were visualised using the Gel Doc EZ Imager (Bio-Rad). DNA markers used for 
agarose gels were DNA HyperLadder I (Bioline) and DNA Hyperladder II (Bioline). 
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2.5.3 Plasmid Ligation 
 
Ligation was performed as outlined in the fermentas T4 DNA Ligase protocol. Three 
times the amount of insert was mixed with plasmid and incubated in the presence of 
T4 DNA ligase (NEB).  
 
2.5.4 Plasmid Transformation 
 
Transformation into rubidium chloride competent DH5α cells was induced through 
heatshock. LB medium was inoculated with cells post-ligation and selected using 
Kanamycin resistance agar plates. A control plate was set up where no insert had 
been added to the ligation mix. Numerous colonies were observed on both the lamin 
A and progerin plates. No colonies were present on the control plate suggesting a 
successful transformation. Four colonies from each insert were used to inoculate 2ml 
overnight cultures. The plasmids were then purified using the NucloeSpin® Plasmid 
purification kit (MACHEREY-NAGEL) and a sample was digested with BamHI 
(Fermentas) and NotI (Fermentas). Colonies with an insert were identified by 0.8% 
Agarose TAE buffer gel electrophoresis with a 0.5μg/Ml concentration of Ethidium 
Bromide. Agarose gels were visualised using the Gel Doc EZ Imager (Bio-Rad). 
DNA markers used for agarose gels were DNA HyperLadder I (Bioline) and DNA 
Hyperladder II (Bioline). 
 
2.5.5 Plasmid Sequencing 
 
Plasmids were sequenced by Beckman Coulter Genomics using two of their 
universal primers, T7P (TAA TAC GAC TCA CTA TAG GG) and T7 term (CTA 
GTT ATT GCT CAG CGG). The sequenced region covered the insert and 
approximately 100bp either side of the insertion site. The sequences were aligned to 
the reference sequence, taken from the in silico plasmid maps, using DNASTAR® 
software. 
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2.5.6 Protein Purification 
 
Plasmids selected from sequencing analysis were transformed into rubidium chloride 
competent RosettaTM cells (Novagen), a BL21 variant which contains tRNAs 
(recognise AGG, AGA, AUA, CUA, CCC, GGA codons) specific for the production 
of human proteins. The RosettaTM cells also contain a plasmid that confers 
chloramphenicol resistance. 0.5mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
was used to induce the production of the proteins under the control of the T7 
promoter. A sample of the culture before and after induction was run on a 10% 
precast polyacrylamide gels PAGE (Mini-PROTEAN® TGXTM Precast Gel Bio-
Rad). This gel was then stained for proteins using Coomassie® Blue. 
Protein were purified from RosettaTM cultures as described by Becker-Hapak et al, 
2001 using Ni- NTA Agarose (Qiagen) resin in a batch method. 20mM, 50mM, 
100mM and 250mM concentrations of imidazole were used to elute the proteins 
from the column.   
 
2.6 Cell Modification 
 
2.6.1 Protein transduction 
 
TAT-Fusion proteins were desalted using PD-10 desalting column and added 
directly to media of ~70% confluent cells at a final concentration of 10ug/ml. 
Indirect immunofluorescence (2.1) was performed after 30 minutes.  
 
2.6.2 Plasmid transformation 
 
Plasmid pc3236 (Figure 5.45) was obtained from Professor Heinrich Leonhardt 
Munich University and transfected into DH5α cells. Purified plasmids were 
transfected into 40-50% confluent fibroblast cultures using X-tremeGENE™ HP 
DNA Transfection Reagent (Sigma-Aldrich®) to a final concentration of 1µg/ml. 
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2.6.3 MG132  
 
MG132 (Sigma M7449-200UL) was added directly to cell media at a final 
concentration of 10 µM. DMSO was added as a loading control, to untreated cells, in 
the same manner. MG132 treated cells were harvested for western blot analysis as 
described in 4.1 at 2, 5, 8 and 24 hour time points.  
 
2.7 Whole exome sequencing 
 
DNA extraction was performed using the QIAamp DNA Mini Kit (Qiagen 51304) 
and quantified using the NanodropTM 2000c Spectrophotometer (Thermo Scientific).  
Exon enrichment was performed using the Nextra Rapid Capture Exome Kit 
(Illumina) 50ng DNA protocol, as illustrated in figure 2.7. 
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Figure 2.7 Diagram demonstrating exome enrichment using the Nextra® Rapid 
Capture Exome kit (Illumina®). 
Image taken from the Nextra Rapid Capture Exomes Datasheet DNA sequencing 
(Illumina). 
 
Exome sequencing was performed using the HiSeqTM  2000 Sequencing System 
(Illumina) as outlined in figure 2.8.  
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Figure 2.8 Diagram showing Next Generation Sequencing Chemistry with the 
HiSeqTM 2000 Sequencing System (Illumina). 
Image taken from “An Introduction to Next Generation Sequencing” (Illumina). 
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Exome sequencing data was analysed using the HiSeqTM analysis software (HAS). 
Reads were aligned to the human hg19 Genome using the Burrows-Wheeler Aligner 
(BWA). Genome Analysis Toolkit (GATK) software was used to identify variants 
and realign any sequences that were out of place due to insertions or deletions (Indel 
Realigner). Figure 2.9 outlines this process.  
 
 
 
 
Figure 2.9 Exome Sequencing Analysis Workflow 
Image taken from the Nextra Rapid Capture Exomes Datasheet DNA sequencing 
(Illumina). 
 
 
Exome sequences were analysed for potentially deleterious variants using 
Ingenuity® Variant Analysis SoftwareTM (Qiagen) as outlined in the Ingenuity® 
Variant Analysis™ Quick-Start Guide (Qiagen). 
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3 Characterisation of hTERT Immortalised, 
Hutchinson Gilford Progeria Syndrome, 
fibroblast cell lines. 
 
3.1 Introduction 
 
The stable transfection of hTERT, which encodes the reverse transcriptase subunit of 
human telomerase, has been shown to lengthen telomeres and bypass replicative 
senescence in human cells (Bodnar et al, 1998). This results in limitless replicative 
potential, whilst seemingly having no effect on cell phenotype or differentiation 
markers (Lee et al, 2004). It has been shown, that unlike other methods for cell 
immortalisation (SV40), ectopic hTERT expression increases replicative lifespan 
without transforming cells or triggering genomic instability (Morales et al, 1999; 
Jiang et al, 1999; Pirzio et al, 2004). The benefit of hTERT immortalization in vitro 
is a stable cell resource that allows long-term investigations to be carried out. 
 
The short replicative lifespan of HGPS cells in culture, characterized by increased 
levels of apoptosis and premature replicative senescence (Bridger &Kill, 2004; 
Benson et al, 2010), reduces their viability for in vitro study. With only a small 
number of HGPS patients world-wide, there are few cells lines available, driving the 
need for a stable cell resource.  
Since 2000, several stable hTERT HGPS cells lines have been produced that show 
lengthened telomeres and increased replicative lifespans (Benson et al, 2010; 
Kudlow et al, 2008; Ouellette et al, 2000; Wallis et al, 2004). The study by Wallis et 
al, 2004 resulted in successful immortalization for several clones, however, a 
significant proportion of clones were found to be resistant to immortalization. Out of 
15 clones, isolated from 3 different donors, 5 continued on to senescence despite the 
expression of hTERT, something not observed in any controls. This suggests that the 
lengthening of telomeres alone is not sufficient to negate replicative senescence in 
HGPS cells, questioning what changes may have occurred between clones that 
immortalized and those that showed resistance.  
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With shortened telomeres and progerin both being identified as factors for replicative 
senescence (Allsopp et al,1992; Decker et al, 2009), telomerase and progerin may 
act as opposing forces within cells, suggesting a need to modulate progerin to 
achieve immortalization. A link has since been established between down-regulation 
of progerin expression, in normal fibroblasts, in response to immortalized with 
hTERT (Cao et al, 2011). One hypothesis is that a reduction in progerin expression, 
in response to hTERT, is a key factor to permit immortalisation in the HGPS cell 
lines (Cao et al, 2011).  
 
A second study, however, identified no changes in progerin expression in response 
to hTERT but they did observe a reduction in telomere related DNA damage 
(Benson et al, 2010). This led to the theory that hTERT negates the progerin-induced 
telomere dysfunction that leads to replicative arrest and premature senescence in 
HGPS cultures (Benson et al, 2010). 
 
Despite hTERT immortalization being described as having no effect on phenotype 
(Lee et al, 2004), if it is modifying progerin within cells, this may have a dramatic 
effect on HGPS cell characteristics. Conversely, a study analysing nuclear shape 
abnormalities, in cells retrovirally transduced with progerin, showed no 
improvement in response to hTERT immortalization, despite having the same 
growth potential as controls and cells transduced with Lamin A (Kudlow et al, 
2008). This makes it optimistic that hTERT immortalized cells may be useful for the 
study of a disease characterized by increased cell senescence. 
 
The primary aim of this chapter is to provide a thorough analysis of the effects of 
hTERT immortalisation on HGPS cell phenotype and assess the viability of this cell 
line for further studies. Using one of the strains created by Wallis et al, 2004, 
TAG06297, several properties will be investigated including; growth potential, 
nuclear abnormalities, nuclear shape, cell movement, DNA damage and protein 
localisation. Details of progeria cell phenotype are outlined in chapter 1.3. 
 
 It has also been suggested that hTERT immortalised cultures, with difficulty in cell 
cycle regulation can result in out-growths of a variant population, indicating HGPS 
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hTERT cell lines may have a stability shelf-life (vanWaarde-Verhagen et al, 2005). 
Therefore, analysis of progeria cell characteristics will be undertaken for both an 
Early (shortly after immortalization) and Late (+2 years growth) passage TAG06297 
culture.  
 
3.2 Results 
 
The AG06297 fibroblast cell line, originating from patients with the classic G608G 
form of the syndrome, was immortalized using hTERT (TAG06297) by Professor 
Richard Faragher (Wallis et al, 2004). Unlike other HGPS cell line all, all four 
colonies from AG06297 immortalised normally (Wallis et al, 2004).  
 
AG06297 primary cells were shown to be relatively long-lived amongst HGPS 
cultures achieving just over 40 population doublings at their maximum replicative 
lifespan (Bridger & Kill, 2004). Analysis of the nuclear morphology of primary 
AG06297 cells showed that primary cells from this cell line do display typical HGPS 
nuclear abnormalities. Early passage cells were found to have 29.2% of nuclei with a 
nuclear abnormality and this rose to above 70% in late passage primary cells. 
Unfortunately, AG06297 cells available from Coriell Cell Repository are at the end 
of their replicative lifespan and as such failed to grow in culture, causing no further 
characterisation of these primary cells to be carried out. 
 
3.2.1 Growth Potential 
 
Cells taken from progeria patients display a diverse but relatively short replicative 
lifespan in culture, which has been characterized by hyperproliferation and increased 
levels of apoptosis (Bridger & Kill, 2004).  
 
To determine the effect of hTERT immortalisation on the TAG06297 cell line, 
separate cultures from two points in the cell line’s history were analysed.  
“TAG06297 Early” is derived from cells shortly after the establishment of the 
hTERT culture, whereas the “TAG06297 Late” cells are derived from cultures with 
more than two years continual growth. To investigate the growth rate and potential 
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of both cultures, growth curves were produced (Figure 3.10A). Cell passage was 
carried out twice weekly to avoid confluence. A fibroblast culture from a healthy 
individual (NB1T), also immortalized with hTERT was used as a control 
(Unpublished Data, see Chapter 2.1.1). At each passage the cell number was counted 
using a haemocytometer and used to calculated the number of Population Doublings 
achieved (3.32 [log(harvested)-log(seeded)]). Cells grown on glass coverslips were 
used to estimate the proportion of proliferating cells, using indirect 
immunofluorescence with an antibody for the proliferation marker Ki-67 (Figure 
3.10B). Despite little understanding of Ki-67 function, it is widely used as a marker 
for proliferation, as it is exclusive to the nucleus of proliferating cells (Kill et al, 
1996). Figure 3.10C shows representative images of the staining pattern observed for 
Ki-67.  
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Figure 3.10 Growth Potential of hTERT immortalised normal and Hutchinson-
Gilford Progeria Fibroblasts 
 (A) Compares the number of population doublings (PD) achieved by a normal 
hTERT immortalized fibroblast cell line (NB1T) and Early and Late passage cell 
lines of the HGPS derived TAG06297, both of which are immortalised with hTERT. 
Growth curves were constructed from data gathered over a 46 day period and the 
number of population doublings was calculated using the formula 3.32 
[log(harvested)-log(seeded)]. (B) Shows the fraction of proliferating cells within 
each culture, determined using the proliferation marker ki-67, plotted against the 
accumulated population doublings (APD) achieved within 46 days. Error bars 
represent Standard Error of the mean. (C)  Representative images displaying how 
proliferating cells were identified by positive staining for ki-67. Scale bar =10µm. 
(D) table summarising the growth of each cell line in the 46 day period.  
 
 
There are observable differences in the growth curves of all three hTERT cell lines, 
the slopes of which varying from 0.91 to 0.36 APD/Time, with NB1T achieving the 
most Population Doublings in the time frame. There is a visible difference between 
the slope of the growth curves for TAG06297 Early and Late, with the TAG062697 
Late passage cell line achieving more APDs placing it closer to that achieved by 
NB1T (Figure 3.10A). The difference of 0.43 PD on average per passage, between 
the two TAG06297 cell lines, had a notable effect in culture. The higher rate of 
growth in the TAG06297 Late cell line made it a more viable asset for gaining cell 
numbers. 
When comparing Ki-67 levels within the cultures, both NB1T and TAG06297 Late 
show a high fraction of proliferating cells, whereas TAG06297 Early has less than 
half of the cells within the culture contributing to growth (Figure 3.10D). This 
difference is statistically significant with T-TEST (two tailed) values of 1x10-11 and 
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1.1x10-11 for NB1T and TAG06297 Late respectively. This difference in proliferating 
cell fractions may explain the differences in the growth curves and the rate of growth 
observed in culture between TAG06297 Early and Late. The difference between 
NB1T (98%) and TAG06297 Late (91%), for Ki-67 positive fraction, is also 
significant, with a T-TEST (two tailed) value of 0.00047. This demonstrates that 
continued growth, following immortalisation with hTERT, results in an increased 
number of proliferative cells within a culture and therefore increase growth. This 
suggests that changes have occurred within the culture as a result of long-term 
hTERT expression. 
 
NB1T and TAG06297 Late show less variation in their percentage proliferative cells, 
suggesting a stability not seen in the TAG06297 Early culture. Analysis of variance 
within the cultures using F-TESTS, showed no significant difference between NB1T 
and TAG06297 Late (F-TEST 0.061), however, both showed significantly less 
variation than TAG06297 Early (F-TEST 0.00031 and 0.016 respectively).  The 
effect of hTERT on Progeria cells appears varied within the TAG06297 Early 
culture, supporting the hypothesis that hTERT and Progerin act as opposing forces 
within cells. Despite growth differences, the growth curves for all three cell lines 
show no indication of levelling off, signifying a stable hTERT immortalisation.  
 
3.2.2 A-Type Lamins 
 
One of the first described characteristics of HGPS fibroblasts is the thickened 
nuclear rim (Goldman et al, 2004). Using electron microscopy the thickness of the 
lamina is able to be accurately measured and was determined to be significantly 
thicker in HGPS fibroblasts than controls (Goldman et al, 2004). This is a 
characteristic that can also be observed by immunofluorescence. As progerin is a 
mutant form of lamin A, unless specifically designed not to, antibodies that target 
lamin A also visualize progerin. To determine if continued growth in hTERT has any 
effect on the localisation of A-type lamins to the nuclear envelope or the thickened 
nuclear rim phenotype, indirect immunofluorescence using antibodies for Lamin A 
and Lamin A/C was performed (Figure 3.11).  
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Figure 3.11 Localisation of A-Type Lamins in hTERT immortalised normal and 
Hutchinson-Gilford Progeria Fibroblasts 
Indirect immunofluorescence of hTERT immortalized control fibroblast cell line 
(NB1T) and Late passage HGPS derived TAG06297 cells, grown on glass coverslip 
and formaldehyde fixed, using antibodies for Lamin A/C shown in (A), Lamin A 
shown in (B). Nucleus visualized using DAPI. Scale bar =10 µm. 
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There are observable differences in the staining pattern of Lamin A and Lamin A/C, 
for NB1T and TAG06297 Late, in the HGPS cell line a slightly thickened nuclear 
lamina can be observed. This was significant enough to allow differentiation of these 
cell lines down the microscope. This is supported by both Lamin A and Lamin A/C 
antibodies conferring the same staining Pattern. This suggests that hTERT 
immortalisation does not affect the localisation of A type lamins to the nuclear 
envelope and suggests a level of progerin within the culture.  
 
3.2.3 Nuclear Morphology 
 
One of the most striking effects of progerin expression within cells is the resulting 
changes in nuclear morphology. Primary HGPS fibroblasts have been shown to 
accumulate significantly higher fractions of cells with nuclear membrane blebs, 
invaginations, micronuclei formation and other abnormal morphologies (Bridger & 
Kill, 2004; Goldman et al, 2004). Since it seems likely that accumulation of gross 
nuclear abnormalities could have a profound effect on cell cycle events, such as 
mitosis, we wished to determine how progeria cells coped with increased levels of 
growth following immortalization with hTERT. Nuclear morphology was analysed 
in the TAG06297 Early and Late cultures as well as the control cell line NB1T. Cells 
were cultured on glass coverslips, fixed and mounted in DAPI for nuclear 
visualisation. The slides were analysed manually and the nuclei showing variation 
from a smooth elliptical nucleus resulted in a score of abnormal morphology. Figure 
3.12A shows examples of normal and abnormal nuclear morphology, the table in 
Figure 3.12B sumerizes the findings within these cultures.  
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Figure 3.12 Abnormal Nuclear Morphology in hTERT immortalised normal and 
HGPS Fibroblast cultures 
Nuclear morphology was revealed using the DNA stain DAPI and was analysed for 
shape abnormalities such as, folds or crevices, herniations, lobules and micronuclei. 
(A) Arrows indicate nuclei identified as having nuclear morphology abnormalities. 
Scale bar = 10µm. The table in (B) shows the percentage of abnormal nuclear 
morphology identified in NB1T and Early and Late passage strains of the hTERT 
HGPS cell line TAG06297 (n=750). Representitative images shown are the 
TAG06297 Late cell line. *Data for primary cultures is the previously published 
work of Bridger and Kill, 2004.  
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NB1T and TAG06297 Late demonstrate a statistically similar fraction of abnormal 
nuclei within the culture (T-TEST two tailed 0.44). This level of nuclear abnormality 
is comparable to that of a high percentage replicative lifespan NB1 primary 
fibroblast culture and much reduced on a high percentage replicative lifespan 
AG06297 primary culture (T-TEST two tailed 2.5x10-4). This demonstrates that after 
a continued period of growth, as a result of hTERT, the fraction of abnormal nuclei 
in TAG06297 Late cultures is more comparable to that of control cells than to 
progeria cells. Comparisons made to low percentage replicative lifespan primary 
NB1 cells show fewer abnormal nuclei 2.3± 0.8%, whereas AG06297 still show a 
significantly higher level 29.2±2.1.  TAG06297 Early, however, demonstrate a level 
of nuclear abnormality statistically alike to that of AG06297 primary fibroblasts (T-
TEST two tailed 0.44). This dramatic change in nuclear morphology between the 
two TAG06297 cell lines (T-TEST two tailed 7.1x10-6) suggests a change in 
progeria cell phenotype, when grown in the presence of hTERT, which results in a 
higher fraction of cells with a healthier nuclear morphology than that seen in young 
primary progeria fibroblasts.  
 
3.2.4 Nuclear Size and Shape 
 
To further investigate the effect of continued growth, in the presence of hTERT, 
image analysis of nuclear size and shape was performed on digital images of 
cultures. Images of cells grown and fixed on glass cover were analysed using ImageJ 
software as described in material and methods 2.1.2. By setting the threshold to 
encompass the nuclear region stained with DAPI, measurements of nuclear size (area 
and perimeter) and shape (aspect Ratio and Circularity) could be produced. Figure 
3.13A gives an example of setting the threshold to encompass the whole DAPI 
stained region and the table summarises the measurements collected. 
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Figure 3.13 Thresholding and measuring the nuclei of hTERT immortalised 
normal and HGPS Fibroblast cultures using ImageJ software 
Cells grown on cover slips were formaldehyde fixed and mounted in DAPI. Images 
of the nucleus were captured and analysed using ImageJ particle analysis software. 
The nuclear regions were defined by adjusting the pixel threshold (red) then 
converted to numbered outlines corresponding to the measurements (A). The table in 
(B) summarizes the measurements collected using this software. 
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Figures 3.14 and 3.15 show data presented as both frequency distributions and box 
plots, in order to sufficiently display variations in the distribution of nuclei observed 
in a culture as well as making comparisons between the means.  Data was collected 
for both NB1T (control) cell line as well as TAG06297 Late cells. 
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Figure 3.14 Computational Analysis of Nuclear Size in hTERT immortalised 
normal and HGPS Fibroblast cultures 
NB1T is a normal fibroblast cell line that has been immortalised with hTERT and 
TAG06297 Late is HGPS derived and hTERT immortalised. Analysis using ImageJ 
software to measurements nuclear area, displayed as a frequency distribution (A) and 
a box plot (B) and nuclear perimeter displayed as a frequency distribution (C) and a 
box plot (D). * identifies statistically significant differences between the two cell 
lines. 
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Figure 3.15 Computational Analysis of Nuclear Shape in hTERT immortalised 
normal and HGPS Fibroblast cultures 
NB1T is a normal fibroblast cell line that has been immortalised with hTERT and 
TAG06297 Late is HGPS derived and hTERT immortalised. Analysis using ImageJ 
software to measurements nuclear Circularity and displayed as a frequency 
distribution (A) and a box plot (B) and nuclear Aspect Ratio displayed as a frequency 
distribution (C) and a box plot (D). * identifies statistically significant differences 
between the two cell lines. 
 
 
Comparisons between NB1T and the TAG06297 Late cultures reveal statistically 
significant differences in nuclear size, as defined by area (T-TEST two tailed 
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<0.0001) and perimeter (T-TEST two tailed <0.0001). In accordance with previous 
findings for primary HGPS fibroblasts, the TAG06297 Late cells were found to have 
smaller nuclei (Choi et al, 2011). This suggests that hTERT expression in HGPS 
cells does not modify nuclear size.  
 
Aspect ratio and Circularity (Figure 3.15) measurements were both used to examine 
nuclear shape. Previous reports show HGPS fibroblasts to have, on average, a higher 
fraction of circular nuclei than those observed in healthy controls (Choi et al 2011). 
Using the same calculation of Circularity, no significant difference was identified 
between NB1T and TAG06297 Late cell lines (T –TEST two tailed 0.6410) with 
even the distribution of nuclei appearing similar. Furthermore, Aspect ratio was 
found to be statistically significantly higher for TAG06297 Late than NB1T (T-
TEST two tailed 0.0171), suggesting that cell of this line do not have a more circular 
appearance but instead have ellipsoid nuclei, such as that observed in healthy cells. 
This shift in nuclear shape supports the hypothesis that hTERT expression modifies 
the phenotype of HGPS cells, resulting in a healthier appearance.  
 
 
3.2.5 DNA Damage 
 
Another characteristic of HGPS cells is the increased level of double strand DNA 
breaks, which are thought to contribute to replicative arrest (Liu et al, 2005). In order 
to investigate the potential effect of hTERT on DNA damage levels in HGPS cells, 
both TAG06297 Early and Late and NB1T were stained using an antibody against 
the double strand break DNA damage marker γH2AX. Figure 3.16A-C shows the 
staining observed using γH2AX and the table in Figure 3.16D summarizes the 
proportions within each culture. 
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Figure 3.16 DNA Damage Markers in hTERT immortalised normal and HGPS 
Fibroblast cultures 
Presence of DNA damage was analysed using an antibody against the DNA damage 
marker γH2AX. Two distinct staining patterns were identified (A) shows the 
presence of many speckles and (B) shows the discrete foci. γH2AX negative cells are 
shown in (C). Scale bar = 10µM. (D) summarizes the percentage composition of a 
normal fibroblast culture immortalised with hTERT and Early and Late strains of the 
HGPS hTERT fibroblast cell line TAG06297. *indicates statistically significant (T-
TEST two tailed) shift from no foci to speckles between the Late and Early passage 
TAG06297 cultures.  
 
 
When analysing the cell lines for the marker γH2AX, two staining patterns were 
identified. One staining pattern includes cells that contained one or several large foci 
within the nucleus (Figure 1.6A), likely correlating to individual or low amounts of 
double strand DNA break sites (Löbrich et al, 2010). The proportion of cells 
displaying this type of staining was consistent between all three cell lines (T-TEST 
two tailed >0.24), highlighting this as a typical level of DNA damage within a 
hTERT culture. The second pattern revealed a great number of small speckles of 
γH2AX throughout the nucleus (Figure 1.5B). This pattern was observed in both 
HGPS cultures although the TAG06297 Early had a statistically significantly higher 
proportion of nuclei with this pattern (T-TEST two tailed 3.95X10-5). This pattern 
correlates with higher levels of DNA damage within the cells, which could result in 
them exiting the cell cycle (Liu et al, 2005). This speckled appearance may in fact 
correspond to increased levels of DNA damage as a consequence of progerin 
expression, as this staining pattern was virtually unidentified in the control cell line. 
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Cells were also observed with no positive staining for γH2AX (Figure 3.16C) 
consistent with no detectable double stranded DNA damage within that cell. The 
majority of NB1T (control) cells, showed no staining for γH2AX. A shift from a 
speckled appearance to more nuclei with no foci can be observed in the TAG06297 
Late culture (Figure 3.16D). This reduction in DNA damage between TAG06297 
Early and TAG06297 Late, suggested that continued growth in the presence of 
hTERT does affect progeria cell characteristics. It is reasonable that a reduction in 
the level of DNA damage would enable cells to continue progressing through the cell 
cycle.  
 
3.2.6 Cell Motility 
 
Despite having the ability to proliferate, primary HGPS fibroblasts have been shown 
to have reduced cell motility, which leads to a decreased ability to heal wounds in 
culture (Verstraeten et al, 2008). In order to investigate whether hTERT has any 
effect on progeria characteristics not directly linked to cell proliferation, cell 
movement was analysed using live imaging. Time lapse videos, with five minute 
intervals, were produced over an eight hour period, for TAG06297 Early and Late 
and NB1T. Once all of the images had been captured they were converted into a 
stack in ImageJ software and the Manual Tracking Pluggin was used to follow an 
individual cell through each image. By following the nucleus of the cell through each 
frame, coordinates were generated that could then be plotted on a graph. Figure 
3.17A shows an example of one cell in the first and the last frame of the stack and 
the yellow line represents the route travelled by that cell. Figure 3.17B-D shows all 
the individual cell tracks for each cell line plotted on separate graphs. It is apparent 
from these graphs that NB1T (Figure 3.17B) travelled further in the 8 hour period, as 
demonstrated by the longer track lines. This is a result of both TAG06297 cell lines 
remaining in the same position between several frames therefore not adding any 
travel to their tracks. Although, TAG06297 Late (Figure 3.17D) does show a higher 
amount of movement than TAG06297 Early (Figure 3.17C), when comparing the 
two graphs. This is consistent with observations made by visual inspection of the 
time lapse videos.  
  Page: 88 
 
 
 
 
  Page: 89 
 
 
Figure 3.17 Generation of Time Lapse Videos showing Cell Movement in hTERT 
immortalised normal and HGPS Fibroblast cultures 
Time lapse images were taken every 5 minutes for an 8 hour period. Using the 
Manual Tracking Plugin on ImageJ software, individual cells were given X and Y 
axis co-ordinates and their movement was tracked through all 96 images. (A) shows 
the first image taken and the black arrow highlights the start position for an 
individual cell and the 96th Image taken, where the black arrow indicates the start 
position of the cell and the red arrow shows the end position. The yellow line shows 
the track of the cell movement between the start and end point. Scale bars  = 10 µm. 
The coordinates for each cell were plotted on a graph, where each line represents a 
single cell’s movement. (B) shows the cell movement for a normal fibroblast cell 
line that has been immortalised with hTERT (NB1T). (C) shows Early and (D) 
shows Late passage strains of the HGPS derived TAG06297, immortalised with 
hTERT.  
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 In order to further analyse the time lapse videos all cell tracks were centred to the 
middle of the graph, allowing comparison form a standardized start point (Figure 
3.18A-C). The average total distance and displacement (distance from start point to 
end point) have been marked on the graphs.  The black circles, represent the average 
total distance achieved by cells in that culture. NB1T achieved the greatest distance 
moved (Figure 3.18A), which was statistically higher than both TAG06297 Early 
and Late cell lines (T-TEST two tailed 5.5x10-6 and 0.0006 respectively). The 
TAG06297 cell lines differed statistically from each other (T-TEST one tailed 0.026) 
with TAG06297 Late cells on average moving a greater distance.  
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Figure 3.18 Analysis of Cell Movement in hTERT immortalised normal and 
HGPS Fibroblast cultures 
Time lapse images taken every 5 minutes for an 8 hour period were used to produce 
X and Y axis co-ordinates for individual cells through all 96 images. The coordinates 
for each cell were centred and plotted on a graph, where each line represents a single 
cell’s movement. The black circle represents the average total distance moved in 8 
hours and the red circle shows the average displacement (the difference between start 
and end locations). (A) shows the cell movement for a normal fibroblast cell line that 
has been immortalised with hTERT (NB1T). (B) shows Early and (C) shows Late 
passage strains of the HGPS derived TAG06297, immortalised with hTERT. (D) 
Summaries the average movement made by each cell line including the velocity and 
the meandering ratio (total displacement/total distance).  
 
 
In order to analyse the type of movement made by each cell line the Meanderings 
Ratio was determined, by dividing the displacement by the distance (Figure 3.18D).  
This identifies if cells are moving round in circles or whether they show greater 
directionality to their movements. The Meanderings Ratios show that NB1T and 
TAG06297 Late demonstrate the same pattern of movement (T-TEST two tailed 
0.62), with a tendency to more linear advances, whereas the TAG06297 Early appear 
to move within a small area. The movement displayed by TAGO6297 Early differs 
significantly from that of both NB1T and TAG06297 Late (T-TEST two tailed 
3.95x10-5 and 0.003 respectively). 
 
 In order to heal wounds effectively cells must move forward into the available space 
(Verstraeten et al, 2008), this suggests that the meandering ratio of NB1T and 
TAG06297 Late is more ideal for this task. The ability to heal wounds is also 
affected by rate of movement (Verstraeten et al, 2008), therefore, the average cell 
velocity was also calculated for each cell line. NB1T cells demonstrated a 
statistically significantly faster velocity compared to both TAG06297 cell lines (T-
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TEST two tailed 0.0006). The rate of velocity (Figure 3.18D) is also increased in the 
TAG06297 Late compared with the Early (T-TEST one tailed 0.026) culture 
bringing it closer to that of the control, yet still statistically less. This suggests that 
the presence of hTERT within HGPS cells has affected the type of movement and 
increased cell velocity, both of which would enable better wound healing, 
demonstrating characteristics of a healthier cell phenotype.  
 
3.3 Discussion 
 
The aim of this study was to determine if hTERT immortalisation of HGPS cells 
resulted in a loss of progeria cell phenotype, which would significantly reduce their 
wide-spread usability in research. From the results it is evident that several 
differences between TAG06297 Early and Late have been observed in response to 
hTERT expression. The continued growth and limitless replicative potential is 
advantageous and in line with previous studies successfully showing lengthened 
telomeres and increased lifespan, including the paper describing the immortalisation 
of this cell line (Benson et al, 2010; Kudlow et al, 2008; Ouellette et al, 2000; Wallis 
et al, 2004). 
 
The fraction of cells contributing to the growth is also in line with previous findings, 
which showed the lack of the senescence marker β-galactosidase in over 80% of 
hTERT HGPS cell (Benson et al, 2010). Here we observe more than 80% of cells 
from the TAG06297 Late culture as positive for the proliferation marker Ki-67. The 
previous study however, reported immediate changes in response to hTERT as soon 
as 14 days later, whereas here we see TAG06297 Early cells have only around 30% 
contributing to growth, with the assumption that the other 70% are senescent. This 
finding supports previous work that suggesting that HGPS cells can still senesce 
despite hTERT expression and suggests an outgrowth of cells not telomerase 
resistance (Wallis et al, 2004). This explains the differences observed between the 
Early and Late cultures.  
 
When comparing nuclear abnormalities, a similar proportion of nuclei were observed 
to have abnormalities as to be proliferatively inactive. Although this study does not 
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make a direct link between these two properties, the changes observed between the 
Early and Late TAGO6297 cultures does provide evidence for a link between 
senescence bypass and healthy cell phenotype. This contradicts previous findings 
where no improvement in nuclear shape was observed (Kudlow et al, 2008). As the 
improvement in nuclear shape was only observed in the Late culture it is possible 
that this reduction was not determined in the previous study as cells were not grown 
for the same time period. This again provides evidence for an outgrowth of 
immortalized HGPS cells from a senescent background and indicates that the 
mechanism by which these cell bypass senescence has impacts on the whole progeria 
phenotype.  
The reduction in DNA damage observed in the TAG06297 Late culture is also in line 
with previous findings, which identified a more than 80% reduction in DNA damage 
specifically associated with telomeres (Benson et al, 2010). Again, however, this 
study identified these changes as rapidly as 7 days after immortalisation, whereas in 
the Early TAG06297 cultures we see a large proportion of cells with a level of DNA 
damage similar to that described for primary cultures. This again suggests an 
outgrowth of cells with a more healthy phenotype, brought about by hTERT, that are 
able to continue through the cell cycle likely due to a reduction in DNA damage.  
 
In this study we have identified a reduction in nuclear abnormalities, a similar 
nuclear shape as control cells, a reduction in DNA damage, an increase in cell 
motility and an increase in the proliferative active proportion of culture between 
Early and Late passage cells. This overall suggests that hTERT immortalization of 
HGPS cells does have long-term effects on progeria cell characteristics, which 
results in a more normal and healthy cell phenotype. This limits the usability of this 
cell line to study HGPS with several of the most common and easily observable 
markers of the disease cell phenotype being rectified to nearly undeterminable from 
a healthy cell population. 
 
Similar results to those observed in this study, have been achieved by RNA 
interference, using shRNAs to reduce the expression of progerin by 26%. This 
reduction in progerin in HGPS fibroblasts improved nuclear morphology, increased 
cell proliferative lifespan and reduced the premature senescence of HGPS cultures 
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(Huang et al, 2005). A second study using splicing correction to eliminating the use 
of the cryptic splice site also observed correction of the HGPS phenotype (Scaffidi & 
Misteli, 2005).  This led to the conclusion that gene therapy could be employed to 
rectify progeria cell characteristics and therefore, treat HGPS. By directly reducing 
the level of progerin within HGPS cells these studies achieved the same result as the 
natural outgrowth of hTERT immortalised HGPS cells. 
This cell line does present a rare opportunity to investigate the changes that have 
taken place over time, in response to hTERT, that have ultimately been able to 
rectify many consequences of progerin production. As previously stated, one 
hypothesis is that telomere length is an upstream regulator of progerin, which 
inversely effect its production (Cao et al, 2011). This would suggest that the 
immortal TAG06297 cells have decreased progerin expression and thus progerin 
protein, resulting in improved cell phenotype. The other theory is that telomere 
length is a key factor in triggering DNA damage-induced by progerin and by 
artificially lengthening the telomere the ability for progerin induced senescence is 
reduced (Benson et al, 2010).  
 
By further understanding the mechanism by which these cells have negated 
premature senescence in response to hTERT, this pathway could be exploited for 
drug development. Current efforts focus on the reduction of progerin by upstream 
processing inhibitors (FTI’s) (Capell and Collins, 2006) or general increase in 
protein turn-over (Rapamycin) to remove the mutant progerin (Cao et al, 2011). The 
use of these drugs in vitro has yielded similar improvements in progeria cell 
characteristics as those observed in this study, including nuclear shape (Capell et al, 
2005; Glynn and Glover, 2005; Toth et al, 2005; Mallanpalli et al, 2005; Cao et al, 
2011), DNA damage (Cao et al, 2011), cell motility (Valerie et al, 2008) and 
increased lifespan in culture (Cao et al, 2011). So although this cell line may have 
little use for the study of long-term effects of these drugs, it opens up new 
possibilities for identifing new targets in the treatment of HGPS.  
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4 Investigation in to the effect of hTERT 
immortalisation on Progerin in HGPS 
Fibroblasts. 
 
4.1 Introduction 
 
The identification of loss of progeria cell phenotype in the hTERT immortalised 
HGPS cell line TAG06297 late (Chapter 3), has raised questions about the 
abundance of the mutant protein progerin within these cells. Progerin has been 
described as having a dominant negative effect (De Sandre-Giovannoli et al, 2003; 
Eriksson et al, 2003), where ectopic expression of progerin in control cells has 
resulted in a progeria cell phenotype (Fong et al, 2009; Luo et al, 2014). The 
exclusion of progerin from HGPS cells has been achieved using oligonucleotides 
that target the cryptic splice site, resulting in only wild type transcripts (Scaffidi and 
Misteli, 2005). In these cells a reversal of the progeria phenotype was observed 
(Scaffidi and Misteli, 2005). This suggests that the improvement in progeria cell 
phenotype in the TAG06297 Late cell line, in response to hTERT immortalisation, is 
linked to a reduction in the toxic mutant protein progerin. 
 
A reduction in Progerin expression in response to hTERT immortalisation of HGPS 
cells has previously been observed (Cao et al, 2011). Using Quantitative PCR, one 
study identified an up to 10 fold reduction in progerin expression relative to total 
LMNA transcription in response to hTERT immortalisation (Cao et al, 2011). A total 
lack of progerin expression was also observed in hTERT immortalised controls cells, 
whereas progerin was detectable in primary control cell lines, albeit at a 50 fold 
lower concentration than in HGPS fibroblasts (Cao et al, 2011). This study 
concluded that lengthened telomeres acts as an upstream signal for regulating 
progerin production in both HGPS and normal cells (Cao et al, 2011).  
 
The method used to detect LMNA expression in this study was QPCR using SYBR® 
Green (Cao et al, 2011). Though this method is often used, largely due to economic 
considerations, several limitations have been observed with the use of SYBR® 
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Green, in particular the inability to determine if the product of interest is really being 
amplifed (Bustin et al, 2009). This is of particular relevance when comparing the 
abundance of lamin A and progerin, that are generated through alternative splicing 
(Eriksson et al, 2003), and therefore share a great deal of sequence homology. False 
positives have been observed in probe-based assays using SYBR® Green, where the 
presence of primer dimers has reduced PCR efficiency (Bustin et al, 2009). The 
study in question identified as much as 15% of LMNA expression products being 
progerin in a control cell and a 5 times higher number of progerin molecules than 
lamin A being expressed in HGPS fibroblasts (Cao et al, 2011). This suggests that 
the use of SYBR® Green to assess LMNA expression has led to the over 
representation of progerin within these cells. 
 
A second study using SYBR® Green to quantify lamin A and progerin expression 
determined substantially less progerin expression in control cells, with progerin 
being identified as accounting for only 1% of LMNA transcripts (Scaffidi & Misteli, 
2006). No increase in this value was seen even when examining control cells from 
elderly donors, and it was concluded that progerin is expressed at a 50x higher level 
in HGPS cells than all controls (Scaffidi & Misteli, 2006). One weakness in the 
experimental design of this QPCR, is the need to induce 3 sequence mutations in 
order to differentiate been lamin A and progerin transcripts (Scaffidi & Misteli, 
2006). This again calls into question the specificity of this approach. 
 
Rodriguez et al, designed a TaqMan® probe method for QPCR analysis of LMNA 
transcription products. This study used 9 HGPS primary cell lines, including 
AG06297 cell line, from which the TAG06297 cell line originates, and found that 
progerin is expressed 160 fold more in cells from HGPS patients than from aged 
matched controls (Rodriguez et al, 2009). They identified an increase in progerin 
expression with age in both HGPS and control fibroblasts (Rodriguez et al, 2009). 
This study demonstrates to date, the most robust method for the quantification of 
LMNA expression, however, the placement of the forward primer 4 nucleotides from 
the probe has been criticised. This methodology again demonstrates a potential bias 
for the over representation of progerin.  
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With limitations in all previous attempts to establish progerin expression, this 
identifies the need for a new QPCR design, capable of reliably distinguishing and 
estimating LMNA transcripts. A new system would also enable more accurate 
estimation of progerin involvement in normal human ageing.  
The aim of this chapter is to identify the effects of hTERT immortalisation on LMNA 
expression and progerin abundance within TAG06297 Late cells. We wish to 
determine if the loss of progeria cell characteristics in the TAG06297 cell line is 
resulting from a reduction in the amount of mutant protein Progerin. This will 
involve the use of a novel QPCR design to quantify LMNA expression and Western 
blot and indirect immunofluorescence analysis to examine progerin at the protein 
level. Through understanding how hTERT immortalisation led to an improved cell 
phenotype in HGPS fibroblasts (Chapter 3), potential avenues for therapy could be 
identified.  
 
4.2 Results 
 
4.2.1 Progerin expression Level 
 
The first step in determining progerin expression in the TGA06297 Late cells was 
using RT-PCR. Primers designed over the exon 11 – exon 12 junction distinguish 
between lamin A and progerin transcripts. For primer details see methods and 
materials 2.3.1 Figure 4.19 shows the resulting agarose gel, following RT-PCR.  
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Figure 4.19 RT-PCR analysis of Lamin A and Progerin expression within hTERT 
Immortalised Normal and Hutchinson-Gilford Progeria Fibroblasts 
Agarose gel image shows RT-PCR produced from NB1T, a hTERT immortalised 
fibroblast cell line and two strains of the HGPS fibroblasts TAG06297 Early and 
Late passage. The lanes on the left of the ladder contain cDNA amplified using 
primers for lamin A and progerin. B identifies the primer placement for the forward 
primer Ex10f1 in exon 10 of LMNA and the reverse primer Ex12r2 in exon 12 of 
LMNA.  Yellow Bars represent the region of sequence homology, whereas the purple 
bar identifies the sequence unique to Lamin A and with the 150 nucleotide deletion 
in progerin.  The lanes on the right of the ladder in A show the loading control using 
primers for exons 7 to 9 of the actin gene. TAG08466 is a hTERT immortalised 
“Atypical” HGPS cell line, with an unknown genetic mutation, although thought not 
to result from progerin expression (see chapter 6).  
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Using RT-PCR, progerin expression is clearly visible in both TAG06297 Early and 
Late cell lines, whereas no band corresponding to progerin is identified in the NB1T 
controls or the “Atypical” (non –G608G) HGPS cell line, TAG08466. This confirms 
the continued expression of progerin in the TAG06297 Late cell line, despite the 
transition from a “progeria cell”  phenotype to a more normal cell phenotype 
previously described (Chapter 3).  
 
The next step is to accurately quantify any changes in the expression level of 
progerin between TAG06297 Early and Late cell lines which could account for the 
observed changes at the cellular level (Chapter 3). With several criticisms being 
made of the established QPCR methods used to quantify lamin A/ progerin 
expression level, we opted to employ a novel QPCR design using TaqMan® probes. 
The TaqMan® Probes are the intellectual property of Dr Evgeny Makarov and are, 
therefore, not described in this work. The probe placement and experimental design 
is, however, summarised in figure 4.20.   
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Figure 4.20 Diagrammatic representation of experimental design to determine 
Lamin A and Progerin expression level in a single reaction, using TaqMan® 
probes 
Diagram represents the exon 11 – exon 12 junction, where lamin A and progerin 
transcripts are distinguished through use of the cryptic splice site.  117 and 124 
represent the positions of the two different forward primers and 110 shows the 
position of the reverse primer. V shows the position of the VIC® dye labelled 
TAMRATM probe for lamin A including the quencher (Q) and F shows the position 
of the FAMTM dye labelled TAMRATM probe for progerin including the quencher 
(Q). Image provided by Dr Evgeny Makarov.  
 
 
Figure 4.20 shows the exon 11 – exon 12 junction, where activation of the cryptic 
splice site gives rise to progerin (Eriksson et al, 2003). QPCR design uses two 
separate TaqMan® Probes, VIC® dye labelled TAMRATM for lamin A and FAMTM 
dye labelled TAMRATM for progerin, positioned over the unique exon junctions in 
these transcripts. The same forward (117) and reverse (110) primers can, therefore, 
be used to quantify both lamin A and progerin transcripts. The additional forward 
primer 124 has been added to negate any potential bias, caused by primer 117 being 
further away from the probe in lamin A transcripts, which could lead to 
underestimation of lamin A from the LMNA gene. The aim of this design is to 
effectively quantify both Lamin A and Progerin within a single reaction.  
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For effective validation of this novel QPCR method, single and dual probe detection 
was used to quantify lamin A and progerin, in TAG06297 Early and Late cells. 
Figure 4.21 shows an experimental schematic where lamin A and progerin are 
detected separately and together, using just primers 117 and 110 and with the 
addition of primer 124.  
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Figure 4.21 QPCR experiment schematic for single and dual probe detection of 
Lamin A and Progerin expression 
Image shows the 96 well plate set up for the assessment of expression level of Lamin 
A and Progerin in: NB1T a control cell line, TAG08466 (T08) an “Atypical” HGPS 
cell line, 1972 a primary HGPS cell line and Early (T06E) and Late (T06L) passage 
versions of theTAG06297 HGPS cell line. Apart from where specified all cell lines 
are hTERT immortalised. Blue highlighting indicates the use of VIC® dye labelled 
TAMRATM for lamin A using primers 124+110 and green highlighting shows wells 
for the detection of Lamin A, with VIC® dye labelled TAMRATM, using primers 
117+110. Pink highlighting shows the use of FAMTM dye labelled TAMRATM probe 
for the detection of Progerin. Grey highlighting shows the use of both 
VIC®TAMRATM and FAMTM-TAMRATM, with all three primers 124+117+110, for 
the assessment of both Lamin A and Progerin expression in a single reaction. F1 and 
F2 are the calibration curve template plasmids which contain amplification 
fragments for lamin A and progerin respectively. Calibration curve range from 1000 
(3F1/3F2) – 100,000,000 (8F1/8F2) copies per well. NTC = Non Template Control. 
Experiment and schematic designed by Dr Helen Foster and Dr Evgeny Makarov. 
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F1 and F2 are the names given to the pJET1.2 cloning vector plasmids which contain 
a copy of the lamin A and progerin amplicons respectively. The purified plasmid was 
quantified using NanoDropTM spectrophotometer and the number of molecules 
calculated using Avogadro’s constant.  This was used to make known concentration 
points for the calibration curve ranging from 1F1/F2 (10 molecules) up to 8F1/F2 
(100000000 molecules).  For each experiment a 6 point calibration curve was used, 
putting the sample concentration within the calibrated range.  The addition of the 
non-corresponding probe to the amplicon resulted in no signal detection, 
demonstrating the probe specificity. The percentage of each transcript, for 
TAG06297 Early and Late, is summarised in figure 4.22 for both single and dual 
probes with both primer sets.  
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Figure 4.22 Comparison of single and dual probe QPCR detection methods for the assessment of Lamin A and Progerin expression in 
hTERT  
Lamin A and Progerin expression levels shown as a percentage of total expression. Bar charts from left to right Comparison of use of primers 
124 and 117 on Lamin A detection in single reactions. Comparison of single and dual probe QPCR detection. Effect of improved QPCR 
efficiency by omission of specific points in the standard curve. Experiment and analysis performed by Dr Helen Foster and Dr Evgeny Makarov. 
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From the various experiments in figure 4.22, the additional use of primer 124 does 
not appear to affect the percentage of lamin A and progerin detected for either 
TAG06297 Early or Late. This suggests that despite the position of primer 117 
making the lamin A transcript significantly longer, it is not causing a bias for the 
higher detection of the smaller product, progerin. This means that primers 117 + 110 
are sufficient for the accurate detection of both lamin A and progerin. The QPCR 
efficiencies (figure 4.22) are within an acceptable range with and without primer 
124. The use of both probes in a single reaction does, however, show an undesirable 
QPCR efficiency of around 170%, something which is remedied by manipulation of 
the calibration curve (figure 4.22). This does however, increase the percentage of 
lamin A and decrease that of progerin in both TAG06297 cell lines, while not 
eliminating the difference between cell lines.  This suggesting the need for both 
single and dual probe detection, in order to validate the findings. Further 
optimisation of the dual probe approach to get accurate results from a single reaction 
would be significant for the study of HGPS and the role of progerin in normal human 
ageing.  
With this in mind both single and dual probes reactions were used for the 
quantification of lamin A and progerin expression in TAG06297 Early and Late 
sample. Figure 4.23 shows the average number of molecules of Lamin A and 
progerin detected in each sample.  
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Figure 4.23 QPCR quantification of Lamin A and Progerin molecules being 
expressed in Early and Late Passage hTERT HGPS Fibroblasts 
Number of molecules of Lamin A and Progerin detected in TAG06297 Late (T06L) 
and TAG06297 Early (T06E) cell lines. Quantity of each protein shown as the mean 
of all three repeats. A shows separate quantification using single probe reactions, 
whereas, the data in B was gathered using dual probes for the detection of both lamin 
A and progerin in one reaction. Experiment and analysis performed by Dr Helen 
Foster and Dr Evgeny Makarov. 
 
 
QPCR efficiencies for the single probe quantification reactions were 93% for lamin 
A and 92.2% for progerin. Using the dual probe the QPCR efficiencies were 105.9% 
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for lamin A and 88.5% for progerin. Both QPCR methods identify a statistically 
significant higher number of lamin A molecules than progerin with T-TEST (two 
tailed) P values of 9.95 X 10-05 for TAG06297 Late and 0.0013 for TAG06297 
Earlies.  Figure 4.24 shows the percentage of each transcript in both cell lines. 
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Figure 4.24 Relative percentage of Lamin A and Progerin expression in Early and 
Late Passage hTERT HGPS Fibroblasts using Single and Dual Probe QPCR 
quantification 
Percentage of lamin A and progerin detected in TAG06297 Late (T06L) and 
TAG06297 Early (T06E) cell lines. Lamin A and progerin expression levels are 
shown as a percentage of total expression. A shows separate quantification using 
single probe reactions, whereas, the data in B was gathered using duel probes for the 
detection of both lamin A and progerin in one reaction. Experiment and analysis 
performed by Dr Helen Foster and Dr Evgeny Makarov. 
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Single probe quantification identifies a 60:40 split between lamin A and progerin in 
the TAG06297 Early cell line, whereas, a 70:30 split of LMNA expression products 
is identified in the TAG06297 Late cell line. The difference in the percentages of 
lamin A and progerin expression between TAG06297 Early and Late is statistically 
significant, whether using either single or dual probes for quantification (T-TEST 
two tailed 0.009076 and 5.65x10-05 respectively). This suggests that changes have 
occurred in the expression level of progerin in response to prolonged growth in the 
presence of hTERT. Figure 4.25 shows the relative ratio of lamin A to progerin in 
both TAG06297 cell lines. 
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Figure 4.25 Ratio of Lamin A and Progerin expression in Early and Late Passage 
hTERT HGPS Fibroblasts using Single and Dual Probe QPCR quantification 
Ratio of lamin A and progerin detected in TAG06297 Late (T06L) and TAG06297 
Early (T06E) cell lines. A shows separate quantification using single probe reactions, 
whereas, the data in B was gathered using dual probes for the detection of both lamin 
A and progerin in one reaction. Experiment and analysis performed by Dr Helen 
Foster and Dr Evgeny Makarov. 
 
 
The 2 fold decrease in the ratio of lamin A to progerin observed between the 
TAG06297 Late and Early cells shows a trend to decrease progerin expression in 
response to hTERT. This is consistent with previous findings (Cao et al, 2011), 
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which used a different QPCR methodology. The extent of the repression of progerin 
transcription in response to hTERT is, however, not as great as 10 fold reduction 
previously reported (Cao et al, 2011). The tendency is to express more lamin A than 
progerin in both TAG06297 cell lines. A 1.2:1 expression ratio has previously been 
observed in primary AG06297 cells (ratio created with data pooled from 8 HGPS 
cell lines) (Rodriguez et al, 2009), which is comparable to the 1:3.1 for lamin A to 
progerin in the TAG06297 Early cell line, signifying no real difference in expression 
ratio between Early and primary cells. The 3:1 ratio identified in TAG06297 Late 
cells, demonstrates the change in response to protracted growth following hTERT 
immortalisation. This, however, is not a substantial enough reduction to bring the 
TAG06297 Late cells in line with control cells, where a ratio of >240:1 was 
previously determined (Rodriguez et al, 2009). With approximately 30% of LMNA 
transcripts being progerin in the TAG06297 Late cell line, changes purely at the 
transcription level may not account for the “healthy” cell phenotype observed in this 
cell line. With a cell phenotype more similar to controls, where no progerin was 
detected (data not shown), it is likely that the TAG06297 Late cell line has adopted 
an alternative route to modulate progerin in order to cope with hTERT growth 
pressure.  
 
4.2.2 Genomic Instability 
 
HGPS cell lines have previously been described as having high levels of genomic 
instability with progerin causing a potential loss of lagging chromosomes during 
mitosis (Cao et al, 2007; Dechat et al, 2007). Primary cells from the TAG06297 
patient have been described as having a normal 46XY karyotype (Coriell Institute). 
In order to determine if the moderate changes in expression level of the LMNA gene 
in response to hTERT are caused by general genomic instability in this cell line, 
chromosome number analysis was performed. For NB1T controls and TAG06297 
Late cells metaphase preparations were identified using Metafer software and the 
number of chromosomes were counted. Figure 4.26 gives examples of metaphase 
preparations and summarises the established chromosome number for each cell line.   
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Figure 4.26 Chromosome Number Analysis in hTERT immortalised normal and 
HGPS Fibroblast cultures 
Metaphase preparations were visualised with DAPI and images captured using 
Metafer software. (A) shows a metaphase images containing different numbers of 
chromosomes. The number of chromosomes per metaphase were determined for 
NB1T a normal fibroblast cell line that has been immortalised with hTERT and a 
hTERT immortalised Late passage strains of the HGPS derived TAG06297 (B). For 
NB1T 180 Metaphases were analysed and for TAG06297 the number analysed was 
224.  
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A T-Test (two-tailed) showed no significant difference in chromosome number for 
NB1T and TAG06297 Late cells, with a P Value = 0.096, where both cell lines had a 
median of 46 chromosomes. This suggests that no broad changes in chromosome 
number have occurred in the TAG06297 Late cell line, despite forced growth of a 
premature ageing diseased cell type where genomic instability is predicted. This 
again, identifies improvement in progeria cell characteristics in response to growth in 
the presence of hTERT (Chapter 3). It also raises questions about the progerin 
protein level within this cell line, where progerin associates with membranes during 
mitosis has been identified as key factor in aneuploidy (Cao et al, 2007; Dechat et al, 
2007). Simple analysis of chromosome number, does suggest relative genomic 
stability, although a more comprehensive karyotype using M-FISH would identify 
any specific changes in chromosome 1 (LMNA locus). The observed changes in 
progerin expression level in TAG06297 Late cells, however, do not occur due to 
global genomic instability of this cell line. 
 
4.2.3 Progerin Protein Level 
 
With moderate increase in the ratio between lamin A and progerin expression being 
demonstrated in the TAG06297 Late compared to the Early cell line, we needed to 
determine the effect at the protein level. Reduction in progerin protein has previously 
been shown to result in improved progeria cell characteristics (Scaffidi & Misteli, 
2005), such as those described in chapter 3. Western blot analysis was used to 
compare progerin abundance between control and TAG06297 Early and Late cell 
lines (figure 4.27C).   
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Figure 4.27 Analysis of Progerin Levels within hTERT Immortalised Normal and 
Hutchinson-Gilford Progeria Fibroblasts 
Indirect immunofluorescence using an anti-Progerin antibody revealed two different 
staining patterns (A) Nuclear Rim stain and Nuclear Aggregates. Table (B) 
summerizes the proportion of each staining pattern found within NB1T, A hTERT 
immortalised fibroblast cell line and two strains of the HGPS fibroblasts TAG06297 
Early and Late passage. (C) Western Blot analysis using an anti- Lamin A/C 
antibody identifies the levels of Lamin A, C and progerin.  
 
 
Using chemiluminescence and loading an equal cell number for each cell line, no 
progerin was detected in the TAG06297 Late cell line, whereas, a band at ~65 kDa 
confirming progerin is observable for the TAG06297 Early cell line. This 
preliminary result identifies a substantial change at the protein level of the 
abundance of progerin between these two cell lines. 
 
Lamin A 
Progerin 
Lamin C 
Vimentin 
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 Using immunofluorescence with an anti-progerin antibody the cellular location of 
progerin was identified (figure 4.27A). For the control cell line, NB1T, no progerin 
protein was detected. Interestingly, progerin staining did give a positive nuclear rim 
stain in 92% of TAG06297 Late cells analysed (figure 4.27B). This is significantly 
higher (T-TEST two tailed 3.6x10-5) than TAG06297 Early cells, where a 
statistically significantly higher proportion of nuclei (25%) were found to have 
progerin nuclear aggregates (T-TEST two tailed 2.7x10-5). The nuclear aggregate 
staining pattern categorises a great build-up of progerin looking to be a catastrophic 
level, with this typically found in cells with extreme nuclear shape abnormalities. 
Progerin is clearly present in the TAG06297 Late cells although at a much lower 
level than in the early cell line. The inability to detect progerin in the TAG06297 
Late cells with Western blot may be due to it being below the level of detection for 
chemiluminescence with only 1x105 cells loaded per sample. This does sugest a 
significant difference between TAG06297 Early and Late cell lines which in all 
likelihood gives rise to the reduction in progeria cell phenotype in the TAG06297 
Late cell line, however the western blot results require verification and quantification 
with densitometry.  
 
4.2.4 Proteasome Inhibition 
 
The observed reduction in protein level does not appear to marry up with the 
moderate changes in expression ratio between lamin A and progerin. This suggests 
that progerin is being regulated at the protein level, leading to the improved progeria 
phenotype previously described for the TAG6297 Late cell line (Chapter 3). 
 
Poly-ubiquitination of proteins has been identified as a signal for protein degradation 
through proteasomal machinery and autophagic clearance (Dikic et al, 2009). Two 
sites for the poly-ubiquitination have been identified (Tan et al, 2008; Belzile et al, 
2010) and one study determined preferential use of K63 for progerin (Graziotto et al, 
2012), which promotes autophagic clearance of aggregated proteins (Tan et al, 
2008). K48 poly-ubiquitination is believed to promote protein degradation through 
the proteasome (Belzile et al, 2010). Further evidence suggests that nuclear envelope 
proteins are not substrates for proteasomal degradation under normal cell conditions 
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(Chen et al, 2002; Dino-Rockel & von Mikecz, 2002; von Mikecz, 2006). Equally 
there is evidence suggesting proteasomal degradation of Emerin, in cells lacking A-
type lamins, credibly not normal cell conditions (Muchir et al, 2006). To further 
investigate if hTERT expression in TAG06297 Late cells had resulted in abnormal 
cellular conditions, which increases the rate of progerin degradation through the 
proteasome, this was examined using the proteasome inhibiting drug MG132.  
 
MG132 is a cell permeable, reversible inhibitor of proteolytic activity of the 26S 
proteasome complex. MG132 has previously been used for the purposes of 
determining protein degradation, whereby monitoring the build of a protein post 
proteasomal inhibition gives insight into the rate of protein degradation (Wu et al, 
2009). Figure 4.28A shows the resulting Western blot analysis of TAG06297 Late 
cells at various time points following 10 µm MG132 treatment. 
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Figure 4.28 Treatment of HGPS cells with the proteasome inhibiting drug MG132 
TAG06297 Late cells, a HGPS patient derived cell line immortalised with hTERT, 
were treated with 10 µm concentration of MG132. (A) Western Blot analysis using 
an anti-Lamin A/C specific antibody shows the build-up of progerin at incremental 
time-points. The sub-cellular location of the build-up of progerin 8 hours after 
inoculation is shown in (B), visualised using an anti-progerin specific antibody.  
Scale bar = 10 µm 
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With the same number of cells loaded for each time-point following MG132 
proteasome inhibition, this preliminary result shows the  internal build-up of protein. 
The accumulation of progerin, lamin A and lamin C demonstrate that inhibition of 
the proteasome results in a cellular increase in these proteins. This does suggest a 
link between proteasome activity and Lamin stability although this a preliminary 
result in need of further investigation. The proteasome was previously not identified 
as the method of degradation for these proteins (Graziotto et al, 2012) and further 
investigation may suggest proteasome degradation through the poly-ubiquitination of 
K48 (Belzile et al, 2010).  
 
2 hours post-incubation with MG132 progerin is no longer below the level of 
detection for chemiluminescence of 1x105 cells. The build-up progerin and lamin A 
and C is observed at 5 and 8 hours post MG132 treatment.  A 24 hour time point 
following MG132 inoculation was also examined, however, total cell death was 
observed, resulting in no Western blot analysis. A DMSO loading control showed no 
effect on cell viability after 24 hours.  
 
The location of progerin build up in response to MG132 proteasome inhibition was 
identified using immunofluorescence and is shown in figure 4.28B. 8 hours post 
MG132 treatment progerin is located in cytoplasmic aggregates, a cellular location 
not previously identified for this nuclear lamina anchored protein (Capell et al, 
2005). This coincides with the known sub-cellular location of proteasomal activity 
(Peters et al, 1994) and adds further evidence to the effective inhibition of the 
proteasome using MG132 and suggests that progerin is degraded via the proteasome. 
Nuclear build-up of progerin is also observed 8 hours after MG132 proteasome 
inhibition, a location where proteasome activity has also been observed (Peters et al, 
1994).  
 
To examine the rate of protein degradation in this cell line, immunofluorescence was 
used as a detection method for Western blot analysis. With fluorescence output being 
linear to sample concentration, comparisons in band intensity can be used to quantify 
protein levels within samples. Figure 4.29 shows the resulting Western blot image 
and the band intensity for each protein.  
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Figure 4.29 Relative ratio of Lamin proteins in hTERT immortalised HGPS 
fibroblasts before and after MG132 proteasome inhibition 
TAG06297 Late cells, a HGPS patient derived cell line immortalised with hTERT, 
were treated with 10µm concentration of MG132. (A) Western Blot analysis using 
an anti-Lamin A/C specific antibody, visualised using fluorescent secondary 
antibodies shows the build-up of progerin post 8 hour incubation with MG132. (B) 
Compares the ratios of band intensities between control NB1T cell line and the 
HGPS cell line TAG06297 before and after MG132 treatment.   
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Through fluorescence detection, progerin is visible in 1x105 cells, determining what 
was previously postulated that progerin is present in the TAG06297 Late cell line, 
albeit at a level below detection using chemiluminescence.  
 
From analysing the band intensity in each lane the ratio of proteins has been 
determined (figure 4.29B). NB1T cells demonstrate a near 1:1 ratio for lamin A: 
lamin C whereas TAG06297 Late shows less than half that ratio. This is not 
surprising as progerin is produced from activation of cryptic splice site within lamin 
A sequence and does not affect lamin C transcripts (De Sandre-Giovannoli et al, 
2003; Eriksson et al, 2003). The totalling of progerin and Lamin A proteins is more 
comparable to lamin A: lamin C ratio observed in the control cell line.  
 
MG132 treatment of TAG06297 Late cells alters the ratios between both lamin A 
and Progerin relative to lamin C. The increase in these ratios shows that both 
proteins are being broken down at a rate quicker than lamin C, as determined by an 
increased build-up. This is similar to the finding using the autophagy promoting drug 
Rapamycin, where rates of progerin degradation were seen at a higher rate than 
Lamin C (Cao et al, 2011). No difference in the ratio between lamin A: progerin post 
drug treatment show that these proteins are building up at a similar rate. This 
provisional result suggests that improvements in progeria cell phenotype previously 
identified for the TAG06297 Late cell line (chapter 3) may result from the increased 
proteasomal degradation of both lamin A and progerin but not lamin C.  
 
4.3 Discussion 
 
In this study we demonstrate the effective use of a novel QPCR design, for the 
estimation of LMNA expression in a single reaction, using dual probes for the 
separate detection of lamin A and progerin. The estimation of progerin relative to 
Lamin A is more in line with previous attempts at quantification using Taqman® 
(Rodriguez et al, 2009), confirming a relative ratio of 1.3:1 Lamin A: progerin 
expression. The moderate difference observed in ratios between AG06297 primary 
fibroblasts (Rodriguez et al, 2009) and TAG06297 Early cells is likely an artefact of 
QPCR design whereby the previous study showed a slight bias to over-represent 
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progerin transcript abundance due to primer placement (Rodriguez et al, 2009). This 
is slight when compared to attempts to quantify using SYBR® Green, where 5x 
more progerin was detected than Lamin A (Cao et al, 2011). This suggests the need 
to use this dual method to repeat work which examined progerin transcription in 
normal human fibroblast and identified its involvement in normal human ageing 
(Scaffidi & Misteli, 2006).  
 
 QPCR expression analysis is in agreement with cell characterisation work, which 
identified TAG06297 Early cells as showing hallmarks of a classic progerin cell 
phenotype (Chapter 3), which results from the dominant negative effect of progerin 
(Scaffidi and Misteli, 2005). TAG06297 Late cells show an improved cell phenotype 
in response to hTERT immortalisation (Chapter 3), something previously suggested 
to occur through downregulation of progerin expression (Cao et al, 2011). QPCR 
data from this study is in agreement with previous findings, which suggest 
downregulation of progerin expression, in response to hTERT immortalisation (Cao 
et al, 2011). This was postulated to occur through telomere length acting as an 
upstream signals in regulating progerin production (Cao et al, 2011). A previous 
study used a 25-mer morpholino oligonucleotide (exo11) to effectively block use of 
the cryptic splice site, reducing progerin expression and improving cell phenotype 
(Scaffidi and Misteli, 2005). This has been suggested as a potential therapy, using a 
small molecule inhibitors to modify splicing. The observed 2 fold decrease in 
response to hTERT immortalisation is significantly less than the 10 fold change 
previously observed (Cao et al, 2011). This moderate change is more difficult to 
interpret when trying to determine the impact on cell function. TAG06297 Late cell 
have been characterised as similar to control fibroblasts for several parameters, 
including nuclear shape (Chapter 3), suggesting a significant reduction in progerin 
protein abundance.  
 
The ratio of progerin to Lamin A protein in TAG06297 Late cells differs from the 
expression ratio determined using QPCR. There are number of reasons for this 
including mRNA stability and translation efficiency (Gingold and Pilpel, 2011). 
Another consideration is that the increased protein degradation observed in the 
TAG06297 Late cells through MG132 proteasome inhibition, is reducing the 
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expression in a negative feedback loop. This system has previously been described 
(Graziotto et al, 2012). Through TAG06297 Late QPCR and proteasome inhibition, 
it is possible that improvement in progeria cell phenotype caused by hTERT 
immortalisation, result from a combination of increased protein degradation and 
reduced progerin expression, which may or may not be linked through a negative 
feedback loop.  
 
The suggestion of proteasomal degradation of lamin A and progerin, likely through 
poly-ubiquitination of k48 (Belzile et al, 2010), offers new therapeutic avenues. 
Increased progrein degradation is already being considered as an avenue for therapy 
using rapamycin, a drug to increase general autophagy (Cao et al, 2011; Graziotto et 
al, 2012). Rapamycin treatment on fibroblasts in culture has resulted in 
improvements in progeria cell phenotype similar to those described in response to 
hTERT immortalisation (Cao et al, 2011; Graziotto et al, 2012). It is possible that 
increased progerin degradation has been achieved in this cell line through 
preferential poly-ubiquitination as a result of either increased E3 ligase abundance or 
changes to progerin sequence increasing its ubiquitin ligase affinity (Fu et al, 2004). 
To further investigate this, other drugs target specific machinery of the 26S 
proteasome could be employed for example; clasto-Lactacystin β-Lactone an 
inhibitor of the 20S proteasome, Epoxomicin an inhibitor of Z catalytic subunits of 
the proteasome (Meng et al, 1999) and Calpeptin an inhibitor of calpain 2. 
Identification of specific E2/E3 ligase combinations and sites on progerin would be 
essential for exploitation of proteasome degradation as therapy for HGPS 
(Marblestone et al, 2013).Comparisons of sequence between Early and Late 
TAG06297 cells may also offer insight into changes in response to hTERT that have 
improved progeria cell phenotype. With serious criticisms of the impending clinical 
trial using rapamycin as a treatment for HGPS (personal communication with Dr 
Joanna Bridger), understanding the changes in response to hTERT immortalisation, 
which have yielded a similar outcome, may offer less risky therapeutic avenues for 
HGPS in the future.  
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5 Analysis of increased Progerin Degradation 
in hTERT Immortalised HGPS Fibroblasts. 
 
5.1 Introduction 
 
It has previously been suggested that HGPS fibroblasts show an increase in progerin 
degradation following long term growth in the presence of hTERT (Chapter 4). It is 
thought that this reduction in the level of the toxic protein progerin results in a loss 
of progeria cell characteristics and a more healthy phenotype than previously 
observed (Chapter 3). Further experiments are needed to demonstrate the causative 
link between reduction in progerin level and reinstatement of a healthy cell 
phenotype. Two separate methods have been employed to determine this 
relationship: TAT mediated protein transduction to quantify the rate of progerin 
degradation and Nanobodies targeted to A type Lamins and conjugated to a ubiquitin 
ligase to confirm that Lamin A and Progerin are broken down through ubiquitination 
and proteasomal degradation.  
 
The Transactivator of Transcription protein (TAT) from the HIV-1 virus was first 
shown to transduce across a plasma membrane in 1988 (Green & Loewenstein 1998, 
Frankel & Pabo, 1988). TAT was shown to penetrate cells, enter into the nucleus and 
perform its normal biological function of activating a viral LTR promoter (Dayton et 
al, 1986; Fisher et al, 1986). The transduction properties of this protein are believed 
to help viral infection by transducing into uninfected cells and changing the 
expression profile (Elliott et al, 1997; Hawiger et al, 1999). The Protein-
Transduction Domain (PTD) of TAT has since been identified as the 11 amino acid 
sequence Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg found at residues 47-57 
of the protein (Schwarze et al, 2000). The method by which the TAT PTD crosses 
the plasma membrane has been shown to be through a process of micropinocytosis 
(Wadia et al, 2004), although some debate still remains about whether TAT can also 
directly penetrate across the plasma membrane (Palm-Apergi et al, 2012). TAT is 
not the only protein containing a cell penetrating peptides or PTD, others include 
Drosophila Antennapedia homeotic transcription factor (ANTP) and the herpes-
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simplex-virus-1 DNA-binding protein (VP22) (Schwarze et al, 2000). The 
availability of expression vectors containing the sequence for these amino acids 
(Becker-Hapak et al, 2001) and the ability to transport proteins as large as β-
galactosidase across the plasma membrane have made TAT a preferential choice for 
protein transduction (Fawell et al, 1994). 
 
Numerous TAT- fusion proteins have been produced, achieving successful 
transduction both in vitro and in vivo (Wadia & Dowdy, 2005). The production of 
TAT-fusion proteins holds great therapeutic value with studies examine their ability 
to targeting cancer cells, for example with TAT-BID (Orzechowska et al, 2014) and 
TAT-FOXO3TM (Esaffi et al, 2011). They have also been of interest for their 
potential therapeutic application for mitochondrial diseases (Lin & Kao et al, 2015), 
for instance in Friedreich’s Ataxia, where a TAT-Frataxin fusion protein was 
injected into a mouse model, which resulted in successful compensation for the 
missing protein (Vyas et al, 2012). 
 
One of the main advantages of using protein transduction over conventional 
transformation of genetic material is the control of protein concentration. Using TAT 
mediated protein transduction the concentration of protein added to the cells can be 
controlled, as cells take up protein in a concentration dependent manner. The 
concentration of protein produced following transformation is dependent on factors 
such as position of incorporation into the genome. This can also cause a large 
amount of variation between cells, whereas, TAT mediated protein transduction has 
been shown to achieve a high level of uniformity. A further advantage of TAT-
mediated protein transduction is that cell penetration occurs as quickly as within 5 
minutes (Becker-Hapak et al, 2001).  
 
The aim of this research is to develop TAT-lamin A and TAT- progerin fusion 
proteins, in order to accurately address the issue of increased protein degradation in 
TAG06297 Early cell line. Through protein transduction the rate of degradation of 
exogenous proteins can be determined and comparisons between TAG06297 Early 
and Late cultures can be drawn. These fusion proteins will also be useful in 
determining the level at which progerin elicits a detrimental effect on cell function, 
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something equally interesting from the perspective of therapy and the role of 
progerin in normal human ageing.  
 
Nanobodies have been identified as a unique component of sera from the camelid 
family of mammals, namely Llamas and Alpacas (Hamers-Casterman et al, 1993). 
Camelids were found to produce conventional heteroteterameric antibodies, but also 
functional heavy chain antibodies (HC Abs) which fail to incorporate a light chain 
(Hamers-Casterman et al, 1993). The VHH (variable domain of heavy chain 
antibodies) or single antigen-binding domain of these antibodies is the smallest 
antigen recognising fragment at approximately 15kDa, cornering the name 
Nanobody (Muyldermans et al, 2013). One explanation regarding the evolution of 
these newly-discovered naturally occurring single antigen binding domains is that 
they enable binding to otherwise inaccessible epitopes, which proved of selection 
value (Flajnik et al, 2011). 
 
The small size, high specificity, straightforward expression and increased stability in 
varying temperatures and pH have made Nanobodies an exciting resource both 
commercially and therapeutically (Muyldermans et al, 2013, Rothbauer et al, 2008). 
The generation of GFP conjugated Nanobodies or Chromobodies has allowed for the 
real-time tracking of endogenous proteins in live cells (Rothbauer et al, 2006). This 
technology has now been used to capture the localization dynamics of cytoskeltetal 
components, at various stages of development, in a living vertebrate organism 
(Panza et al, 2015). Nanobodies, however, are more than just tools for observing 
protein function and can effect change. Nanobodies have been shown to modulate 
endogenous proteins in living cells, making them useful for therapeutic targeting 
(Kirchhofer et al, 2010), with 8 clinical trials currently underway. One such phase II 
clinical trial has reported positive findings for the treatment of Acquired Thrombotic 
Thrombocytopenic Purpura (TTP) with a Nanobody target to inhibit the reaction 
between blood platelets and Ultralarge von Willebrand Factor Multimers (Peyvandi 
et al, 2016).  
 
The aim of this work is to use Nanobodies to enhance the rate of A type lamin 
degradation in the TAG06297 Early cell line. The hypothesis is that an A type lamin 
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specific Nanobody conjugated to a E3 ubiquitin ligase will be capable of mimicking 
the increased degradation observed in the TAG06297 Late cell line (Chapter 4) in 
response to prolonged hTERT expression. This will hopefully replicate the 
improvements observed in progeria cell characteristics, virtually restoring a normal 
cell phenotype. This offers great therapeutic opportunities for HGPS, using a 
technology already going through clinical development.  
 
5.2 Results 
 
5.2.1 Development of TAT-fusion proteins 
 
In order to create lamin A and progerin TAT fusion proteins, a recombinant 
construct was first created through molecular cloning. Two plasmid constructs were 
available from Professor Steven Dowdy’s lab, the pioneer of this technology. The 
two plasmids, called pTATv1 and pTATv2 both contain the genetic sequence for the 
11 amino acids of the TAT protein, controlled under a T7 promoter.  The constructs 
also contain multiple cloning sites allowing for the insertion of the desired sequence, 
in this case lamin A or progerin cDNA. Both plasmids also confer Kanamycin 
resistance and contain histidine tags to allow for protein purification. One difference 
between the two plasmids is that pTATv1 contains a histidine tag at both the 
beginning and the end of the open reading frame, whereas pTATv2 has only one 
histidine tag at the C terminus of the protein. The pTATv2 construct also contains a 
T7 tag sequence, for which there are commercially available antibodies. Figure 5.30 
shows the plasmid maps for pTATv1 and pTATv2.  
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Figure 5.30 Plasmid maps for pTATv1 and pTATv2 plasmids 
Black arrows indicate the TAT sequence and the blue arrows show the T7 promoter. 
The red arrow indicates the only difference between the plasmids, the presence of a 
T7 tag on pTATv2. Kanamycin resistance and various restriction enzyme sites are 
also labelled. Both plasmids based on pET cloning vector backbone. MCS stands for 
multiple cloning site. Plasmid maps for pTATv1 and pTATv2 taken from the 
addgene website (http://www.addgene.org/35620/).  
 
Restriction digestion reactions were used to validate the identity of the pTAT 
plasmids. Both plasmids were linearised with a NotI, enzyme digestion, for which 
both pTATv1 and pTATv2 contain a single recognition site. With both pTAT 
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plasmids containing two recognition sites for the restriction enzyme EcoNI, two 
fragments of 3680bp and 1688bp, were expected. Figure 5.31 shows the agarose gel  
image where the fragments from the digestion reactions were visualised. 
 
Figure 5.31 pTAT plasmid validation using restriction enzyme digestions reactions 
Image of a 0.8% agarose gel showing the DNA fragments following EcoNI and NotI 
restriction enzyme digests of pTATv1 and pTATv2 plasmids. The marker is DNA 
HyperLadder I. 
 
As the expected pattern was observed following the NotI and EcoNI digestion 
reactions, the plasmids were purified from cultures of competent E.coli DH5α cells, 
using kanamycin resistance as a selection marker.  
 
The recombinant constructs were first designed in silico using DNASTAR® 
software. In order to have the correct orientation of the lamin A and progerin inserts 
directional cloning was used by selecting two different restriction sites. BamHI was 
selected based on its extensive use as a restriction enzyme for molecular cloning. 
NotI was the second enzyme selected based on its terminal location and small 
alanine recognition site, hoping to create an open structure at the end of the protein, 
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allowing easy access to the histidine tag.  The resulting constructs are mapped in 
figure 5.32.  
 
Figure 5.32 Constructed plasmid maps for pTATv2 with Lamin A and Progerin 
cDNA inserts 
A shows the pTATv2 plasmid with the 1935bp lamin A cDNA insert, making a total 
plasmid size of 7303bp. B shows the pTATv2 plasmid with the progerin cDNA 
insert of 1785bp. The 150bp size difference reflects the 50 amino acid deletion in the 
progerin protein. Maps show use of BamHI and NotI restriction sites. Plasmid maps 
were constructed using DNASTAR® software. 
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Lamin A and progerin cDNA Insert sequences were prepared from template plasmid 
constructs (Appendix i) obtained as a kind gift from Professor Susan Michaelis, 
Johns Hopkins University.  A PCR reaction was used to amplify the desired insert, 
using primers with adaptors containing the restriction enzyme recognition sequences. 
The forward primer contained the recognition sequence for BamHI and the reverse 
primer contains a NotI recognition sequence, both were designed using DNASTAR® 
software (see methods and materials 2.2.1.) Figure 5.33 shows an image of the PCR 
products after gel electrophoresis using 1% agarose.   
 
Figure 5.33 PCR amplification of Lamin A and Progerin cDNA inserts 
Agarose gel image showing PCR amplification of lamin A and progerin cDNA insert 
sequences. For both cDNA sequences 1ng and 10ng of template DNA were used for 
the PCR reaction. The marker on the gel is DNA HyperLadder I and was visualised 
using the Gel Doc EZ Imager. The 150bp size difference between the two cDNA 
inserts cofirms the progerin deletion.  
 
The gel image in figure 5.33 shows bands of expected sizes for both the lamin A and 
progerin sequences. As the template used to make the inserts was cDNA construct, 
post-splicing, the 150bp size difference between the two inserts apparent in the gel, 
equates to the 50 amino acid deletion in progerin resulting from activation of the 
cryptic splice site.  
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Double digest reactions were then performed on both the plasmids and the insert 
sequences, using BamHI and NotI restriction enzymes. A further double digestion 
reaction was performed on the plasmids using SacI and SalI restriction enzymes. 
Both these enzymes have unique cut sites inbetween the BamHI and NotI recognition 
sites. This digestion was performed inorder to reduce the possibility of religation of 
the plasmid. Calf Intestine alkaline phosphatase (CIP) treatment was used to remove 
the 5’ phosphate group meaning no phosphodiester bonds could be formed. As this 
treatment was not performed on the insert sequences they are still capable of forming 
such bonds with the vectors. Following these treatments a sample of both plasmids 
and inserts were run a 0.8% agarose gel. Figure 5.34 shows an image of this gel.  
 
Figure 5.34 Treated and purified Lamin A and Progerin cDNA inserts and pTAT 
plasmids 
1% agarose gel showing fragments for each cDNA insert following NotI and BamHI 
restriction digestion and fragments for both plasmids following NotI, BamHI, SaII, 
SacI digestion and CIP treatment. The marker on the gel is DNA HyperLadder I. The 
gel was visualised using the Gel Doc EZ Imager. 
 
 
The gel image shown in figure 5.34 was used to estimate each fragmen’s 
concentration, in order to determine what volumes should be taken for the ligation 
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reaction. Based on the advantage of having a T7 tag within the construct, the 
pTATv2 plasmid was selected for molecular cloning. Three times the number of 
insert was mixed with pTATv2 plasmid and incubated in the presence of T4 DNA 
ligase.  
 
Competent DH5α cells were transformed with pTATv2 plasmids with either lamin A 
or progerin inserts. Following successful transformation, where numerous colonies 
were observed on both the lamin A and progerin plates but none were found on 
control plates (no insert), the plasmids were purified from eight separate colonies 
from each of lamin A and progerin. A sample of each plasmid was digested with 
BamHI and NotI . Figure 5.35 shows the products from the digestion reaction run on 
a 1% agarose gel. 
 
 
Figure 5.35 Ligation efficiency of Lamin A and Progerin cDNA inserts and 
pTATv2 plasmid 
The top band seen in all lanes confirm pTATv2. The smaller band confirms the 
presence of the cDNA insert 1L-8L from Lamin A ligation and 1P-8P from progerin 
ligation.  Lanes with two bands show colonies which have taken up a plasmid 
containing the respective cDNA insert. The marker on the gel is DNA HyperLadder I 
. The gel was visualised using the Gel Doc EZ Imager. 
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The plasmids which had taken up an insert were identified in figure 5.35. Two of 
these plasmids for each insert were selected for DNA sequencing.  Plasmids were 
sequenced by Beckman Coulter Genomics using two of their universal primers, T7P 
(TAA TAC GAC TCA CTA TAG GG) and T7 term (CTA GTT ATT GCT CAG 
CGG). The sequenced region covered the insert and approximately 100bp either side 
of the insertion site. The sequences were aligned to the reference sequence, taken 
from the in silico plasmid maps, using DNASTAR® software. The same base pair 
change was found in all four inserts, suggesting that this variation was present in the 
original template DNA. Figure 5.36 shows electropherograms and sequence 
alignment for the sequence variation. 
 
 
 
Figure 5.36 Electropherogram showing sequence variation found in all 4 plasmids 
sequenced 
Graph shows the sequences reads obtained using the T7 term reverse primer. Arrow 
indicates the sequences variation. Image B shows the reference sequence aligned to 
the complimentary T7 term read once it had been inverted.  
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The sequence variation shown in figure 5.36, GAT>GAC at nucleotide 1495, is a 
silent mutation which does not change the amino acid, aspartic acid, at position 441 
of these protein. As it is believed this variation was present in the template DNA, 
plasmids containing this sequence variation could continue to be used. This was the 
only sequence variation found in the 3L plasmid, however, 6L contained several 
sequence changes. Therefore, 3L was selected as the plasmid to be used to produce 
the TAT- lamin A protein. Plasmid 4P was identified as having a variation which 
altered the amino acid sequence of progerin making it unsuitable to use for protein 
production. 8P was found to contain a second synonomous mutation of AAT>AAC 
at nucleotide 1575. As this does not change the amino acid, asparagine, 8P was 
selected for protein production. See Appendix ii for all sequencing data. 
 
The 3L and 8P plasmids were transformed into rubidium chloride competent 
RosettaTM cells (Novagen), a BL21 variant which contains tRNAs (recognise AGG, 
AGA, AUA, CUA, CCC, GGA codons) specific for the production of human 
proteins. The RosettaTM cells also contain a plasmid that confers chloramphenicol 
resistance. 0.5mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) was used to 
induce the production of the proteins under the control of the T7 promoter. A sample 
of the culture before and after induction was run on a 10% SDS PAGE. This gel was 
then stained for proteins using coomassie blue. Figure 5.37 shows an image of the 
gel.  
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Figure 5.37 IPTG protein induction 
Image of a 10% SDS PAGE showing proteins found in RosettaTM cell before and 
after protein induction using IPTG. The additional bands in the +IPTG are at the 
expected molecular weights for TAT-Lamin A (75 KDa) and TAT-Progerin (70 
KDa) respectively.  The ladder is the Precision Plus ProteinTM standard (Bio-Rad). 
The image was taken using the Gel Doc EZ Imager (Bio-Rad).  
 
 
The addition of the TAT domain to proteins is believed to add between 5-10 kDa to 
the observed molecular weight, therefore TAT-lamin A is expected to have a 
molecular weight of 75 kDa and TAT-progerin of 70 kDa. IPTG induction caused 
the production of proteins of expected sizes, shown by the appearance of thick bands 
on the gel in figure 5.37. The 50 amino acid difference between these two proteins 
can be observed on the gel in figure 5.37. After protein induction was confirmed, 
protein purification was attempted using the histidine tag found on the fusion 
proteins.  
 
Protein purification was performed as outlined by Becker-Hapak et al, 2001. Total 
cell extract was produced by incubation with Buffer Z, which contains 8M Urea and 
causes cell lysis and sonication to break open inclusion bodies and shear DNA. 
Centrifugation at 16,000G was enough to separate total cell extract into either pellet 
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(DNA) or supernatant (Proteinaceous). 20mM imidazole was used to increase 
binding efficiency of the supernatant to the Ni- NTA Agarose (Qiagen) resin. The 
unbound proteins (run-through) were removed and elution of proteins from the 
column was attempted with increasing concentrations of imidazole.  
 
Analysis with a Bradford assay identified that no protein was eluted from the column 
in any fractions. Figure 5.38 shows an SDS PAGE analysis of the total cell extract, 
pellet, supernatant and run-through, and was used to determine the stage at which the 
protein was lost.  
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Figure 5.38 Analysis of protein purification for TAT- lamin A and TAT- Progerin 
10% SDS PAGE gels showing before and after IPTG induction for both TAT-Lamin 
A and TAT- Progerin. Image A shows the proteins found in the total cell extract, 
supernatant, pellet and run through for the TAT-Lamin A protein. Image B shows 
the same for the TAT-Progerin protein. Three times the volume of re-suspended 
pellet was loaded onto the gel compared with all other sample. The ladder in both 
gels is the Precision Plus ProteinTM standard. The images were taken using the Gel 
Doc EZ Imager. 
 
      141 
 
Since the protein was present in the total cell extract and supernatant it was not 
affected by sonication and not much was lost into the pellet. Unfortunately, the 
presence of the desired proteins in the run through shows that the protein did not 
bind to the column. In order to remedy this, a lower final concentration of imidazole 
(10 mM) was added to the supernatant. Under these conditions a relatively low yield 
of protein was purified. Figure 5.39 shows the purified fractions which contain lamin 
A (Figure 5.39A) and progerin (Figure 5.39B).  
 
 
Figure 5.39 Protein Purification Fractions 
10% SDS PAGE gels showing purified fractions of TAT-lamin A (A) and TAT-
progerin (B). The ladder in both gels is the Precision Plus ProteinTM standard. The 
images were taken using the Gel Doc EZ Imager. 
 
 
Despite the purification of the desired protein a considerable amount of this protein 
was still found in the run-through. Figure 5.40 shows analysis of the fractions for the 
purification attempt using the lower concentration of imidazole.  
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Figure 5.40 Comparison of run through and protein purification fractions for 
TAT- lamin A and TAT- Progerin 
SDS PAGE gel stained with coomassie blue showing the run through and peak 
purified fragment for both TAT-Lamin A, TAT-Progerin and for a TAT-p16 fusion 
protein (2K) which has a good protein yield and was purified simultaneously with 
the two other proteins. The gel also shows the run-through, first fraction eluted from 
the column  (1) and the peak purified fraction for Lamin A and Progerin this is 
fraction 13, wheras 2K is fraction 18. The image was taken using the Gel Doc EZ 
Imager. 
 
 
The SDS PAGE in figure 5.40 shows the run through and fractions for 3L, 8P and a 
TAT-p16 fusion protein for comparison. After incubation with the resin the level of 
TAT-p16 (2K) is minimal within the run-through, with the majority of protein being 
found in the purified fractions. The reverse can been seen for the TAT-Lamin A and 
TAT-Progerin proteins, suggesting that the nature of the proteins, in particular their 
filamentous structure, may be involved in their low binding efficiency. Further 
optimisation, including increasing incubation times and reducing temperatures all 
failed to increase the binding efficiency.  
 
To determine if the poor binding ability of the proteins to the column is as a result of 
a lack of a histidine tag, western blot analysis was performed on whole cell lysate 
post IPTG protein production. An anti-histidine tag antibody was used in 
combination with a horseradish peroxidase conjugated secondary antibody and 
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visualised using chemiluminescence. An image of the resulting membrane is shown 
in figure 5.41.  
 
 
 
Figure 5.41 Western blot analysis of whole cell extracts before and after IPTG 
induction using antibody raised against the Histadine tag 
Image showing a western blot membrane probed with a histidine tag antibody, 
identifying the presence of proteins with a histadine tag post- IPTG protein 
induction, namely, TAT-p16 (2K), TAT-Lamin A (3L), TAT-Progerin (8P). The 
marker is the Precision Plus ProteinTM standard and membrane was visualised under 
chemiluminescence using the Molecular Imager® ChemiDocTM XRS+ using Image 
LabTM software. 
 
The image in figure 5.41 shows that the proteins produced do contain a histidine tag 
and should, therefore, bind to the Ni-NTA Agarose column. Under the SDS 
conditions we see that the histidine tag is detectable both for TAT-lamin A, TAT-
progerin and as a control TAT-p16. For control, TAT-p16 a single band is visible 
and at the expected molecular weight of 25 kDa.  For TAT-lamin A and TAT-
progerin, the main band in each lane is the expected molecular weight and likely 
indicates the fusion protein, however, several bands revealing larger proteins are also 
visible for both fusion proteins.  This suggests that more than one transcription 
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product is being produced from the plasmid and the interaction between these 
proteins is undetermined.  
 
5.2.2 TAT -Lamin A and TAT-Progerin Protein Transduction 
 
TAT-mediated protein transduction was attempted with the small amount of purified 
fusion-proteins. 2DD primary fibroblasts, grown on glass cover slips, were incubated 
with the fusion protein for a 30 minute period. After this time cells were fixed and 
stained using antibodies against the T7 tag and lamin A/C, as described in section 
2.2.1. Representative Images of the staining pattern observed using these two 
antibodies is shown in figure 5.42.  
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Figure 5.42 T7 TAG and Lamin A/C Immunofluorescence following TAT-Lamin 
A and TAT-Progerin protein transduction 
Images showing the staining pattern observed after protein transduction using lamin 
A/C (A) and T7 tag (B) antibodies and DAPI.  
 
 
The staining patterns shown in figure 5.42 suggests that the proteins have not 
penetrated the plasma membrane and may have formed aggregates outside of the 
cells. To increase the likelihood of cell penetration the 8M urea was removed from 
the buffer before transduction. This was performed using a PD-10 desalting column. 
The use of this column resulted in a successful transduction for the p16-TAT protein.  
The TAT-Lamin A and TAT-progerin proteins both gave the same staining pattern 
as that observed before the desalting step (data not shown).  
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To determine that the antibodies were recognising the correct proteins western blot 
analysis was performed using lamin A/C and T7 tag antibodies. The before and after 
IPTG induction samples were run on 10% gels and probed as described in section 
4.2.4.  Images of the western blot membranes probed with lamin A/C and T7 tag 
antibodies are shown in figures 5.43 and 5.44 respectively.  
 
 
Figure 5.43 Western blot analysis of whole cell extracts before and after IPTG 
induction using antibody raised against Lamin A/C 
Image showing a western blot membrane probed with a lamin A/C antibody, 
identifying the production of Lamin A/C proteins post- IPTG protein induction. 
Bands at 75 kDa confirm TAT- Lamin A (3L) and at 70 kDa (8P) show TAT-
Progerin. Larger than expected bands are also observed in both 3L and 8P. No bands 
are detected in 2k as plasmid encodes a TAT-p16 protein and no lamin proteins. 
TAG06297 is a hTERT immortalised HGPS fibroblast cell line. The marker is the 
Precision Plus ProteinTM standard (Bio-Rad) and membrane was visualised under 
chemiluminescence using the Molecular Imager® ChemiDocTM XRS+ using Image 
LabTM software. 
 
 
The gel in figure 5.43 shows the proteins are of expected size when compared to the 
sample prepared from hTERT HGPS fibroblast cell line TAG06297. The larger 
proteins visualised using the histadine Tag antibody are also visualised with Lamin 
A/C antibody, identifying them as a larger transcript from the pTATv2 plasmid. As 
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expected no bands were identified in the control TAT-p16 sample, also showing that 
the lamin A/C antibody is not interacting with any endogenous bacterial proteins.  
 
 
Figure 5.44 Western blot analysis of whole cell extracts before and after IPTG 
induction using antibody raised against the T7 TAG 
Image showing a western blot membrane probed with a T7 TAG antibody, 
identifying the production of proteins containing T7 TAG post- IPTG protein 
induction. Bands at 75 kDa confer TAT- Lamin A (3L) and at 70 kDa (8P) show 
TAT-Progerin. Larger than expected bands are also observed in both 3L and 8P. 
Bands are detected in 2k as the plasmid encodes a TAT-p16 protein with a T7 TAG. 
TAG06297 is a hTERT immortalised HGPS fibroblast cell line. The marker is the 
Precision Plus ProteinTM standard and membrane was visualised under 
chemiluminescence using the Molecular Imager® ChemiDocTM XRS+ using Image 
LabTM software. 
 
 
Figure 5.44 shows the western blot using an antibody raised against the T7 tag. The 
inclusion of this tag within our fusion protein was aimed to allow differentiation 
between endogenous and transduced proteins within the HGPS cells. For TAT-
Lamin A, TAT-progerin and TAT-p16 bands are visualised at the correct molecular 
weight. For both TAT-Lamin A and TAT-progerin, however, the same 100 kDa 
band, presumed a larger undesired transcription product, and also several smaller 
bands are also visible. The presence of additional transcription products, low 
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purification yield and aggregation upon protein transduction hindered the 
progression of this work. 
 
5.2.3  A-Type Lamin Nanobody Plasmid Transformation 
 
As several issues arose with the use of TAT-lamin A and TAT-progerin fusion 
proteins, as a method for the validation of increase progerin degradation in response 
to growth in the presence of hTERT, a second method using Nanobody technology 
was attempted. An A type lamin targeted nanobody with a conjugated E3 ubiquitin 
ligase was designed by Professor Heinrich Leonhardt’s laboratory, the pioneers of 
this technology. The aim of this work was to recreate the process that we believe 
occurred naturally within the TAG06297 cultures in response to hTERT expression. 
By targeting A-type lamins and bringing them into close proximity to an E3 
ubiquitin ligase, an increase in the rate of A-type lamin degradation through 
polyubiquitination was expected. It is hypothesised that through a reduction in the 
level of progerin in HGPS fibroblasts, a similar loss of progeria cell characteristics 
could be observed as that seen in the TAG06297 Late culture in chapter 3. The 
pc3236 plasmid was provided by Professor Leonhardt’s group and a map of this 
plasmid is shown in figure 5.45. 
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Figure 5.45 pc3236 plamid map 
Plasmid map showing the E3 ligase coding sequence in blue, next to the A type 
lamin recognition sequence shown in green.  Shown in red is the red fluorescent 
protein DsRed. Map provide by Professor Leonhardt’s group.  
 
 
Pc3236 was transiently transfected into NB1T hTERT control fibroblast cultures as 
well as TAG06297 early and late hTERT HGPS cultures. Transfected cells were 
cultured for 24 and 48 hour periods followed by fixation and visualisation using 
fluorescence microscopy. A plasmid expressing GFP was used as a negative control. 
No antibodies were needed as cells expressing pc3236 were expressing DsRed and 
were therefore distinguishable. The transfection efficiency for the control GFP 
plasmid was 30% and for pc3236 was 10%. Data was gathered and analysis 
performed by Dr Joanna Bridger. 
 
Analysis of cells 24 hours post transfection show nuclear morphology changes 
detected using DAPI staining. Control NB1T fibroblasts show elongated nuclei in 
100% of cells positive for DsRed as compared to elliptical structure of non-
transfected cells. In NB1T cells expressing the pc3236 plasmid clumping of 
chromatin was also visible which is reminiscent of chromocentres. Similarly 
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TAG06297 Late cell also show an elongated nuclear morphology in response to the 
A type Lamin nanobody. They also show the presence of bright foci accumulation 
and a tendency to form multinuclei. The TAG06297 Early cells, however, seem less 
affected by the pc3236 plasmid with <40% of DsRed positive cells showing changes 
to nuclear morphology and chromatin aggregation. Figure 5.46 shows representative 
images of the DAPI staining in response to transfection with pc3236. Very few 
changes to nuclear morphology were observed following transfection with the GFP 
control plasmid.  
 
 
 
Figure 5.46 Fluorescence image analysis of hTERT HGPS cells following 
transfection of pc3236 encoding A type lamin specific nanobody conjugated to an 
E3 ubiquitin ligase 
Pc3236 expression shown in red by the expression of DsRed. Control plasmid 
encoding GFP shown in green. Nuclei stained with DAPI and visualised using 
fluorescent microscopy. Transfection performed on an early passage and late passage 
version of the TAG06297 HGPS fibroblast cell line immortalised with hTERT. 
Images captured and analysed by Dr Joanna Bridger. Scale bar = 10µm.  
 
 
The difference in effect of the A type lamin targeted Nanobody on TAG06297 Early 
and Late can be explained by the difference in level of A type lamin proteins within 
these cells. Loss of progeria cell characteristics (as described in chapter 3) has been 
attributed to an increase in protein degradation of both lamin A and progerin (as 
described in chapter 4) resulting in less toxic A type lamins and therefore, explaining 
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the similarity in response of both control (NB1T) cells and the TAG06297 Late 
cultures.  
The TAG06297 Early culture still demonstrate the negative effects of progerin 
expression and ultimately benefit in the short term from the reduction of A type 
lamin proteins. 48 hours after transfection, however, cell loss, thought to be through 
apoptosis, is observable in all three cell lines, inhibiting the gathering of data from 
these slides. Cell death in TAG06297 Early cells was observed at a slower rate, again 
providing tentative support to the hypothesis.  
 
Ultimately this finding suggests that targeting A-type lamins through pc3236 does 
not support cell viability. The Nanobody recognition sequence binds to all A-type 
lamins, knockdowns of which have previously been shown to reduce viability in 
mice (Sullivan et al, 1999). This supports the observation that cells were undergoing 
the early stages of apoptosis 24 hours after the Nanobody transfection. Further 
information would be better gathered using a Nanobody specific to Lamin A and 
progerin as neither of these are essential for cell survival, with an entirely health 
lamin C only mouse model having been created (Fong et al, 2006). 
 
5.3 Discussion 
 
In this work we have shown the production of TAT- lamin A and TAT- progerin 
fusion proteins. The next step in the development of these proteins is to optimise the 
purification protocol. The 8M Urea should be ample to denature the proteins and 
open up their structure. Through western blot analysis we know the histidine tag is 
present in these fusion proteins, yet is unable to bind to the Ni-NTA column. With 
the difficulty previously observed in immunoprecipitation of these filament proteins 
(Herrmann, 2004), this could suggest that even in denaturing conditions they are 
forming secondary structures masking the histidine tag. One option to overcome this 
would be to use the pTATv1 plasmid as this contains two histidine sequences (see 
figure 5.30), hopefully increasing the purification efficiency. Screening with three 
different antibodies (Lamin A/C, Histidine tag and T7 tag) all reveal the production 
of several proteins of increased molecular weight. Though the majority of the protein 
produced is of the correct molecular weight, the effect of these contaminating 
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proteins is unknown and pure product is required for protein transduction. The 
plasmids were selected based on low levels of genetic variation from the reference 
sequences and as no splicing occurs in bacteria cells one protein product was 
expected. With optimisation of the purification process, greater stringency by 
increased imidazole concentration, may enable the selection of pure protein products. 
Once proteins of the correct size have been purified TAT-mediated protein 
transduction can be attempted. It is possible that the nature of these filaments affinity 
for dimer formation (Dechat et al, 2010) is also inhibiting the transduction process, 
in particular as no improvement was seen following desalting, a step known to 
increase transduction efficiency for other TAT fusion proteins (Becker-Hapak et al, 
2001). Successful protein transduction and incorporation into the nuclear lamina 
must be observed before further experiments can be conducted using the TAT 
proteins.  
 
The aim of developing these TAT-fusion proteins was to determine the rate of 
progerin degradation in HGPS fibroblasts and show an increased rate of degradation 
in response to long term growth in the presence of hTERT. Progerin degradation, in 
response to Rapamycin treatment of HGPS fibroblast, has previously been explored 
using radiolabelled- pulse chase experiments followed by immunoprecipitation, 
which showed an increase in breakdown of the soluble fraction of progerin compared 
to lamin C (Cao et al, 2011). This technique could also be employed to look at the 
effects of hTERT. 
 
Another potential use of these transducing proteins is to determine at what level 
progerin causes an effect on cell function. Small levels of progerin have been 
detected in cells and skin from elderly donor (Scaffidi & Misteli, 2006; Rodriguez et 
al, 2009; McClintock et al, 2007), however, it is not known if this is a cause of 
ageing or if it is a by-product. In order to investigate this, increasing concentrations 
of TAT- progerin could be added to control cells until it is determined it has elicited 
a detrimental effect, by the appearance of progeria cell characteristics.  
 
It would be interesting to determine if only a small amount of progerin is required to 
harm cell function or if there is a critical level at which progerin can no longer be 
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tolerated. If this is the case therapeutic efforts, such as the proposed rapamycin 
treatment (Cao et al, 2011), can be put into reducing progerin to below the critical 
level. It could also be that the ratio between progerin and lamin A is the key factor, 
therefore, transduction of lamin A would restore cell function. In this case future 
treatments of HGPS could involve increasing cellular levels of lamin A. This would 
be in contradiction to previous findings, however, which suggest that the toxic effect 
of progerin is not negated by Lamin A abundance (Scaffidi & Misteli, 2005).  
A further use of the TAT fusion proteins is to investigate how progerin and lamin A 
enter the nuclear lamina. There is much confusion about how lamin A and progerin 
are incorporated into the nuclear lamina (Dittmer & Misteli, 2011).  
 
Immunofluorescence analysis at time points after protein transduction could add 
clarity to this matter. The fusion proteins can also be used to identify lamin A and 
progerin binding partners using a ChIP type method. The addition of the histidine tag 
to these proteins will allow easy purification for the ChIP like assay. This would add 
insight into the differences between lamin A and progerin within the nuclear lamina. 
It could also determine whether lamin A and lamin B co-polymerise (Ye & Worman, 
1995; Georgatos et al, 1988; Dittmer & Misteli, 2011).   
 
The use of Nanobodies targeted to A type lamins, conjugated to a E3 ubiquitin 
ligase, was aimed at replicating the natural occurring events observed in response to 
prolonged growth in the presence of hTERT, whereby TAG06297 Late cells had 
reduced their progerin and improved cell phenotype (Chapter 4). By transfecting a 
plasmid encoding an A type lamin target Nanobody conjugated to an E3 ligase it was 
thought that TAG06297 Early cells would begin to present like TAG06297 Late 
cells.  
 
 We observed that the A type Lamin target Nanobody -E3 ubiquitin ligase did 
elicited an effect, it is unfortunate that by targeting both Lamin A and Lamin C cell 
death occurred. It is not surprising that increasing the breakdown of all of these 
proteins led to cell death, but it does demonstrate the potency of this approach. A 
Nanobody designed to specifically increase the degradation of Lamin A and 
Progerin, would better mimic the effects observed in the TAG06297 Late cell line, 
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offering possibilities for therapy. With potential therapies, such as rapamycin 
treatment (Cao et al, 2011), already exploring the option of increased protein 
degradation, Nanobodies offer a more specific approach than increased autophagy. 
With many concerns about the suitability of Rapamycin it may be a case of the right 
approach but the wrong method. Nanobodies are already being employed 
therapeutically (Peyvandi et al, 2016) and may be the right method.  
 
The production of TAT-lamin A and TAT-progerin offer a novel approach to 
investigating HGPS. The proteins offer the opportunity to investigate the cell 
biology underlying HGPS as well as the potential to identify new genes and 
therapeutic targets for this disease. Although in their infancy TAT-Lamin A and 
TAT-progerin fusion proteins are an exciting and useful tool in studying HGPS. The 
first experiments using Nanobodies conjugated to an E3 ubiquitin ligase in HGPS 
cells show therapeutic promise for the treatment of this so far incurable disease.   
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6 Characterisation of hTERT Immortalised, 
“Atypical” Progeria Cell line in the Search for 
a new Causative Genetic Mutation. 
 
6.1 Introduction 
 
Identification of new genes involved in the progeriod process will give a better 
understanding of the underlying mechanisms of HGPS. One of the main aims of this 
research is to identify new genes responsible for the rare “Atypical” form of HGPS. 
Several uncommon gene mutations have already been reported (see section 1.5), 
which alter lamin A binding partners and proteins involved in lamin A processing. 
This highlights the importance of lamin A and nuclear envelope proteins in this 
disease, suggesting potential candidate genes may be proteins that form lamin A 
interactions. 
 
The rare nature of this disease means there are a limited number of patients and thus 
cell lines available. One available cell line, AG08466 (Coriell Institute), is a 
fibroblast cell line, established in 1985, originating from an 8 year old girl with 
“Atypical HGPS”. The skin biopsy used to establish the cell line was taken ante-
mortem and information about the longevity of this patient is unavailable. The 
patient had a normal 46, XX karyotype and some classic characteristics of HGPS 
such as loss of subcutaneous fat, osteoarthritis and venous prominence; however, the 
patient experienced no alopecia and developed some Marfan syndrome like 
characteristics (Coriell Institute). The underlying mutation in this patient has yet to 
be established. Sequence analysis has revealed a normal genotype for nucleotide 
c.1824C in the LMNA gene (Personal communications Professor Nico Lévy). Further 
sequencing analysis, performed at Brunel University London, showed no mutation in 
the lamin A binding partners emerin and LAP2α (Godwin, 2010).  
 
The low incidence of this disease makes normal methods of disease gene 
identification more challenging, as for instance there are not enough patients to 
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perform a genome wide association study (GWAS). It is difficult because some 
mutations are found only in a small number of patients or may be specific to an 
individual.  
 
Micro-cell mediated chromosome transfer (MMCT) is one proposed method for 
identifying the underlying mutation in the AG08466 cell line. This technique allows 
the removal of genetic material from a cell line (donor) and subsequent incorporation 
of this chromosome into a second cell line (recipient) (Fournier & Ruddle, 1977). 
This is a well-established technique that was first developed in the 1970’s and has 
proved an effective tool for gene discovery, especially in the cancer field (Anderson 
& Stanbridge, 1993; Yoshida et al, 2000; Meaburn et al, 2005).  Most notably p53 
and pRB were identified using this method (Stanbridge 1992). The breakthrough in 
this technique came when an entire human genome library was created in a mouse 
cell background (Cuthbert et al, 1995). Each chromosome from a healthy individual 
was transferred into separate mouse cells. The easy removal of the human 
chromosome from the mouse background allowed for complementation studies, 
which have led to the identification of a large number of tumour suppressor genes 
(Meaburn et al, 2005).  Chromosomes from the mouse library are transferred into 
tumour cells and if complementation occurs loss of neoplastic characteristics such as 
growth in soft agar can be observed. This indicates that a tumour suppressor gene, 
which has been inactivated in the tumour cell, is encoded within the transferred 
chromosome. Upon transfer of the chromosome, it is incorporated into its normal 
nuclear location and thus has a normal expression profile (Tindall et al, 1998). One 
method that has been employed to determine the specific locus of the tumour 
suppressor gene within the chromosome involves transferring chromosome 
fragments that have been produced by exposure to γ- irradiation, in a deletion 
mapping type exercise (Dowdy et al, 1990). For example the colorectal cancer 
tumour-suppressor gene has been mapped to a 900-kilobase region on the short arm 
of chromosome 8 through MMCT of chromosome fragments (Flanagan et al, 2004). 
This technique has also been applied to identify senescence associated genes, by first 
identifying chromosomes with the ability to allow immortalised cells to senesce 
(Meaburn et al, 2005).   
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 MMCT has been used to identify a large number of disease associated genes, all of 
which have been recessive, and identified through complementation. A novel 
application of this technique was theorised for this research, where MMCT would be 
used to identify a dominant disease causing gene. The Majority of cases of HGPS 
result from de novo mutations that alter one copy of a gene giving rise to a disease 
phenotype (Eriksson et al, 2003; De Sandre-Giovannoli et al, 2003). With this in 
mind and the fact there is no history of a consanguineous marriage in the case of 
AG08466 (Coriell Institute), it is likely that the underlying mutation is dominant. By 
transferring single chromosomes from the AG08466 cell line into a control cell line 
the aim is to identify which chromosome contains the gene mutation. This will be 
determined by the appearance of a diseased phenotype in the control cells, which 
contain the chromosomes with the gene mutation. As this is a novel application of 
this technique the proof of principle would be to transfer chromosome 1 from a 
classic G608G progeria cell into a control cell, and observe changes to a disease 
phenotype. Figure 6.47 summarises the proposed use of MMCT.  
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Figure 6.47 Diagrammatic representation of Microcell Mediated Chromosome 
Transfer 
A diagram summarising the process of microcell mediated chromosome transfer for 
the identification of a chromosome containing a progeria causing mutation. Image 
adapted from Meaburn et al, 2005.   
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The AG08466 cell line is one of a few HGPS cell lines to be successfully hTERT 
immortalised (Wallis et al, 2004) and it is anticipated that offers new opportunities 
for cell characterisation and gene discovery. Through hTERT immortalisation the 
projected increased cell number offers opportunities to use, previously successful 
methods for gene discovery, that require a large cell number such as Micro-cell 
Mediated Chromosome Transfer. 
 
Through characterisation with the hTERT immortalised TAG08466 cell line and the 
classic G608G cell line TAG06297, it is postulated that further insight into the 
underlying mechanism will also be gained and a list of potential candidate genes 
generated. 
 
Whole Exome Sequencing, is another potential method for gene identification for the 
TAG08466 cell line, with cells available from three unaffected relatives for 
comparison (Coriell Institute). Whole exome sequencing has already been effectively 
used for the identification of a BANF1 mutation in two patients with “Atypical” 
progeria (Puente et al, 2011). Our knowledge of how these cells behave in the 
presence of hTERT can be used to aid in the bioinformatics of gene discovery and 
help hypothesis about any potential causative mutations mode of action.   
 
The aim of this chapter is to identify new genes involved in HGPS, by identifying 
the causative mutation in a cell line derived from an “Atypical” progeria patient. By 
identifying further causes of the disease greater understanding of the disease 
pathology will be achieved. Knowledge about premature ageing disease can also add 
greater understanding to the processes behind normal human ageing. 
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6.2 Results 
 
6.2.1 Growth Potential 
 
Cells taken from progeria patients display a diverse but relatively short replicative 
lifespan in culture, which has been characterized by hyperproliferation and increased 
levels of apoptosis (Bridger & Kill, 2004). The AG08466 fibroblast cell line, 
originating from an “Atypical” progeria patient with an as yet unknown causative 
genetic mutation, was immortalized using hTERT (TAG08466) by Professor 
Richard Faragher (Wallis et al, 2004). AG08466 primary cells were shown to be 
relatively long-lived amongst HGPS culture achieving just over 45 population 
doublings at their maximum replicative lifespan, more than the classic HGPS cell 
line AG06297(Bridger & Kill, 2004).  
 
To investigate the growth rate and potential of the “Atypical” TAG08466 cells, 
growth curves were produced and compared to the hTERT immortalised classic 
HGPS cell line TAG06297 (Figure 6.47). Cell passage was carried out twice weekly 
to avoid confluence. A fibroblast culture from a health individual (NB1T), also 
immortalized with hTERT was used as a control (Unpublished Data, see Chapter 
2.1.1). At each passage the cell number was counted using a haemocytometer and 
used to calculated the number of Population Doublings achieved (3.32 
[log(harvested)-log(seeded)]). Cells grown on glass coverslips were used to estimate 
the proportion of proliferating cells, using indirect immunofluorescence with an 
antibody for the proliferation marker Ki-67 (Figure 6.47). Despite little 
understanding of Ki-67 function, it is widely used as a marker for proliferation, as it 
is exclusive to the nucleus of proliferating cells (Kill et al, 1996). Figure 6.48 shows 
representative images of the staining pattern observed for Ki-67. TAG06297 cells are 
defined as TAG06297 Late to coinside with previous chapters, TAG08488 and 
NB1T are also late passage cultures with more than 2 years continued growth in 
culture.  
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Figure 6.478 Growth Potential of hTERT immortalised “Atypical” Hutchinson-
Gilford Progeria Fibroblasts 
 (A) Compares the number of population doublings (PD) achieved by a hTERT 
immortalized Atypical progeria cell line TAG08466, with control fibroblast cell line 
NB1T and classic HGPS derived TAG06297, all of which are immortalised with 
hTERT. Growth curves were constructed from data gathered over a 46 day period 
and the number of population doublings was calculated using the formula 3.32 
[log(harvested)-log(seeded)]. (B) Shows the fraction of proliferating cells within 
each culture, determined using the proliferation marker ki-67, plotted against the 
APD achieved within 46 days. (C)  Representative images displaying how 
proliferating cells were identified by positive staining for ki-67. Scale bar =10µm. 
(d) table summarising the growth of each cell line in the 46 day period.  
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There are observable differences in the growth curve of “Classic” (TAG06297) and 
“Atypical” (TAG08466) hTERT cell lines, the slopes of which varying from 0.5 to 
0.93 APD/Time, with TAG08466 achieving the most population doublings in the 46 
day period. The difference of 1.17 PD on average per passage, between TAG06297 
and TAG08466 cell lines, had a substantial effect in culture. The higher rate of 
growth in the TAG08466 cell line makes it a very practical asset for gaining cell 
numbers. Interestingly, there is no statistically significant difference between the 
growth rate (T- TEST two tailed 0.59) of TAG08466 and the NB1T control cell line, 
demonstrating the practical value of this cell line as a resource for progeria cells.   
When comparing Ki-67 levels within the cultures, all three cell lines show a high 
fraction of proliferating cells, with more than 90% of cells within the culture 
contributing to the growth.  Again, there is no significant difference between 
TAG08466 and NB1T cell lines with T-TEST (two tailed) P value of 0.46. The 
difference between for Ki-67 positive fraction of TAG06297 (91%) compared to 
NB1T (98%) and TAG08466 (97%), is significant, with a T-TEST (two tailed) 
values of 0.00047 and 0.00591 respectively. This difference in proliferating cell 
fractions may explain the differences in the growth curves and the rate of growth 
observed in culture between the two HGPS cell lines. This does suggest a difference 
in response to hTERT immortalisation between the classic G608G mutated cells and 
the “Atypical” cell line with the unknown mutation, pondering the influence the 
underlying mutation may have played in this extremely successful immortalisation.  
 
 
6.2.2 Nuclear Shape 
 
One of the most observable effects of progerin expression within cells is the 
resulting changes in nuclear morphology. Primary classic HGPS fibroblasts nuclei 
have been shown to accumulate significantly higher fractions of cells with nuclear 
membrane blebs, invaginations, micronuclei formation and other abnormal 
morphologies (Bridger & Kill, 2004). The TAG08466 cell line does not contain the 
G608G mutation (Bridger & Kill, 2004) and no progerin expression or protein has 
been detected in this cell line (See Chapter 4). Primary AG08466 cells were found 
not to have a significantly higher percentage of abnormal nuclei than controls at low 
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a percentage of their replicative lifespans (T-TEST two tailed 0.12), however, an 
increase was observed when comparing cells with a high (T-TEST two tailed 0.024) 
percentage replicative lifespan (Bridger & Kill, 2004). The primary AG08466 
showed significantly lower levels of nuclear abnormalities than primary AG06297s, 
however, at both stages of the cultures lifespan (T-TEST two tailed 0.002 and 0.008 
respectively). As the underlying mutation in the AG08466 cell line is unknown, the 
cause of the increased number of nuclear abnormalities is not understood.  Since it 
seems likely that accumulation of gross nuclear abnormalities could have a profound 
effect on cell cycle events, such as mitosis, we wished to determine how the 
TAG08466 cells coped with increased levels of growth following immortalization 
with hTERT.  
 
 Nuclear morphology was analysed in TAG08466 and TAG06297 cultures as well as 
the control cell line, NB1T. Cells were cultured on glass coverslips, fixed and 
mounted in DAPI for nuclear visualisation. The slides were analysed manually and 
the nucleus that showed variation from a smooth elliptical nucleus resulted in a score 
of abnormal morphology. Figure 6.48A shows examples of normal and abnormal 
nuclear morphology, the table in Figure 6.49 summarizes the findings within these 
cultures.  
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Figure 6.49 Abnormal Nuclear Morphology in hTERT immortalised “Atypical” 
HGPS Fibroblast cultures 
Nuclear morphology was revealed using the DNA stain DAPI and was analysed for 
shape abnormalities such as, folds or crevices, herniation's, lobules and micronuclei. 
(A) Arrows indicate nuclei identified as having nuclear morphology abnormalities. 
Scale bar = 10µm. The table in (B) shows the percentage of abnormal nuclear 
morphology identified in; NB1T – a normal fibroblast culture, TAG06297 - a classic 
HGPS cell line and TAG08466 a cell line from an “Atypical” HGPS patient (n=750). 
All three cell lines have been immortalised with hTERT.  
 
 
Upon visual inspection of the DAPI stained nuclei, TAG08466 cells were observed 
as having a “wrinkly” nucleus unlike that observed in either the TAG06297 or NB1T 
cultures (Figure 6.48A). NB1T and TAG06297 Late demonstrate a statistically 
similar fraction of abnormal nuclei within the culture (T-TEST two tailed 0.44). 
TAG08466 cells, with the appearance of the “wrinkly” nucleus, showed statistically 
significantly higher percentages of nuclear abnormalities than the late passage 
TAG06297 cells (T-TEST two tailed 0.00002) and NB1T cells (T-TEST value of 
      166 
 
two tailed 0.000009). The percentage of nuclear abnormalities observed for the 
TAG08466 cell line is more comparable to that of the TAG06297 Early cell line (T-
TEST two tailed 0.023) two tailed, before the increase in progerin degradation and 
subsequent loss of progeria cell characteristics (Chapter 3 & 4). The percentage is 
also more comparable to classic G608G primary fibroblasts with high percentage 
replicative lifespan (T-TEST two tailed 0.099), than the primary counterparts of the 
TAG08466. This demonstrates that hTERT immortalisation does not improve 
progeria cell characteristics, in a cell line not expressing progerin and despite the 
increased growth potential has exacerbated a common progeria cell characteristic. 
This again adds interest to the nature of the underlying mutation and its role in 
nuclear structure and how that leads to HGPS patient phenotype.  
 
To further investigate the effect of continued growth, in the presence of hTERT, 
image analysis of nuclear size and shape was performed on digital images of 
cultures. Images of cells grown and fixed on glass cover were analysed using ImageJ 
software as described in material and methods 2.2.2. By setting the threshold to 
encompass the nuclear region stained with DAPI, measurements of nuclear size (area 
and perimeter) and shape (aspect Ratio and Circularity) could be produced. Figure 
6.50 shows data presented as frequency distributions for NB1T (control) TAG06297 
and TAG08466 cells.  
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Figure 6.50 Computational Analysis of Nuclear Size and Shape in hTERT 
immortalised “Atypical” HGPS Fibroblast cultures 
Cells grown on cover slips were formaldehyde fixed and mounted in DAPI. Images 
of the nucleus were captured and analysed using Image J particle analysis software. 
The nuclear regions were defined by adjusting the pixel threshold. Nuclear regions 
were analysed for (A) Area, (B) Perimeter, (C) Circularity (4pi(area/perimeter)) and 
(D) Aspect Ratio (major axis/minor axis). TAG08466 cell line originates from a 
patient with Atypical HGPS, TAG06297 Late is derived from a classic HGPS patient 
and NB1T is a healthy control fibroblast cell line. All three cell lines have been 
immortalised with hTERT. 
 
 
Comparisons between NB1T and the TAG06297 Late cultures reveal statistically 
significant differences in nuclear size, as defined by area (T-TEST two tailed 
<0.0001) and perimeter (T-TEST two tailed <0.0001). In accordance with previous 
findings for primary HGPS fibroblasts, the TAG06297 Late cells were found to have 
smaller nuclei (Choi et al, 2011). TAG08466 cells were found to have nuclei of a 
similar size to NB1T cells (T-TEST two tailed area 0.3070 and perimeter 0.8437) 
that were statistically significantly larger than TAG06297 (T-TEST two tailed 
<0.0001 area and perimeter). 
 
Aspect ratio and Circularity (Figure 6.50) measurements were both used to examine 
nuclear shape. Previous reports show HGPS fibroblasts to have, on average, a higher 
fraction of circular nuclei than those observed in healthy controls (Choi et al 2011). 
Using the same calculation of Circularity, no significant difference was identified 
between NB1T and TAG06297 Late cell lines (T –TEST two tailed 0.6410) with the 
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distribution of nuclei appearing similar. TAG08466 cells, however, showed a 
statistically significant higher number of circular nuclei than both NB1T and 
TAG06297 (T-TEST two tailed <0.0001). Furthermore, the measurement of Aspect 
Ratio also identified rounder nuclei in TAG08466 cell line than either NB1T (T-
TEST two tailed <0.0001) or TAG06297 (T-TEST two tailed <0.0001). The 
identification of larger, rounder and more “wrinkly” nuclei in response to hTERT 
immortalisation is the opposite effect to that observed in a cell line with the classic 
G608G mutation. Although a large amount of growth has been observed in the 
TAG08466 culture, cells appear worse than the classic G608G cell, where less 
growth was witnessed. This raises the question of how the underlying mutation, 
which differs from progerin, has affected the cells response to hTERT.  
 
6.2.3 Cell Motility 
 
Despite having the ability to proliferate, classic primary HGPS fibroblasts have been 
shown to have reduced cell motility, which leads to a decreased ability to heal 
wounds in culture (Verstraeten et al, 2008). With the unknown mutation in the 
TAG08466 and a less well characterised cell phenotype, it is not known if this cell 
line exhibits a reduced cell motility. On visual inspection of the culture, however, 
TAG08466 cell can be seen to grow in colonies or patches rather than spreading 
throughout the dish, suggesting an issue with cell motility.  
 
Cell motility in this cell line was investigating using live cell imaging. Time lapse 
videos, with five minute intervals, were produced over an eight hour period, for 
TAG06297 Early and Late passage, TAG08466 and NB1T. Once all of the images 
had been captured they were converted into a stack in ImageJ software and the 
Manual Tracking Pluggin was used to follow an individual cell through each image. 
By following the nucleus of the cell through each frame, coordinates were generated 
that could then be plotted on a graph (see chapter 3.2.6). Cell coordinates were 
centred to the middle of the graph, allowing comparison form a standardized start 
point (Figure 6.51).  
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Figure 6.51 Time Lapse Video analysis of Cell Movement in hTERT immortalised 
“Atypical” HGPS Fibroblast cultures 
Time lapse images were taken every 5 minutes for an 8 hour period. Using the 
Manual Tracking Plugin on Image J software, individual cells were given X and Y 
axis co-ordinates and their movement was tracked through all 96 images. The 
coordinates for each cell were centred and plotted on a graph, where each line 
represents a single cell’s movement. The black circle represents the average total 
distance moved in 8 hours and the red circle shows the average displacement (the 
difference between start and end locations). (A) shows the cell movement for a 
normal fibroblast cell line NB1T. (B) shows the cell movement for the “Atypical” 
HGPS fibroblast culture TAG08466. (C) shows Early and (D) shows Late passage 
strains of the classic HGPS derived TAG06297. All cell lines are hTERT 
immortalised. (E) Summaries the average movement made by each cell line 
including the velocity and the meandering ratio (total displacement/total distance).  
 
 
The average total distance and displacement (distance from start point to end point) 
has been marked on the graphs.  The black circles, represent the average total 
distance achieved by cells in that culture. TAG08466 achieved the greatest distance 
moved (Figure 6.51B), which was statistically higher than both TAG06297 Early 
and Late cell lines (T-TEST two tailed 1.41 x10-10 and 1.15 x10-12 respectively) and 
NB1T (T-TEST two tailed 0.0012). The TAG08466 cell line, therefore, also 
achieved the fastest cell velocity, which was significantly greater than the other three 
cell lines (T-TEST two tailed <0.0012). As the TAG08466 showed a significantly 
higher velocity and distance moved than the TAG06297 Early cells, the most 
representative of a classic G608G mutation, this suggests that this cell line is not 
affected, with the same reduction in rate of cell movement as that observed in classic 
progeria cells.  
 
In order to analyse the type of movement made by each cell line the Meanderings 
Ratio was determined, by dividing the displacement by the distance (Figure 6.51D).  
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This identifies if cells are moving round in circles or whether they show greater 
directionality to their movements. The Meanderings Ratios show that NB1T and 
TAG06297 Late demonstrate the same pattern of movement (T-TEST two tailed 
0.62), with a tendency to more linear advances. 
 
 TAG08466, however, demonstrates a movement statistically similar to 
theTAG06297 Early (T-TEST two tailed 0.17), where they appear to move within a 
small area. As the TAG08466 cells have a greater velocity they achieved a greater 
distance in the 8 hour time period, all be it moving in a small area. This pattern of 
movement does explain the patchy growth observed in culture and would do little to 
aid wound healing in Vivo. The progeria like movement pattern observed in the 
TAG08466 cell line, along with the “wrinkly” nuclear shape, put forward the 
involvement of the cytoskeleton in this case of progeria, with the interaction between 
lamins and SUN proteins having been previously established as occurring through 
the LINC complex (Gruenbaum et al, 2005; Haque et al, 2006; Haque et al, 2010).  
  
6.2.4 Chromosome Number 
 
Genome instability has previously been reported to occur in classic HGPS cells, with 
one study identifying the inclusion of progerin in membranes during mitosis leading 
to lagging chromosomes and loss of genetic material (Cao et al, 2007). TAG06297 
Late cells were shown to have a similar level of genomic instability to the hTERT 
immortalised controls NB1T with a median chromosomes number per cell of 46 
(Chapter 4).  As the TAG08466 cell line does not express progerin, the effect of the 
unidentified mutation on genomic stability is unknown, however, the primary cell 
line was karyotyped by Coriell Cell Repository and described as 46 XX. In order to 
determine genomic stability, fixed metaphase preparations were assayed by DAPI 
staining, captured using Metafer software. Figure 6.52 contains a box plot displaying 
the number of chromosome per metaphase analysed for TAG08466, TAG06297 and 
NB1T. 
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Figure 6.52 Chromosome Number Analysis in hTERT immortalised “Atypical” 
HGPS Fibroblast cultures 
Metaphase preparations were visualised with DAPI and images captured using 
metacyte software. The number of chromosomes per metaphase were determined for 
NB1T a normal fibroblast cell line that has been immortalised with hTERT and a 
hTERT immortalised Late passage strains of the HGPS derived TAG06297. For 
NB1T 180 Metaphases were analysed, for TAG06297 the number analysed was 224 
and for TAG08466 167 Metaphases were analysed.  
 
 
A T-test revealed no significant difference in the chromosome number of NB1T and 
TAG06297 (two tailed P value 0.096), with both cell lines having a median 
chromosome number of 46. TAG08466, however, was found to have a median 
chromosome number of 69, which differs statistically from NB1T (T-Test two tailed 
<0.001) and TAG06297 Late (T-Test two tailed <0.001). As the TAG08466 cell line 
was observed as having a median chromosome number of 69, further analysis of the 
karyotype of this cell line was performed by Dr Rhona Anderson and Dr Mehmet 
Bikkul, using M-FISH. Figure 6.53 shows all the chromosomes of one TAG08466 
cell aligned to their chromosome number.  
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Figure 6.53 Representative M-FISH karyotype of the “Atypical” HGPS fibroblast 
culture TAG08466 
Cell 21 showing 
83,XXX,t(X;1),ins(1;14),der(1)t(14;1;17),del(2p),del(3p),der(4)t(4;19),der(5)t(5;10),
del(5p),-6,der(7)t(7;21),-13,-14,der(14)t(10;14),-15,der(15)t(8;15),-16,del(17q). M-
FISH carried out by Dr Rhona Anderson and Dr Mehmet Bikkul.  
 
 
Analysis of 17 metaphase spreads identified the TAG08466 cells as having a near 
tetraploid (XXXX) karyotype with a large amount of aneuploidy and genomic 
instability. For a full karyotype of all cells analysed see Appendix iii. This near 
tetraploid karyotype is in complete contrast to the relative stability of the TAG06297 
cell line previously observed (Chapter 3). With hTERT cultures a level of genomic 
instability may be expected (van Waarde-Verhagen et al, 2005), but the TAG08466 
demonstrate this at a significantly higher level than controls (T-TEST two tailed 
<0.001). 
 
6.2.5 Possibility of Micro-cell mediated chromosome transfer? 
 
Through characterisation of both hTERT immortalised progeria cell lines, with 
growth curves, increased replicative potential has been determined (Figure 6.47). 
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This would enable a higher number of donor cells to be grown for micronucleation 
and ultimately increase the yield of hybrid colonies. In order to perform the 
chromosomes transfer an assay to distinguish between control and diseased cell 
phenotype must be identified. Several well established hallmarks of progeria cells 
were characterised for the “Atypical” TAG08466 cell line and tested for suitability 
as an assay. With a statistically significant difference in nuclear shape having been 
observed between NB1T controls and TAG08466 cells, it provides a logical assay 
for differentiation between healthy and disease cells. Cell motility was also able to 
distinguish between diseased and control cells, however, its low throughput 
approach make it less ideal assay.   
 
Further characterisation of these cell lines has, however, revealed genomic instability 
and a near tetraploid karyotype for the TAG08466 cell line. The increased 
chromosomes number has the potential to dilute the statistical power of the 
chromosome transfer. More colonies would need to be generated in order to have a 
full panel of hybrids containing each chromosome from the TAG08466 cells. With 
the complex Karyotype and genomic instability (figure 6.52 & 6.53), there would be 
no guarantee that all genetic information had been transferred. This instability of the 
immortalised cell lines has highlighted their unsuitability as donors for the MMCT. 
MMCT is only made viable with use of immortalised cell lines to act as both donor 
and recipients to increase the potential yield and negate the low replicative potential 
of primary progeria cells. This causes the need for a new method to identify the 
causative mutation in the “Atypical” HGPS cell line TAG08466.  
 
6.2.6 Candidate Genes 
 
With MMCT ruled out as a method for determining the underlying mutation in 
TAG08466 cell line, a list of candidate genes was drawn up. From analysis of the 
characterisation data, it was apparent that the TAG08466 cell line demonstrated an 
unusual pattern of movement (figure 6.54). This led to interest in the proteins linking 
the lamina and the cytoskeleton. SUN1 and SUN2 provide a link between the 
Nesprin proteins and the nucleus through attachments with the nuclear lamina 
(Haque et al, 2006; Haque et al, 2010). Nesprin proteins bind to actin filaments and 
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are believed to form a link between the nucleus and the extracellular matrix 
(Gruenbaum et al, 2005). Work performed by Dr Derek Warren’s group shows that 
Nesprin dysfunction in older tissue lead to stronger attachments and abnormal 
movement (Mellard et al, 2011). Therefore, a mutation in the Nesprin or SUN 
proteins could also be the underlying cause of progeria in the TAG08466 cell line. 
As there are several Nesprin isoforms, first investigating the SUN proteins would 
prove a logical step in identifying the underlying mutation in the TAG08466 cell 
line. Interestingly, SUN1 and SUN2 mutations have been identified as causes for 
several muscle dystrophies, another disease type typically associated with LMNA 
mutations, through disruption of the nuclear-cytoplasmic connection (Meinke et al, 
2014). Western blot analysis was initially performed in order to determine the 
abundance of SUN1 and SUN2 in the TAG08466 cell line. Figure 6.54 shows the 
western blot results for both proteins 
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Figure 6.48 Western Blot analysis of SUN1 and SUN2 proteins in “Atypical” 
HGPS Fibroblasts 
Image A shows a western blot membrane probed with an anti-SUN1 antibody. Image 
B depicts a western blot membrane probed with an anti-SUN2 antibody. Both 
antibodies were used in conjunction with horseradish peroxidase secondary 
antibodies and visualised under chemiluminecence on the Bio-Rad gel dock system. 
The ladder in both gels is the Precision Plus ProteinTM standard (Bio-Rad). NB1T is 
a normal fibroblast culture, TAG06297 is a classic HGPS cell line and TAG08466 a 
cell line from an “Atypical” HGPS patient. All three cell lines have been 
immortalised with hTERT.  
 
 
Through western blot analysis it can been seen that both SUN1 and SUN2 are 
present in the TAG08466, although in particular for SUN1 no conclusions can be 
drawn about its abundance due to the poor nature of the antibody. The sensitivity of 
western blot analysis does not allow for the determination of small changes to the 
proteins, which could affect their function despite a stable protein level.  
 
N
B
1
T 
TA
G
0
6
2
9
7 
La
te
 
TA
G
0
8
4
6
6
 
kDa 
 
200 
150 
100 
 
75 
 
 
50 
 
37 
A 
TA
G
0
6
2
9
7
 L
at
e 
N
B
1
T 
TA
G
0
8
4
6
6
 
kDa 
200 
150 
100 
 
75 
 
 
 
50 
 
 
37 
B 
      179 
 
The only known progeria causing mutation not yet ruled out for the TAG08466 cell 
line is the BANF1 mutation, which has been shown to cause a dramatic reduction in 
its encoded homodimer protein BAF (Puente et al, 2011). Figure 6.55 shows the 
Western blot membrane probed with an anti-BAF antibody.  
 
Figure 6.49 Western Blot analysis of BAF in “Atypical” HGPS Fibroblasts 
Image shows a western blot membrane probed with an anti-BAF antibody used in 
conjunction with horseradish peroxidase secondary antibodies and visualised under 
chemiluminecence on the Bio-Rad gel dock system. The ladder is the Precision Plus 
ProteinTM standard (Bio-Rad). NB1T is a normal fibroblast culture, TAG06297 is a 
classic HGPS cell line and TAG08466 a cell line from an “Atypical” HGPS patient. 
All three cell lines have been immortalised with hTERT.  
 
 
The results of this western blot do not show a loss of the band corresponding to BAF 
at 10 kDa in any of the three cell lines, indicating that the previously described 
BANF1 mutation is not the underlying cause for progeria in TAG08466. This again 
does not rule out a different mutation within the BAMF1 gene, with a different effect 
on the BAF protein, from being the genetic cause of HGPS in the TAG08466 cell 
line. 
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A more appropriate approach would be to sequence a list of candidate genes, 
including lamin A binding partners. The problem with this technique is that lamin A 
is believed to interact with a large number of proteins, many of which may have not 
yet been identified (Gruenbaum et al, 2005, Cau et al, 2014).  
 
6.2.7 Whole Exome Sequencing 
 
Whole genome sequencing or exome sequencing is becoming more available with 
next generation sequencing technologies. Although a relatively costly option, it may 
be appropriate for the identification of progeria causing variants in the AG08466 cell 
line, with the availability of cell lines from three direct relatives. The BANF1 
mutation was identified in two unrelated patients predominantly due to a 
consanguineous marriage pointing to a recessive inheritance of the disease (Puente et 
al, 2011). Several other laminopathies have been identified using WES and pedigree 
information for instance a servere cardiomyopathy (Roncarati et al, 2013) and a 
cardiac conduction disorder (Lai et al, 2013). The likely mode of inheritance and 
genetic information from three unaffected direct relatives made exome sequencing 
possible. In the majority of cases de novo mutations have been found as the 
underlying cause, resulting in a dominant disease effect. Therefore, the use of 
sequencing would be required to identify SNPs in the patient not found in direct 
relatives, which would most likely give a more extensive list than the four 
homozygous recessive mutations only identified in the BANF1 mutation patient. In 
order to achieve this, whole exome sequencing of the patient, both parents and a 
sibling was performed. Primary cell lines were obtained from the Coriell Cell 
Repository and DNA was exon enriched using the Nextra® Rapid Capture All 
Exome Kit. Sequencing was performed on the Illumina HiSeq2500 at University 
College London, in collaboration with Dr Mike Hubank. Figure 6.56 shows the filter 
cascade used to sort through identified variants, in order to identify those of interest.  
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Figure 6.50 Ingenuity Variant Analysis of whole exome sequencing data for the 
“Atypical progeria” cell line TAG08466, compared to three unaffected family 
members 
A shows a screenshot of the filter cascade and identifying the number of identified 
variants before and after filters. Filter cascade shows results for TAG08466 analysed 
at the default confidence. B shows custom setting in Ingenuity Analysis software 
used to increase the confidence by removing variant where there was a low read 
depth. C shows the custom filter used to remove common variants based on 
occurrence in the 1000 Genomes Project and the Public Complete Genomics 
Genomes.   
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Ingenuity Variant Analysis software was used to filter through identified variants 
based on a dominant inheritance pattern, therefore, heterozygous de novo variants 
were selected. HGPS was entered as a key term and as a result one biologically 
relevant variant was identified. The variant identified was a deletion in the intronic 
promoter region of the LMNA gene. Figure 6.57 shows the location and description 
of the LMNA variant.  
 
 
Figure 6.51 Ingenuity Variant Analysis software information on the LMNA 
variation identified in TAG08466 “Atypical” Progeria cell line 
Screenshot showing information on variant position, gene region, classification and 
transcription variation, created using Ingenuity Variant Analysis software. 
 
 
The only observed variant, identified as having biological relevance was the LMNA 
variant shown in figure 6.57. This variant was identified under the least stringent 
filtering parameters and was removed from the filter once the confidence rating was 
increased. This variant was only covered by a low read depth and is likely an 
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artefact. It is thought that a variant of this nature would affect lamin A abundance in 
cells, something which had previously been examined, see figure 4.19 chapter 4.  
 
Analysis of the TAG08466 cell line through saturating PCR revealed lamin A 
transcripts, but no progerin as predicted for a cell line known not to possess the 
G608G LMNA mutation (personal communication Professor Nico Levy). Despite 
searching for nuclear membrane proteins and premature ageing disease, no other 
biologically relevant variants were identified using the ingenuity variant analysis 
software.  
The exome data was specifically searched for variants in genes previously identified 
in HGPS, such as BANF1 and ZMPSTE24, however, no variants in these genes were 
present. Using the information gathered from the characterisation of the hTERT 
immortalised TAG08466 cell line, the exome data was also analysed for variations in 
proteins linking the nucleus and the cytoskeleton, such as Nesprins, SUN1 and 
SUN2, however, no variants in these proteins were identified either. A full list of 
genes and variants identified under 3 separate filter stringencies is available in 
Appendix iv.  
 
In collaboration with Dr Eric Schirmer’s group at the University of Edinburgh, 
further analysis of the exome sequencing data was performed. These searches 
identified variants in DNA repair genes, which may have significance in this 
“Atypical” progeria patient. Several studies have previously identified links between 
DNA damage and classic HGPS (Liu et al, 2005; Liu et al, 2006; Mukherjee and 
Costello, 1998). A heterozygous frameshift variant resulting in an early stop codon 
in INO80E a DNA repair protein was identified. hTERT immortalisation of the 
AG08466 cell line has resulted in a large amount of genomic instability and 
suggesting deficiencies in DNA repair and cell cycle progression in this cell line. 
The early stop codon in IN080E may truncate the foot domain of the protein, 
affecting in particular the ARP8 (Actin-Related Protein) binding module (Tosi et al, 
2015). The INO80 complex has previously been shown to be recruited to DNA 
damage sites in an ARP8 dependent manner (Kashiwaba et al, 2010; Osakabe et al, 
2014). To validate this potential candidate gene knowdown experiments using RNAi 
would identify if loss of this protein causes the “Atypical” progeria-like cell 
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characterisitcs seen in TAG08466. Complimentation studies coulds also be used 
whereby functional copies of the mutated gene are introduced into the patient cell 
line, with the aim of improving cell characterisitcs.  If this candidate genes is not 
found to be causative, one potential next step in the analysis of this data series is to 
identify any clinically relevant findings in this patient such as the Marfan like 
features and exploit these as an avenue to search the exome data.  
 
6.3 Discussion 
 
All known genetic causes of progeria are in proteins associated with lamin A, the 
mutated protein in classic HGPS cases (Eriksson et al, 2003; De Sandre-Giovannoli 
et al, 2003). These include transcription factor BANF1 (Puente et al, 2011) and lamin 
processing enzyme ZMPSTE24 (Shackleton et al, 2005). The lamina has a large 
number of nuclear functions, including nuclear shape and structure, heterochromatin 
organisation, transcription regulation and cell cycle progression (Zastrow et al, 2004; 
Gruenbaum et al, 2005; Starr et al, 2010). This creates a great number of lamin A 
interacting proteins (Kubben et al, 2010), which could cause a progeria like 
syndrome such as that seen in patient AG08466. With such a large scope of potential 
candidate genes an inclusive approach such as exome sequencing was essential. With 
an estimated 85% of all disease causing variant being found within exome 
boundaries, WES is a method for analysing the majority of coding DNA whilst 
reducing the statistical power required (Wang et al, 2013).  In this study we have 
ruled out all previously identified progeria causing mutations (BANF1 and 
ZMPSTE24), through exome sequencing and protein analysis  
 
Through characterisation of the hTERT immortalised TAG08466 cell line, 
interesting observations have been made. Unlike the classic HGPS cell line 
TAG06297 (Chapter 3), the TAG08466 appeared less stable after prolonged growth 
in the presence of hTERT. This was demonstrated by the increased nuclear shape 
abnormalities and genomic instability. This again reveals the volatility of progeria 
cells to hTERT immortalisation and demonstrates their instability in future studies.  
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The observed effect of hTERT immortalisation were, however, exploited for analysis 
of the exome sequencing data with candidate genes such as SUN proteins and 
Nesprins being posed. Despite the corresponding genes not being responsible for 
APS in patient AG08466, they do pose credible candidates for other case of APS. 
Considering that normal aged fibroblasts show changes in cell motility linked to 
Nesprins (Mellard et al, 2011) and the identification of a LMNA mutation (Q432X) 
responsible for a cardiomyopathy/ premature ageing phenotype resulting from 
changes in lamin A- Nesprin-2 interactions (Yang et al, 2013). Changes in 
chromosome stability were also identified in this cell line, similar to those observed 
in TAG08466. 
 
When taken in combination, identification of genomic instability in response to 
hTERT and previously described lamin A-telomere interactions (Wood et al, 2014), 
suggests a role of cell cycle regulation and activation of DNA damage checkpoints in 
“Atypical” HGPS. Classic HGPS cells have been shown to have constitutively active 
DNA damage checkpoints and stochastically shortened telomeres (Campisi et al, 
2001; Decker et al, 2009). The inclusion of progerin in nuclear envelope, during 
mitosis, has been shown to cause lagging chromosome, one possible explanation of 
aneuploidy in HGPS (Dechat et al, 2007).  
 
The identification of a rare, genetic variations in a gene encoding DNA damage 
repair protein IN080E, in this cell line, is of interest. Further information regarding 
the phenotype of this patient, in particular any cancer development, would add 
evidence to the role of DNA repair in this case of HGPS. This would suggest a great 
deal ofoverlap with the adult premature ageing disease Werners Syndrome, which is 
characterised by high incidence of cancer, resulting from the mutated WRN protein, 
a REQ helicase involved in DNA damage repair (Yu et al, 1996). Conversely the 
hTERT immortalisation of WS fibroblasts, was found to reduce levels of genomic 
instability (Crabbe et al, 2006), concluding that genome instability in WS is 
dependent on telomere dysfuction. Interestingly IN080E has been described as 
having a role in telomere maintenance and chromosome segregation. The 
relationship between IN080 complex function, telomeres and cell division, needs to 
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be further eluicidated, but current knowledge based on this APS cell lines reaction to 
telomerase does add significance to IN080E as a candidate gene for APS.  
 
By identifying further genetic causes of the disease greater understanding of the 
disease pathology will be achieved. With lamin As involvement in a large number of 
cellular process, further mutation identification may add more insight into thoses 
involved in premature ageing. Knowledge about premature ageing disease can also 
add greater understanding to the processes behind normal human ageing.  
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7 Discussion 
 
7.1 hTERT immortalisation  
 
The classic disease causing LMNA mutation which accounts for approximately 80% 
of progeria cases has been well characterised since its discovery in 2003 (Eriksson et 
al, 2003; De Sandre-Giovannoli et al, 2003). Expression of the mutant lamin A 
protein progerin, has a dominant negative effect on cell function (Scaffidi and 
Misteli, 2005), disrupting the numerous roles of lamin A within the nucleus. This 
includes the appearance of abnormal shaped nuclei (Goldman et al, 2004; Bridger & 
Kill, 2004), increased levels of DNA damage (Mukherjee and Costello, 1998; Liu et 
al, 2005), aberrant transcription (Kubben et al, 2012), chromosome re-positioning 
(Meaburn et al, 2007; Mehta et al, 2007), loss of heterochromatin anchoring 
(Goldman et al, 2004; Scaffidi and Misteli, 2005; Shumaker et al, 2006) and 
decreased cell motility and mechanical strength (Verstraeten et al, 2008; Paradisi et 
al, 2005).  
 
There has been much debate about the implications of hTERT immortalisation on 
HGPS cells. Cells from classic progeria patients, expressing the mutant protein 
progerin through activation of a cryptic splice site, have been shown to have 
shortened replicative potential in culture (Bridger and Kill, 2004). This has been 
linked to premature senescence thought to occur through stochastic telomere 
shortening, resulting in activation of DNA damage checkpoints (Allsopp et al, 2004; 
Campisi et al, 2001). Increased levels of apoptosis have also been observed in 
fibroblast cultures (Bridger and Kill, 2004). The effect of exogenous hTERT 
expression has been postulated to act as an opposing force to progerin (Cao et al, 
2011), with some studies identifying loss of progeria cell characteristics in response 
to hTERT immortalisation of HGPS cells (Benson et al, 2010; Cao et al, 2011).  
 
7.1.1 Progerin 
 
This study aimed to identify if hTERT immortalised cells could provide a useful tool 
for future research into HGPS. After two years continuous growth the TAG06297 
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cell line was found to show little resemblance to a classic progeria cell in parameters 
such as shape, movement and DNA damage (Chapter 3). This suggests that hTERT 
expression does have long-term effects on progerin, which result in a healthier cell 
phenotype. It has previously been suggested that this occurs through decrease in 
progerin expression relative to lamin A (Cao et al, 2011). This phenomenon was 
replicated in this study although to a lesser extent. A two fold reduction in progerin 
transcripts relative to lamin A is hard to quantify. Preliminary western blot analysis 
identified a significant reduction in progerin protein. This appeared to be more 
extensive than the 2 fold decrease in expression suggesting modulation at the protein 
level. The proteasome degradation of progerin was proposed in response to the 
proteasome inhibiting drug MG132. Lamin proteins were previously thought to be 
degraded through autophagy (Graziotto et al, 2012).  
 
This suggests that in response to the growth pressure of hTERT immortalisation, 
clonal expiation has occurred. Through modulation of progerin protein or increased 
E3 Ubiquitin ligase affinity (Fu et al, 2004), a subset of cells within the culture may 
have become better able to cope with hTERT, resulting in a clonal expansion (van 
Waarde-Verhagen et al, 2005). This supports the theory that hTERT and progerin act 
as opposing forces in cells and that hTERT immortalisation is not a viable method 
for gaining cell number in disease characterised by short cell replicative lifespans. 
This evidence adds weight to the theory that hTERT negates the progerin induced 
telomere dysfunction that leads to replicative arrest and premature senescence in 
HGPS cells (Benson et al, 2010). Unlike previous findings, however, this study does 
not provide support for the notion of telomere length being an upstream signal of 
progerin expression. This study suggests that cells have evolved to cope with 
increased growth pressure, as a result of the artificial environment. The difficulty in 
hTERT immortalisation of this cell line may support the argument for clonal 
evolution.  This raises questions about the suitability of hTERT cell lines for the 
study of a number of diseases which have defects in cell cycle control, DNA damage 
and genomic stability. 
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7.1.2 Therapeutic Potential 
 
The successful hTERT immortalisation of progeria cells and resulting clonal 
expansion has opened up new avenues for therapy. Previously progerin was thought 
to be broken down via autophagy (Graziotto et al, 2012), which led to perspective 
clinical trial for the autophagy promoting drug rapamycin (Cao et al, 2011; Graziotto 
et al, 2012). Studies using fibroblast cultures identified improvements in progeria 
cell characteristics such as nuclear shape and heterochromatin organisation (Cao et 
al, 2011; Graziotto et al, 2012). Identification of a model cell line, which 
demonstrate preferential breakdown of progerin through the 26S proteasome, 
resulting in similar improvement in cell phenotype (Chapter 4), may offer a novel 
target avenue for therapy. To test this a U3 conjugated Nanobody targeted to A type 
lamins was employed. This demonstrated the ability of Nanobodies to effectively 
target A type lamins for degradation, all be it not determined if through proteasome 
or autophagosome. Further use of more specifically target Nanobodies may replicate 
the effect achieved through prolonged growth in the presence of hTERT. If a 
reduction in progerin protein is produced this has previously been shown to improve 
cell phenotype (Scaffidi and Misteli, 2005), a common goal of treatments. This is 
particularly exciting because Nanobodies are an emerging field, with several clinical 
trials currently underway (Peyvandi et al, 2016). 
 
The development of TAT-Lamin A and TAT-Progerin fusion proteins may prove 
valuable in determining the effectiveness of therapy. Through hTERT 
immortalisation a significant reduction in progerin abundance and distribution has 
been observed (Chapter 4). It is not known what level of progerin is tolerated by 
cells, with some studies identifying a role of progerin in normal human ageing 
(Scaffidi and Misteli, 2006). Through concentration dependent studies a proper 
investigation into the level of progerin toxicity could be performed, adding evidence 
to that  Chojnowski et al, 2015 described a threshold of progerin toxicity. With 
current treatments estimated to extend life-expectancey by only 1.6 years (Gordon et 
al, 2014), new stratergies for HGPS are essential.  
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TAT proteins may also be used to increase our understanding of lamin A and 
progerin interacting partners, through pulldown studies (Kubben et al, 2010). This 
could add insight into the Lamina fuctions most associated with premature ageing, 
which could aid in futher APS gene discovery and identify new therapeutic targets. 
These proteins can also be used to evaluate nuclear entry, whether it is using the 
NLS (Wu et al, 2014) or farnesylation. This would help determine the need for 
farnesylation (Smallwood and Shackleton, 2010) and add further insight to the use of 
FTIs as current progeria treatment (Servick, 2014).  
 
7.1.3 Atypical Progeria 
 
20% of cases of progeria are not caused by the well characterised LMNA mutation 
(Hennekam, 2006). These patients demonstrate a more diverse spectrum of 
characteristics which is represented by the underlying cell phenotype (Hennekam, 
2006). To date only two other genes have been shown to cause progeria and one of 
those is a lamin post-translational modification protein (ZMPSTE24) (Shackleton et 
al, 2005). With atypical patients showing overlap with other disease as well as 
normal human ageing (McKenna et al, 2013), the addition of more genes would help 
paint a more detailed picture. In this study we described the use of exome 
sequencing to search for the mutated gene. With the identification of DNA repair 
gene IN080E as a potential candidate, this study suggests a link between telomere 
function and cell cycle control in this case of APS. A recent study by Professor 
Wendy Bickmore has, however, suggested that DNA damage is not a mechanism for 
progeria related cell ageing (Deniaud et al, 2016). With this in mind more 
information about the clinical presentation of the patient, in particular a cancer 
phenotype, may add insight into DNA damage in this patient or highlight other lamin 
A processes to target in the WES data. 
 
7.1.4 Normal ageing 
 
Progerin expression and protein have been observed in several studies in cells and 
tissues from healthy individuals (Scaffidi & Misteli, 2006; Rodrigue et al, 2009; Cao 
et al, 2011; McClintock et al, 2007; Olive et al, 2010). Thus has led to the belief that 
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progerin build up as impact on normal human ageing (Scaffidi and Misteli, 2006), 
potentially through telomere interactions (Decker et al, 2009). The novel QPCR 
designed by Dr Evgeny Makarov, Brunel University London and implemented in 
this study (Chapter 4) offers the opportunity to more accurately quantify progerin 
involvement in normal human ageing.  
 
7.2 Key Findings 
 
7.2.1 Future work 
 
Key work to be carried out following this study includes further characterisation of 
the reduction of progerin within the TAG06297 Late cells, in particular the proposed 
proteasomal degradation in response to hTERT immortalisation. This could be 
achieved through analysis using other proteasome/Ubiquitin Ligase inhibiting drugs 
clasto-Lactacystin β-Lactone an inhibitor of the 20S proteasome, Epoxomicin an 
inhibitor of Z catalytic subunits of the proteasome), as well as panels to identify 
E2/E3 ubiquitin ligases (Fu et al, 2004, Marblestone et al, 2013).  
 
Identifying specific changes in the hTERT immortalised cell line to understand how 
they cured themselves. This will involve LMNA sequence analysis and even micro-
array expression profiling. Could also analyse changes to miRNA expression 
profiles, as other nuclear envelope disease and laminopathies have been linked to 
changes in miRNA, which have an adverse effect on cell cycle progression (Malhas 
et al, 2010; Sylvius et al, 2011). MiRNA 9 expression been shown to regulate 
changes in lamin and progerin in neuronal tissue, suggested to be neuro protective, 
no ageing associated neurological impairments in HGPS patients (Nissan, 2012). It 
could be interesting to identify changes in miRNA expression in response to hTERT 
to identify new targets for therapy.  
 
Continued development of Nanobodies targeted to progerin is an exciting potential 
therapy. Once a more specific Nanobody has been developed the impact on cell 
phenotype can be examined. 
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Further mining of the exome data will allow potential discovery of a progeria 
causing gene. The addition of new disease causing genes increases understanding of 
progeria pathology, and allows further comparisons to normal human ageing. This is 
particularly exciting as hTERT cell characterisation suggests the involvement of 
genes involved in cell cycle control or telomere interactions. 
 
7.3 Conclusion 
 
This study has identified several phenotypical changes in response to hTERT 
immortalisation, concluding that hTERT immortalisation does not yield an effective 
tool for studying HGPS. This work has, however, identified a potential new 
therapeutic approach using proteasomal degradation through Nanobody targeting and 
raised questions about telomere and cell cycle control in a specific case of atypical 
progeria. Finally, this study has also employed a novel method for QPCR and 
suggest this would be useful for further examination of progerin in normal human 
ageing. 
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Appendix III. M-FISH karyotypes of TAG08466 cel 
 
Table 10 M-FISH karyotypes of TAG08466 cells 
Cell 
number 
Karyotype 
0001 61,XXX,del(Xp),der(1)t(1;17),-2,-3,-3,-4,-4,del(4p),-5,del(5p),-6,-6,-7,-8, ,-
9,del(9q),-10,-11,-11,-12,-13,-13,del(13q),del( 13q),-14,-14,der(15)t(8;15),-
15,-15,-16,-16,-17,-18,-18,-19,-20,-21,-22,-22,+2mar 
0002 62,XXXY,-1,der(1)t(1;13),der(1)t(1;17),ace(1p),-3,del(3p),-4,-5,-5,-5,del(5p),-
6,-7,-8,-8, -9,-9,der(9)t(1;9),-10,-10,-10,-11,-11,-12,-13,-13,-
14,der(15)t(8;15),-16,-17,der(17)(1;17),del(18q),-19,-19,-20,-
20,der(22)t(18;22),-22 
0005 79,XXX,der(X)t(X;18),der(1)t(14;1;17),ins(1;14),del(1q),der(2)t(1;2),del(3p),-
4,-5,der(6)t(6;19),der(7)t(7;21),-9,-12,-13,der(14)t(10;14),ace(14;21),-15,-15, 
der(15)t(8;15),-20,-21,+2mar 
0011 76,X,-X,-X,-X,ins(1;14),der(1)t(1;18),del(1q),-2,der(2)t(2;15),del(3p),-
4,del(5p),del(5q),der(6)t(6;19),-7,-7,-8,der(12)t(12;20), -13,-
14,der(14)t(10;14), der(15)t(8;15),del(15q),-17,-18,-19,-21,-22+3mar 
0013 78,XXX,der(X)t(X;18),der(1)t(14;1;17),ins(1;14), 
der(1)(1;14),del(1q),der(2)t(1;2),del(3p),-4,-5,del(5p),-
6,der(6)t(6;10),del(7q),-9,del(9q),-11,-13,-14,der(14)(10;14),der(15)t(8;15),-
16,-18,del(18q),-19,-20,-20,-21 
0018 66,XXX,der(X)t(X;1),der(1)t(14;1;17),der(1)t(1;18),del(1p),der(1)ins(15;1;X),de
l(2p),-3,del(3p),der(4)t(4;19),del(5p),del(5q),-6,-6,-6,-6,-7,-7,-9,-10,-11,-11,-
12,-13,-13,-14,der(15)t(8;15),del(15q) ,-18,der(18)t(17;18) ,-20,-20,-20,-21,-
21,-21,-22,-22 
0019 85,XXX,der(X)t(X;18),del(Xq),ins(1;14),der(1)t(14;1;17),der(2)t(1;2),del(3p),-
4,del(5p),der(6)t(6;13),der(7)t(7;21),dic(8;17)+ace(8q),-9,-12,-13,-
14,der(14)t(10;14),-17,der(18)t(18;20),-19,-21 
0020 79,XXX,der(X)t(X;18),ins(1;14),der(2)t(1;2),-3,-4,del(5p),del(5p),-
6,der(7)t(7;21),-9,-12,-12,-13,-14,der(14)t(10;14),der(15)t(8;15),-17,del(18p),-
19,del(20p)+del(20q),-20,-22,+mar 
0021 83,XXX,t(X;1),ins(1;14),der(1)t(14;1;17),del(2p),del(3p),der(4)t(4;19),der(5)t(5
;10),del(5p),-6,der(7)t(7;21),-13,-14,der(14)t(10;14),-15,der(15)t(8;15),-
16,del(17q) 
0025 79,XXX,der(X)t(X;18),ins(1;14),der(1)t(14;1;17), der(2)t(1;2), del(3p),-4,-
5,del(5p), der(6)t(6;19), der(7)t(7;21),-8,-9,-11,der(14)t(10;14),del(14q), 
der(15)t(8;15),-16,-20,-22,-22 
0029 86,XXX,t(X;1),ins(1;14),der(1)t(14;1;17),der(1)(1;17),der(1)t(1;18),del(2p),del(
3p),der(4)t(4;19), del(5p),-6,der(7)t(7;21),-13,-
14,der(14)t(10;14),der(15)t(8;15),ace(15p),-
16,der(16)t(14;16),+del(18p)+del(18q),-20,-22,del(22q)+ace(22q) 
0030 71,XXX,del(Xp),der(1)t(1;17),ace(1;17),ace(1q),ace(1p),der(1)t(1;13),der(3)t(3
;10),-4,-4,del(5p),-6,der(7)t(2;7),-8,del(9p),-10,-14,-15,der(15)t(8;15),-16,-16,-
17,-18,-18,-19,-19,-20,-20,-22,-22 
      xvi 
 
0034 73,XXX,der(X)t(X;18),ins(1;14),der(1)t(14;1;17),der(2)t(1;2),del(3p),-
4,del(5p),del(5p),-6,-7,-9,-9,-10,-11,-12,-13,-14,der(14)t(10;14),-
15,der(15)t(8;15),del(18p),-19,-20,der(20)t(18;20),-21 
0041 81,XXX,t(X;1),ins(1;14),der(1)t(14;1;17),del(1p),del(1q),del(2p),del(2q),-
3,del(4p),del(5p),-6,der(7)t(7;21),-12,-13,-14,-15,der(15)t(8;15),ace(15p),-
17,der(17)t(Y;17),der(18)t(18;21),-19,+mar 
0046 81,XXX,der(X)t(X;18),ins(1;14),der(1)t(14;1;17),der(2)t(1;2),der(3)t(3;22),-
4,del(5p),-6,der(7)t(7;21),-9,-12,-13,-14,der(14)t(10;14),-15,der(15)t(8;15),-
19,der(20)t(18;20),+mar 
0049 75,X,-X,-X,t(X;1),ins(1;14),der(1)t(14;1;17),x2ace(1q),-2,del(2p),-
3,del(3p),der(4)t(4;19),-5,-6,der(7)t(7;21),-8,-9,-12,-12,-13,-13,-
14,der(14)t(10;14),-15,-15,-16,der(16)t(16;?),der(17)t(X;17),del(17q),-19,-
19,der(20)t18;20),-22,+2mar 
0051 70,XXX,der(X)t(X;18),-1,ins(1;14),der(1)t(1;14),der(1)t(1;18),der(2)t(1;2),-4,-
5,-5,-5,-6,-6,der(6)t(6;19),-7,-9,-12,-13,-13,-
14,der(14)t(10;14),der(15)t(8;15),-16,-16,-17,-17,del(18p),-20,-21,-
22,del(22q)+ace(22q),+mar 
 
 
 
    xvii 
 
 
Table 11 Occurrence of structural rearrangements in TAG08466 cells 
 Observed in cell number 
Number of 
cells 
 1 2 5 11 13 18 19 20 21 25 29 30 34 41 46 49 51  
t(Xcen;1)         X  X   X  X  4 
der(X)t(Xcen;1)      X            1 
der(X)t(Xcen;18?ce
n) 
  X  X  X X  X   
X  X  X 8 
der(1)t(1cen;13)  X          X      2 
der(1)t(1cen;14)     X            X 2 
ins(1?cen;14)   X X X  X X  X X  X X X X X 12 
der(1)ins(15;1;X)      X            1 
der(1)t(1;17) X X         X X      4 
der(1)t(14;1cen;17)   X  X X X  X X X  X X X X  11 
ace(1;17)            X      1 
der(1)t(1cen;18)    X  X     X      X 4 
der(2)t(1?cen;2cen)   X  X  X X  X   X  X  X 8 
der(2)t(2pter;15)    X              1 
der(3)t(3;10)            X      1 
der(3)t(3cen;22)               X   1 
der(4)t(4cen;19) X     X   X  X     X  5 
der(5)t(5;10)         X         1 
der(6)t(6cen;13)       X           1 
der(6)t(6cen;19)   X X      X       X 4 
der(7)t(2;7)            X      1 
der(7)t(7?qter;21)   X    X X X X X   X X X  9 
dic(8cen;17)       X           1 
der(9)t(1;9)  X                1 
      xviii 
 
 
der(12)t(12cen;20)    X              1 
der(14)t(10;14cen)   X X X  X X X X X  X  X X X 12 
ace(14;21)   X               1 
der(15)t(8;15) X X X X X X  X X X X X X X X  X 15 
der(16)t(14;16cen)           X       1 
der(16)t(16;?)                X  1 
der(17)t(X;17cen)                X  1 
der(17)t(Y;17)              X    1 
der(17)(?1;17)  X                1 
der(18)t(5;18)           X       1 
der(18)t(17;18cen)      X            1 
der(18)t(18cen;20)       X           1 
der(18)t(18cen;21)              X    1 
der(20)t(18;20cen)             X  X   2 
der(22)t(18;22cen)  X                1 
 
  
      xix 
 
 
Table 12 Occurrence of structural deletions in TAG08466 cells 
 Observed in cell number 
Number of 
cells 
 1 2 5 11 13 18 19 20 21 25 29 30 34 41 46 49 51  
del(Xp) X           X      2 
del(Xcenq)       X           1 
ace(1p)  X          X      2 
ace(1q)            X    X  2 
ace(1q)                X  1 
del(1q)   X X X             3 
del(1cenq)      X        X    2 
del(2cenp)      X   X  X   X  X  5 
del(2cenq)              X    1 
del(3p)  X X X X X X  X X X  X   X  11 
del(4cenp)              X    1 
del(5cenp) X X  X X X X X X X X X X X X   14 
del(5cenq)    X  X            2 
del(7q)     X             1 
ace(8q)       X           1 
del(9cenp) X           X      2 
del(9q)     X             1 
del(13q) X                 1 
del(13q) X                 1 
del(14cenq)          X        1 
ace(15p)           X   X    2 
del(15q)    X  X            2 
del(17q)         X       X  2 
del(18cenp)        X   X  X    X 4 
      xx 
 
 
del(18cenq)  X   X      X       3 
del(20cenq)        X          1 
del(22q)           X      X 2 
ace(22q)           X      X 2 
 
 
  
      xxi 
 
 
Table 13 Occurrence of numerical aberrations TAG08466 cells 
 Observed in cell number Number of cells 
 1 2 5 11 13 18 19 20 21 25 29 30 34 41 46 49 51  
-1  X               X 2 
-2 X   X            X  3 
-3 X X    X  X      X  X  6 
-3 X                 1 
-4 X X X X X  X X  X  X X  X  X 12 
-4 X           X      2 
-5 X X X  X     X      X X 7 
-5  X               X 2 
-5  X               X 2 
-6 X X   X X  X X  X X X X X X X 13 
-6 X     X           X 3 
-6      X            1 
-6      X            1 
-7 X X  X  X       X    X 6 
-7    X  X            2 
-8 X X  X      X  X    X  6 
-8  X                1 
-9 X X X  X X X X  X   X  X X X 12 
-9  X           X     2 
-10 X X    X      X X     5 
-10  X                1 
-10  X                1 
-11 X X   X X    X   X     6 
-11 X X    X            3 
-12 X X X   X X X     X X X X X 11 
      xxii 
 
 
-12        X        X  2 
-13 X X X X X X  X X  X  X X X X X 14 
-13 X X    X X         X X 6 
-14 X X  X X X X X X  X X X X X X X 14 
-14 X                 1 
-15 X  X      X  X X X X X X  9 
-15 X  X             X  3 
-16 X X   X    X X X X    X X 9 
-16 X           X     X 3 
-17 X X  X   X X    X  X   X 8 
-17                 X 1 
-18 X   X X X      X      5 
-18 X           X      2 
-19 X X  X X  X X    X X X X X  11 
-19  X          X    X  3 
-20 X X X  X X  X   X X X   X X 11 
-20  X   X X    X  X      5 
-20      X            1 
-21 X  X X X X X      X    X 8 
-21      X            1 
-21      X            1 
-22 X X  X  X  X  X X X    X X 10 
-22 X     X    X  X      4 
-X    X            X  2 
-X    X            X  2 
-X    X              1 
                   
+22     X             1 
 
      xxiii 
 
 
Table 14 Occurrence of clonal structural rearrangements in TAG08466 cells 
 Observed in cell number 
Number of 
cells 
 1 2 5 11 13 18 19 20 21 25 29 30 34 41 46 49 51  
t(X;1)         X  X   X  X  4 
der(X)t(X;18)   X  X  X X  X   X  X  X 8 
der(1)t(1;13)  X          X      2 
der(1)t(1;14)     X            X 2 
ins(1;14)   X X X  X X  X X  X X X X X 12 
der(1)t(1;17) X X         X X      4 
der(1)t(14;1;17)   X  X X X  X X X  X X X X  11 
der(1)t(1;18)    X  X     X      X 4 
der(2)t(1;2)   X  X  X X  X   X  X  X 8 
der(4)t(4;19) X     X   X  X     X  5 
der(6)t(6;19)   X X      X       X 4 
der(7)t(7;21)   X    X X X X X   X X X  9 
der(14)t(10;14)   X X X  X X X X X  X  X X X 12 
der(15)t(8;15) X X X X X X  X X X X X X X X  X 15 
der(20)t(18;20)             X   X  2 
 
  
      xxiv 
 
 
Table 15 Occurrence of clonal structural deletions in TAG08466 cells 
 Observed in cell number 
Number of 
cells 
 1 2 5 11 13 18 19 20 21 25 29 30 34 41 46 49 51  
del(Xp) X           X      2 
ace(1p)  X          X      2 
ace(1q)            X    X  2 
del(1q)   X X X             3 
del(1cenq)      X        X    2 
del(2cenp)      X   X  X   X  X  5 
del(3p)  X X X X X X  X X X  X   X  11 
del(5cenp) X X  X X X X X X X X X X X X   14 
del(5cenq)    X  X            2 
del(9cenp) X           X      2 
ace(15p)           X   X    2 
del(15q)    X  X            2 
del(17q)         X       X  2 
del(18cenp)        X   X  X    X 4 
del(18cenq)  X   X      X       3 
del(22q)           X      X 2 
ace(22q)           X      X 2 
 
  
      xxv 
 
 
Table 16 Occurrence of clonal numerical aberrations in TAG08466 cells 
 Observed in cell number Number of cells 
 1 2 5 11 13 18 19 20 21 25 29 30 34 41 46 49 51  
-2 X   X            X  3 
-3 X X    X  X      X  X  6 
-4 X X X X X  X X  X  X X  X  X 12 
-5 X X X  X     X      X X 7 
-6 X X   X X  X X  X X X X X X X 13 
-6 X     X           X 3 
-7 X X  X  X       X    X 6 
-8 X X  X      X  X    X  6 
-9 X X X  X X X X  X   X  X X X 12 
-10 X X    X      X X     5 
-11 X X   X X    X   X     6 
-11 X X    X            3 
-12 X X X   X X X     X X X X X 11 
-13 X X X X X X  X X  X  X X X X X 14 
-13 X X    X X         X X 6 
-14 X X  X X X X X X  X X X X X X X 14 
-15 X  X      X  X X X X X X  9 
-15 X  X             X  3 
-16 X X   X    X X X X    X X 9 
-16 X           X     X 3 
-17 X X  X   X X    X  X   X 8 
-18 X   X X X      X      5 
-19 X X  X X  X X    X X X X X  11 
-19  X          X    X  3 
-20 X X X  X X  X   X X X   X X 11 
      xxvi 
 
 
-20  X   X X    X  X      5 
-21 X  X X X X X      X    X 8 
-22 X X  X  X  X  X X X    X X 10 
-22 X     X    X  X      4 
 
 
 
    xxvii 
 
 
Appendix IV. Refined Search 
 
Table 17 Refind Search 
Name #Variants #Cases #Controls 
NBPF10 (includes others) 4 1 0 
IRF2BPL 3 1 0 
MUC2 3 1 0 
MUC3A 3 1 0 
ANKRD36 2 1 0 
ARMCX4 2 1 0 
ATXN1 2 1 0 
ATXN7 2 1 0 
CHD3 2 1 0 
FAM157A/FAM157B 2 1 0 
IGFN1 2 1 0 
LENG9 2 1 0 
LOR 2 1 0 
LURAP1L 2 1 0 
mir-3150 2 1 0 
MUC6 2 1 0 
NKX1-1 2 1 0 
OR2A1/OR2A42 2 1 0 
POTEG (includes others) 2 1 0 
PRAMEF1 (includes others) 2 1 0 
PRSS48 2 1 0 
REC8 2 1 0 
SLC35G4 2 1 0 
SOCS7 2 1 0 
TTN 2 1 0 
ZNF714 2 1 0 
ACSS2 1 1 0 
ALMS1 1 1 0 
ANKLE1 1 1 0 
APOB 1 1 0 
ARHGEF17 1 1 0 
ARHGEF26 1 1 0 
ASCL1 1 1 0 
ATAD3B 1 1 0 
ATAD5 1 1 0 
ATMIN 1 1 0 
ATP6V1C2 1 1 0 
ATXN3 1 1 0 
      xxviii 
 
 
AUTS2 1 1 0 
BAIAP2L2 1 1 0 
C11orf95 1 1 0 
C20orf96 1 1 0 
C6orf132 1 1 0 
C7orf49 1 1 0 
CACNA1A 1 1 0 
CACNA1I 1 1 0 
CACNB2 1 1 0 
CAMKK2 1 1 0 
CBWD3/CBWD6 1 1 0 
CCER2 1 1 0 
CCL3L1 1 1 0 
CCL3L3 1 1 0 
CDC42EP1 1 1 0 
CDKL4 1 1 0 
CEBPB 1 1 0 
CELA1 1 1 0 
CFAP44 1 1 0 
CGA 1 1 0 
CHD7 1 1 0 
CKAP4 1 1 0 
CLSPN 1 1 0 
CNTN4 1 1 0 
COL18A1 1 1 0 
COPZ2 1 1 0 
CPXM2 1 1 0 
DCHS2 1 1 0 
DDX31 1 1 0 
DDX56 1 1 0 
DMGDH 1 1 0 
DMRTA2 1 1 0 
DNHD1 1 1 0 
DOK3 1 1 0 
DPP9-AS1 1 1 0 
DSE 1 1 0 
EGR1 1 1 0 
EIF4E2 1 1 0 
EMC7 1 1 0 
ENGASE 1 1 0 
ESRP2 1 1 0 
FAM117B 1 1 0 
FAM86B1 1 1 0 
FAM98C 1 1 0 
      xxix 
 
 
FBN1 1 1 0 
FBXO24 1 1 0 
FBXW10 1 1 0 
FHOD3 1 1 0 
FIGNL2 1 1 0 
FIP1L1 1 1 0 
FLG2 1 1 0 
FOXF2 1 1 0 
FOXN3 1 1 0 
FOXO3 1 1 0 
FREM2 1 1 0 
FSCB 1 1 0 
GHDC 1 1 0 
GIGYF2 1 1 0 
GJC2 1 1 0 
GNL3 1 1 0 
GPRIN2 1 1 0 
GSPT1 1 1 0 
GTF3C4 1 1 0 
GXYLT1 1 1 0 
HEG1 1 1 0 
HELQ 1 1 0 
HERC2 1 1 0 
HERC3 1 1 0 
HMGB4 1 1 0 
HNRNPC 1 1 0 
HOXD11 1 1 0 
HRC 1 1 0 
HSP90B1 1 1 0 
HTT 1 1 0 
IFI27 1 1 0 
IGDCC4 1 1 0 
IGFBP2 1 1 0 
IGSF10 1 1 0 
INO80E 1 1 0 
IQSEC2 1 1 0 
JMJD8 1 1 0 
JPH3 1 1 0 
KANSL3 1 1 0 
KBTBD7 1 1 0 
KCNJ12 1 1 0 
KCNJ18 1 1 0 
KCNN3 1 1 0 
KDM6B 1 1 0 
      xxx 
 
 
KIF1A 1 1 0 
KLHL40 1 1 0 
KLRC2 1 1 0 
KRT3 1 1 0 
KRT39 1 1 0 
KRTAP4-6 1 1 0 
KRTAP9-4 1 1 0 
LEPREL2 1 1 0 
LFNG 1 1 0 
LILRA6 1 1 0 
LILRB3 1 1 0 
LMTK3 1 1 0 
LOC729159 1 1 0 
LRP5 1 1 0 
LRRIQ1 1 1 0 
LSR 1 1 0 
MAN2A1 1 1 0 
MAP3K7 1 1 0 
MAPK8IP2 1 1 0 
MCM9 1 1 0 
MDFIC 1 1 0 
MED15 1 1 0 
MEGF9 1 1 0 
MEOX2 1 1 0 
mir-181 1 1 0 
mir-663 1 1 0 
mir-6859 1 1 0 
MIR8078 1 1 0 
MMP17 1 1 0 
MPL 1 1 0 
MROH8 1 1 0 
MST1L 1 1 0 
MUC12 1 1 0 
MUC16 1 1 0 
MUC20 1 1 0 
MUC5B 1 1 0 
MYRIP 1 1 0 
NADK 1 1 0 
NAP1L2 1 1 0 
NAV1 1 1 0 
NKD2 1 1 0 
NOTCH2 1 1 0 
NOTCH4 1 1 0 
NPIPB4 (includes others) 1 1 0 
      xxxi 
 
 
NXNL2 1 1 0 
OR1M1 1 1 0 
OR2B11 1 1 0 
OR2T27 1 1 0 
OR2T33 1 1 0 
OR4C45 1 1 0 
OR5P2 1 1 0 
OR6C6 1 1 0 
OR9G1 1 1 0 
OR9G9 1 1 0 
OTUD4 1 1 0 
PADI2 1 1 0 
PALD1 1 1 0 
PASD1 1 1 0 
PAXBP1 1 1 0 
PCDH12 1 1 0 
PCDHGB4 1 1 0 
PCLO 1 1 0 
PCMTD1 1 1 0 
PDZD7 1 1 0 
PFKFB2 1 1 0 
PGBD4 1 1 0 
PKD1L3 1 1 0 
PKP2 1 1 0 
PLCL1 1 1 0 
PLEKHM3 1 1 0 
PLXNA2 1 1 0 
PLXNA4 1 1 0 
PNPLA8 1 1 0 
POMZP3 1 1 0 
POTEE/POTEF 1 1 0 
PPM1E 1 1 0 
PRAMEF11 1 1 0 
PRAMEF14 1 1 0 
PRAMEF4 (includes others) 1 1 0 
PRR18 1 1 0 
PRX 1 1 0 
PTPN13 1 1 0 
PVRL2 1 1 0 
QRICH2 1 1 0 
RASA4 1 1 0 
RASA4B 1 1 0 
RBM10 1 1 0 
RBMXL3 1 1 0 
      xxxii 
 
 
RGPD4 (includes others) 1 1 0 
RHPN2 1 1 0 
RPL14 1 1 0 
RRAGD 1 1 0 
RRN3 1 1 0 
RSPH6A 1 1 0 
RTTN 1 1 0 
RXFP1 1 1 0 
SERF2 1 1 0 
SERINC2 1 1 0 
SH3PXD2A 1 1 0 
SKIDA1 1 1 0 
SMTNL2 1 1 0 
SORCS3 1 1 0 
SPATA31A6 (includes 
others) 1 1 0 
SPHKAP 1 1 0 
SPIRE2 1 1 0 
SSC5D 1 1 0 
SSUH2 1 1 0 
SUPT20H 1 1 0 
SYNRG 1 1 0 
TBC1D8B 1 1 0 
TBP 1 1 0 
TDRD6 1 1 0 
TDRP 1 1 0 
TET2 1 1 0 
TIGD1 1 1 0 
TMEM109 1 1 0 
TMEM163 1 1 0 
TMEM229A 1 1 0 
TMEM52 1 1 0 
TMTC2 1 1 0 
TNRC18 1 1 0 
TPSAB1/TPSB2 1 1 0 
TRIOBP 1 1 0 
TSC22D1 1 1 0 
TSPYL1 1 1 0 
TTC34 1 1 0 
UBXN11 1 1 0 
UBXN2B 1 1 0 
UNC93B1 1 1 0 
UQCR10 1 1 0 
UTF1 1 1 0 
      xxxiii 
 
 
VCX2 (includes others) 1 1 0 
VPS13A 1 1 0 
VPS45 1 1 0 
VWDE 1 1 0 
WASH1 1 1 0 
WASL 1 1 0 
WDHD1 1 1 0 
WNK1 1 1 0 
YTHDC1 1 1 0 
ZBED6 1 1 0 
ZBTB33 1 1 0 
ZBTB47 1 1 0 
ZC3H10 1 1 0 
ZDHHC16 1 1 0 
ZFHX4 1 1 0 
ZMAT5 1 1 0 
ZNF598 1 1 0 
ZNF705G 1 1 0 
ZNF792 1 1 0 
 
  
      xxxiv 
 
 
Appendix V. Strict Search 
 
Table 18 Strict Search 
Name #Variants #Cases #Controls 
NBPF10 (includes others) 4 1 0 
MUC2 3 1 0 
ANKRD36 2 1 0 
ARID1B 2 1 0 
ATXN1 2 1 0 
CHD3 2 1 0 
CKAP4 2 1 0 
COL18A1 2 1 0 
FAM157A/FAM157B 2 1 0 
IRF2BPL 2 1 0 
LOR 2 1 0 
MUC5B 2 1 0 
MUC6 2 1 0 
REC8 2 1 0 
SOCS7 2 1 0 
ACSM2A 1 1 0 
ALMS1 1 1 0 
ANKLE1 1 1 0 
APOB 1 1 0 
ARHGEF17 1 1 0 
ATAD5 1 1 0 
ATXN3 1 1 0 
BAIAP2L2 1 1 0 
BET1L 1 1 0 
C19orf33 1 1 0 
C20orf96 1 1 0 
C5orf60 1 1 0 
C6orf132 1 1 0 
CACNA1I 1 1 0 
CACNB2 1 1 0 
CAMKK2 1 1 0 
CCDC144NL 1 1 0 
CCER2 1 1 0 
CD3EAP 1 1 0 
CDC27 1 1 0 
CDC42EP1 1 1 0 
CELA1 1 1 0 
CLSPN 1 1 0 
      xxxv 
 
 
CNTNAP3B 1 1 0 
CPXM2 1 1 0 
DCHS2 1 1 0 
DEFB126 1 1 0 
DNHD1 1 1 0 
DOK3 1 1 0 
DSE 1 1 0 
E2F4 1 1 0 
ERCC1 1 1 0 
FAM155B 1 1 0 
FAM58A 1 1 0 
FAM86B1 1 1 0 
FBN1 1 1 0 
FCGBP 1 1 0 
FHOD3 1 1 0 
FOXN3 1 1 0 
FOXO3 1 1 0 
GIGYF2 1 1 0 
GJC2 1 1 0 
GPRIN2 1 1 0 
GRIN2C 1 1 0 
GSPT1 1 1 0 
GXYLT1 1 1 0 
HEG1 1 1 0 
HELQ 1 1 0 
HRC 1 1 0 
HTT 1 1 0 
IFI27 1 1 0 
IGFBP2 1 1 0 
IGFN1 1 1 0 
IGSF10 1 1 0 
IST1 1 1 0 
KCNN3 1 1 0 
KIAA1549 1 1 0 
KIZ 1 1 0 
KLHL40 1 1 0 
KLRC2 1 1 0 
KRT3 1 1 0 
KRTAP4-6 1 1 0 
KRTAP9-6 1 1 0 
LENG9 1 1 0 
LFNG 1 1 0 
LMTK3 1 1 0 
LOC729159 1 1 0 
      xxxvi 
 
 
LRP8 1 1 0 
LRRIQ1 1 1 0 
LSR 1 1 0 
LURAP1L 1 1 0 
MAN2A1 1 1 0 
MAPK8IP2 1 1 0 
MED15 1 1 0 
MEGF9 1 1 0 
MEOX2 1 1 0 
mir-3150 1 1 0 
mir-663 1 1 0 
MIR3131 1 1 0 
MMP12 1 1 0 
MMP17 1 1 0 
MOGAT1 1 1 0 
MPL 1 1 0 
MST1L 1 1 0 
MUC12 1 1 0 
MUC16 1 1 0 
MUC3A 1 1 0 
NADK 1 1 0 
NAP1L2 1 1 0 
NCOR2 1 1 0 
NKD2 1 1 0 
NOTCH2 1 1 0 
NOTCH4 1 1 0 
OR13C5 1 1 0 
OR2B11 1 1 0 
OR2T27 1 1 0 
OR2T33 1 1 0 
OR4C3 1 1 0 
OTUD4 1 1 0 
PAXBP1 1 1 0 
PCDH12 1 1 0 
PCDHGB4 1 1 0 
PCLO 1 1 0 
PDZD7 1 1 0 
PKD1L3 1 1 0 
POTEG (includes others) 1 1 0 
PPM1E 1 1 0 
PRSS48 1 1 0 
PRX 1 1 0 
QRICH2 1 1 0 
RASA4 1 1 0 
      xxxvii 
 
 
RASA4B 1 1 0 
RBM10 1 1 0 
RBMXL3 1 1 0 
RHPN2 1 1 0 
RIC8A 1 1 0 
RPL14 1 1 0 
RRAGD 1 1 0 
RRN3 1 1 0 
RTTN 1 1 0 
RXFP1 1 1 0 
SART3 1 1 0 
SEMA3B 1 1 0 
SERINC2 1 1 0 
SGK223 1 1 0 
SLC35G4 1 1 0 
SNRPF 1 1 0 
SSC5D 1 1 0 
SSUH2 1 1 0 
SYNRG 1 1 0 
TBP 1 1 0 
TCHH 1 1 0 
TDRD6 1 1 0 
TDRP 1 1 0 
TMEM229A 1 1 0 
TNRC18 1 1 0 
TRIOBP 1 1 0 
TSC22D1 1 1 0 
TSPYL1 1 1 0 
TTC34 1 1 0 
TTN 1 1 0 
UBXN11 1 1 0 
USP37 1 1 0 
UTF1 1 1 0 
VPS13A 1 1 0 
VPS45 1 1 0 
WASL 1 1 0 
YIF1B 1 1 0 
YTHDC1 1 1 0 
YY1 1 1 0 
ZBTB33 1 1 0 
ZBTB40 1 1 0 
ZFHX4 1 1 0 
ZNF705G 1 1 0 
ZNF792 1 1 0 
      xxxviii 
 
 
 
